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Résumé	  
Les inhibiteurs sélectifs de recapture de la sérotonine (ISRS), agonistes indirects des 
récepteurs de la sérotonine (5-HT), ont un début d'effet antidépresseur retardé de plusieurs 
semaines. Des travaux antérieurs suggèrent que le récepteur 5-HT4 de la sérotonine serait une 
cible directe pour traiter la dépression et un nouvel espoir pour traiter plus rapidement ces 
pathologies anxio-dépressives. Toutefois, l'hypothèse « 5-HT4 » doit encore être validée dans des 
modèles animaux d'anxiété/dépression. Les questions posées étaient : la stimulation des récepteurs 
5-HT4 centraux est-elle nécessaire aux effets comportementaux des ISRS ? la neurogenèse 
hippocampique adulte contribue-t-elle à ces effets ? En utilisant le modèle de stress chronique à la 
corticostérone (CORT) chez la souris, nous avons évalué les effets sur ces paramètres d’un 
traitement chronique avec un agoniste du récepteur 5-HT4 (RS67333, 1,5 mg/kg/jour pendant 4 
semaines) comparé à un traitement à la fluoxétine (18 mg/kg/jour). Nous avons ensuite utilisé ce 
modèle murin combiné à l’ablation de la neurogenèse hippocampique par rayons-X afin 
d’examiner si la neurogenèse est nécessaire aux effets comportementaux d’un traitement 
subchronique (7 jours) ou chronique (28 jours) avec le RS67333. Nous avons également évalué le 
blocage des effets de la fluoxétine par un antagoniste du récepteur 5-HT4 (GR125487, 1 
mg/kg/jour). Le traitement chronique avec RS67333, comme celui de la fluoxétine, induit une 
activité anxiolytique/antidépressive et stimule la neurogenèse hippocampique adulte. Cependant, 
contrairement à la fluoxétine , les effets anxiolytiques du RS67333 sont déjà présents après 7 
jours de traitement, sans nécessité l’activation de la neurogenèse. Le traitement chronique avec le 
GR125487 empêche les deux effets anxiolytique/antidépresseur et neurogènique de la fluoxétine, 
indiquant que l'activation du récepteur 5-HT4 est nécessaire à ces effets de l’ISRS. Nous avons 
ensuite cherché à savoir si le court délai d’action antidépresseur du RS67333 peut être prédit par 
l'expression d'un biomarqueur périphérique. Des données de la littérature indiquent que la cascade 
de signalisation de β-arrestine 1 (impliquée dans la désensibilisation et l’internalisation du 
récepteur 5-HT4) serait un biomarqueur potentiel pré-clinique/clinique des états dépressifs et des 
effets d’un traitement antidépresseur. À cette fin, nous avons développé une nouvelle méthode 
d’évaluation des taux de protéines circulantes grâce à une analyse par immunoblot des leucocytes 
(PBMC) isolés à partir du sang total de souris. Les taux de β-arrestine 1 sont diminués dans les 
leucocytes des souris pré-traitées à la CORT. Il faut 7 jours de traitement avec le RS67333, mais 
28 jours avec la fluoxétine chez ces animaux pour restaurer un taux de β-arrestine 1 comparable à 
celui des animaux contrôles. Ces résultats suggèrent que le taux sanguin de β-arrestine 1 est un 
biomarqueur de la rapidité de la réponse antidépressive. Enfin, l'activation du récepteur 5-HT4 
dans le cerveau peut représenter une approche thérapeutique innovante d’apparition pour traiter 
plus rapidement des symptômes dépressifs associés à l’anxiété.	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Abstract	  
Selective serotonin reuptake inhibitors (SSRIs) display a delayed onset of antidepressant action of 
several weeks. Past work demonstrated evidence that the 5-HT4 receptor may be a direct target for 
treating depression and a new hope for fast acting antidepressant treatment. However, the 5-HT4 
hypothesis still needs to be validated in models of anxiety/depression. 
We decided to investigate whether 5-HT4 receptor stimulation was necessary for the 
effects of SSRIs in a mouse model of anxiety/depression and whether hippocampal neurogenesis 
contributed to these effects. Using the mouse corticosterone (CORT) model of anxiety/depression, 
we assessed whether chronic treatment with a 5-HT4 receptor agonist (RS67333, 1.5 mg/kg/day) 
had effects on anxiety and depression-related behaviors as well as on hippocampal neurogenesis 
in comparison to chronic fluoxetine treatment (18 mg/kg/day). Then, using our model combined 
with ablation of hippocampal neurogenesis, we investigated whether neurogenesis was necessary 
for the behavioral effects of subchronic (7-days) or chronic (28-days) RS67333 treatment. We 
also assessed whether a 5-HT4 receptor antagonist, (GR125487, 1 mg/kg/day) could prevent the 
behavioral and neurogenic effects of fluoxetine in CORT pre-treated mice. Chronic treatment with 
RS67333, similar to fluoxetine, induced anxiolytic/antidepressant-like activity and stimulated 
adult hippocampal neurogenesis. However, unlike fluoxetine, the anxiolytic effects of RS67333 
were already present after 7 days and did not require hippocampal neurogenesis. Chronic 
treatment with GR125487 prevented both anxiolytic/antidepressant-like and neurogenic effects of 
fluoxetine in CORT pre-treated mice, indicating that 5-HT4 receptor activation is necessary for 
these effects of SSRIs.   
We then explored whether the fast onset of action of the 5-HT4 receptor agonist RS67333 
could be predicted by expression of a peripheral biomarker. The β-arrestin-signaling cascade 
which is involved in 5-HT4 receptor desensitization and internalization, has recently gained 
attention as a potential pre-clinical/clinical bridging biomarker for depressive states and treatment 
effects. To this end, we developed a new method to assess levels of circulating proteins through 
immunoblot analyses of mouse peripheral blood mononuclear cells (PBMCs) isolated from whole 
blood of anesthetized animals. β-arrestin 1 levels was decreased in CORT pre-treated mice. 
RS67333 restored the level of this protein to control levels after only 7 days of treatment, while 
fluoxetine did it after 28 days. These results suggest that blood levels of β-arrestin 1 may be a 
useful biomarker to predict rapid antidepressant/anxiolytic activities.  
Finally, the activation of 5-HT4 receptors in the brain may represent an innovative and 
rapid onset therapeutic approach to treat depressive symptoms with comorbid anxiety.	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Abréviations	  
5-HT : sérotonine/serotonin 
5-HT1A, 1B, 2C, 3, 4, 5, 6, 7 : récepteurs de la sérotonine 1A, 1B, 2C, 3, 4, 5, 6, 7/ 1A, 1B, 
2C, 3, 4, 5, 6, 7 serotoninergic receptor 
5-HTT/SERT : transporteur de la sérotonine/serotoninergic transporter 
AC : Adenylate cyclase/adenylyl cyclase 
Ach : acetylcholine 
AMPA : acide 2-amino-3-(5-méthyl-3-hydroxy-1,2-oxazol-4-yl)propanoïque/ 2-amino-3-(3-
hydroxy-5-methyl-isoxazol-4-yl)propanoic acid 
ARN/ARNm/mRNA : acide ribonucléique/acide ribonucléique messager/messenger 
ribonucleic acid 
β-CD : β-cyclodextrine/β-cyclodextrin 
BDNF : brain derived neurotrophic factor 
CA : corne d’ammon/ammon's horn 
cAMP : Adénosine monophosphate cyclique/cyclic adenosine monophosphate 
CNS : système nerveux central/central nervous system 
CMS : stress chronique modéré/chronic mild stress 
CORT : corticostérone/corticosterone  
CREB :C-AMP Response Element-binding protein  
CT : thérapie cognitive/cognitive therapie 
DA : dopamine 
DAT : inhibiteur de recapture de la dopamine/dopaine reuptake inhibitor 
DCX : doublecortine/doublecortin 
DG : gyrus dentelé/dentate gyrus 
DRN : noyaux du raphe dorsal/dorsal raphe nucleus 
DSM : the diagnostic and statistical manual of mental disorders 
ECT : electro-convulsivo therapie/electroconvulsive therapy 
EPM : labyrinthe en croix surélevée/elevated plus maze 
FDA : food and drug administration 
FST : test de la nage forcée/ forced swim test 
GIP : proteine interagissant avec les récepteurs couplés aux protéines G/GPCR interacting 
proteins  
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GPCR : récepteurs couplés aux protéines G/G-protein coupled receptor 
GRK : kinase des récepteurs couplés aux proteines G/G-protein-regulated kinase 
HPA : hypothalamo-hypophyso-surrénalien/ hypothalamic-pituitary-adrenal axis 
HRSD : Echelle d’évaluation d’Hamilton/Hamilton rating scale for depression  
IMAO : inhibiteur de la monoamine oxydase/monoamine oxydase inhibitor 
IP : intrapéritonéale/intraperitoneal 
ISRN : inhibiteur sélectif de recapture de la noradrénaline/selective norepinephrin reuptake 
inhibitor 
ISRS/SSRI : inhibiteur sélectif de recapture de la sérotonine/selective serotonin reuptake 
inhibitor 
LTP : potentialisation à long terme/long term potentiation 
KO : knock out 
MASSA : agoniste mélatoniergiques/antagoniste des récepeurs sérotoninergiques/melatonin 
agonist and selective serotonin antagonist 
MDD : major depressive disorders 
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specific serotonergic antidepressants 
NDMA : N-methyl-D-aspartate receptor 
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OMS/WHO : Organisation mondiale de la Santé/world health organization 
PCR : réaction en chaîne par polymérase/polymerase chain reaction 
PBMC :  cellules sanguines mononuclées/peripheral blood mononuclear cells 
PFC :  cortex prefrontal/prefrontal cortex 
sAPPα : soluble amyloid precursor protein 
SARI : antagoniste des récepteurs 5-HT2 et inhibiteur de recapturee/Serotonin 2 receptor 
antagonist and reuptake inhibitor 
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Introduction	  
1-­‐Les	  Episodes	  dépressifs	  Majeurs	  	  
I. Généralités	  sur	  les	  maladies	  dépressives	  	  
Les troubles dépressifs et l'anxiété sont un lourd fardeau pour la société. 
L'Organisation Mondiale de la Santé (OMS) prévoit que d'ici 2030 la dépression, une maladie 
potentiellement mortelle, sera la deuxième cause d'invalidité dans le monde entier (Kessler et 
al., 2003). Les troubles de l'humeur touchent 7% de la population mondiale, tandis que les 
formes sévères de dépression ont une incidence sur 2-5% de la population américaine 
(Kessler et al., 2005). En outre, environ 32 à 35.000.000 adultes dans la population 
américaine (16%) connaitront un épisode dépressif majeur au cours de leur vie. En Europe, 
une méta- analyse fondée sur 27 études cliniques, comprenant plus de 150.000 sujets de 16 
pays européens, a estimé la prévalence de la dépression entre 3 à 10 % au cours des 12 
derniers mois. Un individu sur six environ succombera à une des formes de dépression au 
cours de sa durée de vie (Kessler et al., 2005). En 2000, le fardeau économique américain des 
troubles dépressifs était estimé à 83,1 milliards de dollars, dont près d’1/3 sont attribuables à 
des frais médicaux (Greenberg et al., 2003). Des pertes de productivité de la main-d'œuvre 
liés à la dépression seraient de 24 milliards de dollars par an (Birnbaum et al., 2009). La co-
morbidité des troubles dépressifs avec des troubles anxieux, puisqu’on rapporte que 50-60% 
des patients souffrant de ces troubles ont aussi un historique de trouble anxieux qui précèdent 
souvent l’apparition des symptômes dépressifs (Kaufman et Charney, 2000). Ces résultats 
soulèvent la question de savoir si les troubles anxieux et dépressifs, malgré les distinctions 
faites de leur diagnostic clinique, partagent une physiopathologie commune.  
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Malgré une certaine variabilité, un élément commun à ces deux pathologies est que la 
dépression majeure est presque deux fois plus fréquente chez les femmes que chez les 
hommes (Burt et Stein, 2002; Waraich et al., 2004). Il faut également tenir compte de 1.3 à 
4.4% de toutes les incapacités et des décès prématurés dans le monde.  
La dépression se caractérise par plusieurs symptômes biologiques et psychologiques 
qui affectent de nombreux aspects du quotidien. Selon le Manuel diagnostique et statistique 
des troubles mentaux (DSM-V), le trouble dépressif majeur est plus que de la tristesse 
occasionnelle, mais comprend plutôt une humeur dépressive ou une perte de plaisir ou 
d'intérêt dans les activités quotidiennes pendant au moins deux semaines, et ces épisodes sont 
souvent récurrents. Les liens sociaux, professionnels et personnels du patient sont altérés par 
ces symptômes. La dépression se caractérise par des changements dans les fonctions 
biologiques de base y compris le sommeil et l'alimentation, ainsi qu’un dynamisme réduit. 
D’un point de vue cognitif, les patients décrivent souvent des sentiments d'inutilité ou de 
culpabilité, et peuvent envisager le suicide, si oui ou non il existe effectivement un plan en 
place pour tenter de passer à l’acte (Tableau 1). La dépression est clairement un changement 
dans la biologie normale d'une personne. Ces symptômes de l'humeur existent sur un 
continuum, et dans les cas graves, décrivent une pathologie qui doit être diagnostiquée et 
traitée. 
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II. La	  Dépression,	  une	  pathologie	  hétérogène	  
La dépression est une pathologie hautement héréditaire : 40-50% du risque de 
dépression serait d’origine génétique, mais les gènes spécifiques qui sous-tendent ce risque 
restent inconnus. Les 50-60% de risques restants, non génétiques, sont également mal 
définis : des hypothèses mettent en cause des événements tels que des traumatismes de la 
petite enfance, un stress émotionnel, une maladie physique, et même des infections virales, 
seraient (Figure 1) (Hasin et al., 2005; Berton et Nestler, 2006; Leonardo et Hen, 2006; Tanti 
et Belzung, 2010). Élucider les bases neurobiologiques de la dépression et l'anxiété est l'un 
des défis majeurs pour la société d'aujourd'hui. De même, l'imagerie humaine et les études 
post-mortem de personnes qui ont souffert de dépression ont servi de contribution à la 
connaissance croissante des structures cérébrales impliquées dans la diversité des symptômes 
dépressifs. (Drevets, 2001; Drevets, 2003; Drevets et al., 2002; Nestler et al., 2002; 
Rajkowska, 2003; Morilak et Frazer, 2004).  
Plusieurs arguments suggèrent qu'il existe des circuits neuronaux spécifiques du 
système cortico-limbique intervenant dans la réactivité au stress, l'humeur et la régulation 
émotionnelle. Le cortex préfrontal et le cortex cingulaire ainsi que l'hippocampe ont reçu le 
plus d'attention, en particulier dans les études animales de la dépression. On suppose que ces 
régions du cerveau sont plus particulièrement associées à des anomalies cognitives et à des 
déficits de mémoire observés chez de nombreux patients souffrant de dépression (Berton & 
Nestler, 2006). D'autres régions cérébrales jouent un rôle important dans la dépression comme 
l'amygdale pour son implication dans les stimuli aversif ou enrichissant, et le noyau 
accumbens qui joue un rôle important dans les niveaux de récompense, le plaisir, la 
motivation et l'énergie qui sont parmi les anomalies qu’on retrouve chez les personnes qui 
souffrent de dépression (Hasler et al., 2004; Sibille et al., 2009) . Ensemble, ces régions du 
cerveau participent à une série de circuits neuronaux hautement interactifs impliqués dans la 
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dépression (Zhu et al., 1999; Drevets, 2001; Liotti et Mayberg, 2001; Manji et al., 2001; 
Nestler et al., 2002; Krishnan et Nestler, 2008).  
La dépression est également associée à des facteurs environnementaux, et en 
particulier à l'exposition au stress. Il est bien connu que, outre l'hippocampe, l'axe 
hypothalamo-hypophyso-surrénalien joue un rôle important (Nestler et al., 2002; Dranovsky 
et Hen, 2006). L'hétérogénéité de la dépression implique que des facteurs biologiques, 
psychologiques et sociaux soient des éléments pivots de la pathophysiologie et du 
développement de nouveaux traitements. 
 
Figure 1 : Representation of aetiological factors involved in depression.  
Examples of triggers in humans are given in blue boxes. Examples of experimental models used in animals to 
reproduce these triggers are given in purple boxes. These aetiological factors are thought to induce changes in 
pathophysiological end points precipitating a depression. Antidepressant treatments may act by reversing these 
changes. BDNF, brain-derived neurotrophic factor; MDD, major depressive disorder; MDMA, 
methylenedioxymethamphetamine (from Tanti and Belzung, 2010). 
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2-­‐	   Les	   traitements	   antidépresseurs	   &	  
leurs	  limitations	  
I. Traitements	  Antidépresseurs	  
Des traitements efficaces de la dépression sont disponibles, y compris une variété 
d'antidépresseurs, la thérapie par électrochocs (électro-convulsivo thérapie ou ECT), et 
certains types de psychothérapie ciblée comme la thérapie cognitivo-comportementale et 
interpersonnelle (Schatzberg, et Nemeroff, 2009). L’objectif d’un traitement antidépresseur 
est de soulager les symptômes. Cependant, d'autres traitements qui n’impliquent pas des 
antidépresseurs sont également efficaces pour soulager la dépression. Ceux-ci incluent la 
thérapie cognitive (CT) et d'autres formes de psychothérapie, comme la thérapie par 
électrochocs et la stimulation électrique du nerf vague (Tableau 2). Des interventions plus 
récentes, telles que la stimulation chronique de la région cingulaire subgenual (aire 25 de 
Brodmann) ont également montré des effets prometteurs lors d'essais cliniques récents 
(Mayberg et al., 2005). 
L'hypothèse monoaminergique de la dépression et de son traitement a été à la base de 
la recherche sur les troubles d'humeur au cours des 50 dernières années. Les antidépresseurs 
tricycliques (par exemple, l'imipramine), qui inhibent la recapture de la sérotonine et de la 
noradrénaline, et les Inhibiteurs de la MonoAmine Oxydase (IMAO comme par exemple 
l’iproniazide), les premiers médicaments utilisés ent clinique pour traiter la dépression, sont 
apparus dans les années 1960 (Nestler et al., 2002). Ces médicaments ont été depuis 
remplacés par de nouveaux antidépresseurs ayant une tolérance supérieure et un meilleur 
profil de sécurité. Malgré les progrès indéniables qui ont été réalisés concernant la sélectivité 
d'effet et le rapport bénéfices/risques, d’importantes questions demeurent sans réponse 
concernant tous les antidépresseurs :  
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- leur efficacité limitée (30% de patients déprimés résistants),  
- leur trop long délai d'action (voir ci-dessous) avant d’observer un bénéfice clinique  
- les raisons des rechutes et récidives.  
Même parmi les patients qui reçoivent un traitement adéquat et étroitement surveillé 
avec la psychothérapie ou des antidépresseurs, tous ne répondent pas complètement à ce 
traitement. Dans le traitement de la dépression, une réponse complète ou une rémission, est 
définie comme la résolution complète des symptômes dépressifs et un retour complet de 
fonctionnement, généralement définie comme la réalisation d'un score <8 sur l’échelle 
standardisée « Hamilton Rating Scale for Depression » (HRSD). 
Tableau 2: Recommended modalities for acute phase treatment of Major Depressive 
Disorders (MDD) (adapted from Care Management Program Clinical Guidelines). 
Modality 
Severity Pharmacotherapy 
Depression-
Focused 
Psychotherpy 
Pharmacotherapy in 
combination With 
Depression-Focused 
Psychotherapy 
Electroconvulsive 
Therapy 
Mild to 
Moderate 
 
Yes Yes 
May be useful for 
patients withpsycho-
social or interpersonal 
problems, intrapsychic 
conflict, or co-
occurring Axis II 
disorder 
Yes, for certain 
patients 
Severe Without 
Psychotic 
Features 
Yes NO Yes Yes 
Severe With 
Psychotic 
Features 
Yes, provide both 
antidepressant and 
antipsychotic 
medication 
NO 
Yes, provide both 
antidepressant 
and antipsychotic 
medication 
Yes 
 
La découverte des effets antidépresseurs des premiers antidépresseurs et de leurs 
cibles moléculaires a conduit à la conception de médicaments de deuxième et troisième 
génération, tels que les Inhibiteurs Sélectifs du Recapture de la Sérotonine (ISRS) et les 
Inhibiteurs Sélectif du Recapture de la noradrénaline (ISRN). Depuis cette découverte, la 
dépression a été associée à une atteinte de la neurotransmission sérotoninergique, 
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noradrénergique et, dans une moindre mesure, dopaminergique centrale. Aujourd'hui, la 
plupart des médicaments utilisés pour augmenter les concentrations cérébrales de sérotonine 
et traiter la dépression, y compris les médicaments les plus couramment prescrits, les ISRS 
(comme par exemple, la fluoxétine), sont efficaces pour traiter les deux pathologies, l'anxiété 
et la dépression. (Schatzberg et Nemeroff, 2009; Samuels et al., 2011) (Figure. 2).  
II. Limites	  des	  traitements	  antidépresseurs	  
Au cours des dernières décennies, des milliards de dollars ont été dépensés en efforts de 
la recherche pour cibler de nouveaux médicaments plus sélectifs des récepteurs de la 
sérotonine ou de la noradrénaline, agonistes ou antagonistes ayant des effets semblables aux 
médicaments antidépresseurs déjà sur le marché, mais avec une réponse plus rapide et 
présentant moins d’effets indésirables. Malheureusement, en dépit de la recherche et des 
connaissances acquises sur le mécanisme d'action des antidépresseurs classiques et de leurs 
propriétés thérapeutiques, de nombreuses questions restent sans réponse. Le traitement 
pharmacologique de la dépression reste  peu satisfaisant. Bien que les antidépresseurs 
actuellement disponibles aient une réelle efficacité curative (démontrée par des études 
cliniques « contre placebo » ou en comparaison à la référence, l’ECT) dans le traitement de 
cette pathologie, il faut attendre plusieurs semaines pour qu’ils démontrent une pleine 
efficacité, de nombreux patients répondent peu au traitement, les symptômes concomitants 
sont souvent peu contrôlés et certains antidépresseurs peuvent engendrer des problèmes de 
tolérance ou de dépendance (pour revue, Martinowich et al., 2013). Environ 60% des patients 
souffrant de dépression ne répondent pas de façon adéquate aux antidépresseurs ou sont 
résistantes à ces médicaments. Moins de 50 % des patients souffrant de dépression montrent 
une complète amélioration (Trivedi et al., 2006; Samuel et al., 2011). Les effets indésirables 
des ISRS sont fréquemment décrits lors d’un traitement chronique, notamment l'insomnie, 
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somnolence, sensation vertigineuse, akathisie et dysfonction sexuelle à long terme (par 
exemple, diminution de la libido, l'éjaculation retardée, etc… ).  
Comme les antidépresseurs de première génération, les ISRS nécessitent au moins 2 à 4 
semaines d'administration avant l'obtention de bénéfices thérapeutiques (Wong et Licinio, 
2001). Le fait que la réponse au traitement antidépresseur soit si imprévisible chez un 
individu et qu’il soit souvent nécessaire d'essayer plusieurs antidépresseurs pour obtenir un 
effet optimal, peut causer de la frustration chez le patient, favoriser une mauvaise observance 
de ce traitement, ce qui en limitera son efficacité et involontairement servira à renforcer la 
dépression (Fava, 2000; Trivedi et al., 2006). L'écart entre les effets aigus des ISRS (in vitro, 
le blocage des transporteurs SERT et/ou NET est rapide) et l'apparition tardive de leurs effets 
in vivo après administration chronique chez l’animal et chez l’Homme suggèrent un 
mécanisme d'action complexe (cf Chapitre 3, Articles 1 et 2 concernant le rôle de la 
neurogenèse hippocampique adulte). Cette distinction apparente entre les effets aigus et 
chroniques des ISRS a fait émerger l'hypothèse de la nécessaire activation de plusieurs 
mécanismes pharmacologiques dans le cerveau lors d'un traitement chronique avec des ISRS.  
L'efficacité modeste des antidépresseurs conventionnels tels que les ISRS appelle à de 
nouvelles approches pour traiter les différentes formes légères, modérée ou sévères des 
épisodes dépressifs associés ou non à des troubles anxieux. Des études cliniques mettant en 
oeuvre des thérapies pharmacologiques combinées, telles que le blocage des récepteurs 
monoaminergiques centraux en plus de l'inhibition d’un des transporteurs des monoamines, 
ont déjà été proposées afin de raccourcir le délai d’apparition de l'effet antidépresseur et/ou 
d'augmenter l'efficacité de ces médicaments.  
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Figure 2: Mechanisms of action of antidepressants available in the market. 
(MAOI: monoamine oxidase inhibitor; MASSA: Melatonin Agonist and Selective Serotonin Antagonist; 
NASSA: Noradrenergic and specific serotonergic antidepressants; NDRI: Norepinephrin Reuptake Inhibitor; 
SSRI: Selective Serotonin Reuptake Inhibitor; TCA: Tricyclic Antidepressant) (Figure from David and Felice). 
III. Nouveaux	  traitements	  antidépresseurs	  
Malgré l'accumulation de preuves indiquant la pertinence d’augmenter la fonction du 
système sérotoninergique central dans le traitement des épisodes dépressifs, de nombreuses 
lacunes subsistent concernant l'aspect pharmacologique. Les efforts actuels de développement 
de médicaments visent à découvrir de nouvelles cibles et de nouvelles classes 
d'antidépresseurs dans l'espoir d’identifier de nouveaux composés ayant une efficacité plus 
large et / ou d’apparition des effets plus rapide avec un meilleur profil d'effets indésirables 
(Tableau 1). Pour exemples: les inhibiteurs de recapture doubles ou triples, des molécules 
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nouvelles capables d'agir sur plusieurs systèmes de neurotransmetteurs à la fois (Roose et al., 
1994). 
Ainsi, la vortioxetine (Lu AA21004; 1-[2-(2,4-diméthyl-phénylsulfanyl)-phényl]-
pipérazine) est un nouvel antidépresseur ayant une activité antidépressive « multimodale » 
développé par des Laboratoires Lundbeck (Figure 3). Dans des cellules recombinantes 
exprimant soit des récepteurs humains, soit SERT, la vortioxetine agit comme un inhibiteur 
du transporteur de la 5-HT (SERT, Ki = 1,6 nM). C’est également :  
- un antagoniste des récepteurs 5-HT3, 5-HT7 et 5-HT1D (Ki = 3,7, 19 et 54 nM, 
respectivement),  
- un agoniste partiel des récepteurs 5-HT1B (Ki = 33 nM),  
- un agoniste du récepteur 5-HT1A (Ki = 15 nM) (Bang-Andersen et al., 2011; Mork 
et al., 2012; Westrich et al., 2012).  
Chez le rat, les affinités de liaison sont Ki = 1,1, 200, 3.7, 16 et 230 nm respectivement 
pour les récepteurs 5-HT3, 5-HT7, 5-HT1D, 5-HT1B et 5-HT1A, et un Ki de 8,6 nM pour le 
SERT (Mork et al., 2012; Westrich et al., 2013).  
Récemment, explorant l'activité comportementale chez la souris adulte, nous avons 
montré que l'administration aiguë et répétée de vortioxetine produit un effet 
anxiolytique/antidépresseur plus prononcé que celui de la fluoxétine, associé à une 
augmentation de la prolifération cellulaire et de l’arborisation dendritique (Guilloux et al., 
2013).  
Fin Septembre 2013, la « Food and Drug Administration » (FDA) américaine a 
approuvé la mise sur le marché de la vortioxetine (BRINTELLIX®) avec pour indication le 
traitement des adultes souffrant de trouble dépressif majeur. Six études cliniques dans 
lesquelles les adultes ayant de tels troubles ont été randomisés pour recevoir soit un placebo, 
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soit la vortioxétine ont démontré son efficacité supérieure à celle du placebo pour traiter la 
dépression (Communiqué de presse de la Food Drug Administration, 30 septembre 2013). 
 
Figure 3: Lu AA21004 binding for the SERT and various 5-HT receptors after systemic 
administrations in rat (From Mork et al., ECNP Philadelphia 2012).  
	  
Autre exemple, le développement de l’agomélatine, médicament antidépresseur ayant 
à la fois des propriétés agoniste mélatonergique et antagoniste du récepteur 5-HT2C est 
prometteur car les troubles affectifs sont caractérisés par des rythmes circadiens anormaux 
(pour revue, voir De Bodinat et al., 2010). L'agomélatine (S20098, N-[2 - (7-
méthoxynaphthalén-1-yl) éthyl] acétamide) est nouveau antidépresseur (agissant comme un 
agoniste sur les récepteurs mélatonergiques et antagonistes des récepteurs 5-HT2C Après 
évaluation pharmacologique complète et étendue des essais cliniques. agomélatine 
(VALDOXAN®/ THYMANAX® développé par les Laboratoires IRIS) a obtenu l'autorisation 
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de commercialisation en 2009 pour le traitement des épisodes dépressifs majeurs en Europe, 
devenant ainsi un des premiers antidépresseurs approuvés avec un mécanisme d’action non 
exclusivement monoaminergique.  
Les antagonistes du récepteur ionotropique glutamatergique NMDA, en particulier la 
kétamine, sont apparus comme des candidats àe la prochaine génération d'antidépresseurs 
d’action rapide (pour revue, voir Martinowich et al., 2013; Maeng et al., 2008). De façon 
étonnante, il semble que les effets de la kétamine sur le comportement reposent sur 
l'activation du récepteur AMPA, un autre type de récepteur canal ionique du L-glutamate et, 
par conséquent, des médicaments capables d'activer directement le récepteur AMPA ou un de 
ses sites modulateurs allostériques pourraient produire des actions antidépresseurs rapides et 
de longue durée. 
Malgré les énormes progrès réalisés en recherche, l'utilisation de traitements physiques 
ou somatiques comme la psychothérapie, la thérapie par électrochocs (ECT) et la 
pharmacologie des antidépresseurs visant à élucider la physiopathologie des troubles anxio-
dépressifs, de nombreuses questions restent en suspens concernant le mécanisme d’action des 
antidépresseurs et leur lien avec la dépression (Nestler et al., 2002). Ainsi, il est essentiel 
d'avoir une compréhension de ce qui sous-tend le retard du délai d'action des antidépresseurs 
pour être en mesure d'avoir un traitement bénéficiant à chaque patient déprimé. 
 
 
 
32 
 
32 	  
3-­‐	   La	   Neurogenèse	   Hippocampique	  
Adulte:	   un	   acteur	   de	   l’activité	   de	   type	  
antidépressive	  
Une hypothèse récente concernant le rôle de la neurogenèse dans l’origine des troubles 
dépressifs et/ou dans le mécanisme d’action des antidépresseurs gagne du terrain. Des 
arguments convaincants ont été apportés surtout quant à la capacité d’un traitement 
antidépresseur chronique à augmenter:  
- l’expression du BDNF et celle de son récepteur TrkB de haute affinité dans les 
neurones hippocampiques (Nibuya et al., 1995),  
- la neurogenèse hippocampique, processus nécessaire pour observer une réponse 
bénéfique dans certains paradigmes comportementaux, suite à un traitement antidépresseur 
chronique chez les Rongeurs (van Praag et al., 1999; Malberg et al., 2000; Santarelli et al., 
2003).  
Un aspect particulier de la plasticité cérébrale a donc reçu beaucoup d'attention ces 20 
dernières années : il s’agit de la neurogenèse hippocampique adulte, ou la capacité de 
l'hippocampe à générer de nouveaux neurones tout au long de la vie. Il est maintenant bien 
établi que chez les Mammifères, dont les humains, de nouveaux neurones sont générés et 
intégrés dans le réseau neuronal fonctionnel du cerveau adulte en continu (Eriksson, 1998). 
Très récemment, une équipe Suédoise dirigée par Jonas Frisen, réussi à prouver, en mesurant, 
dans les cerveaux de 55 personnes décédées en Suède, âgées de 19 à 92 ans, le rapport entre le 
carbone 12 (le carbone normal) et le carbone 14 (son isotope radioactif), que les neurones de 
l’hippocampe humain se renouvellent durant toute la vie. Cette études montrent aussi que le 
renouvellement des neurones de l'hippocampe chez l'homme était d'environ 1,8 % par an, ce 
qui correspond à la production moyenne de 1 400 nouveaux neurones par jour dans 
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l'hippocampe d'un adulte. Ces recherches ont également révélé, de manière surprenante, que 
ce taux de renouvellement restait constant tout le long de la vie (Spalding et al., 2013). 
On sait que l'hippocampe joue un rôle essentiel dans l'apprentissage et la mémoire. De 
même, cette région cérébrale est l'une des structures limbiques dans laquelle la neurogenèse se 
produit. Ceci a été également étudié chez des individus souffrant de troubles psychiatriques et 
neurologiques (Boldrini et al., 2009, 2012, 2013). En effet, au fil du temps, un grand nombre 
de publications ont montré que ces diverses pathologies cérébrales sont marquées par une 
diminution du volume et de la fonction de l’hippocampe. Par exemple, lors d’épisodes 
dépressifs majeurs, dans la schizophrénie, la maladie d'Alzheimer. L’atrophie de 
l'hippocampe, les difficultés d'apprentissage et de mémorisation, et des dérèglements de 
l'humeur sont des facteurs qui favorisent l’apparition de troubles mentaux (Sapolsky, 2000; 
Nestler et al., 2002).  
L’Article 1 qui suit est une revue des principaux modèles animaux 
d’anxiété/depression comme le stress modéré chronique, la défaite sociale ou l’administration 
chronique de corticosterone chez les Rongeurs et leurs consequences sur la neurogenèse 
hippocampique chez l’adulte avec ou sans traitement antidépresseur.  
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ROLE OF HIPPOCAMPAL NEUROGENESIS IN THE 
MECHANISM OF ACTION OF ANTIDEPRESSANT/
ANXIOLYTIC DRUGS IN ANIMAL MODEL OF 
DEPRESSION AND ANXIETY
BENJAMIN ADAM SAMUELS, INDIRA DAVID, QUENTIN RAINER,  
ALAIN MICHEL GARDIER, RENÉ HEN, DENIS JOSEPH DAVID
Abstract: Depression and anxiety are psychiatric illnesses that are major burdens on society and 
affect as much as 7% of the world’s population. Here we review common approaches used to model 
depression in rodents such as chronic mild stress (CMS), social defeat, and chronic corticosterone 
treatment. We discuss the pros and cons of these different approaches. Furthermore, we provide a 
detailed review of adult hippocampal neurogenesis, including the distinct phases that a cell passes 
through when transitioning from precursor to neuron. Finally, we discuss at length the experiments 
that have related adult hippocampal neurogenesis to treatments of depression and anxiety, and 
why neurogenesis might be necessary for these treatments. We end by revisiting the neurogenesis 
hypothesis of depression and by providing suggestions for future research directions.
INTRODUCTION
Depressive and anxiety disorders are a major burden on society. Mood disorders affect 7% of 
the world’s population, while severe forms of depression impact 2-5% of the US population [1, 
2]. Furthermore, approximately 32-35 million adults in the US population [16%] experience an 
episode of major depression in their lifetime [3]. The heterogeneous nature of depression suggests an 
involvement of multiple distinct brain regions, which may be responsible for the diverse symptoms. 
Human imaging and post-mortem studies have supported this hypothesis, implicating brain areas 
including the prefrontal and cingulate cortex, hippocampus, striatum, amygdala, and thalamus 
[4]. Together, these brain regions operate a series of highly interacting circuits that forms a neural 
circuitry involved in depression [5]. The hippocampus is one of several limbic structures that have 
been extensively studied in individuals with psychiatric and neurologic disorders in the last decade 
[5, 6]. Besides its critical role in learning and memory, the hippocampus is one of only two areas in 
mammalian brain where adult neurogenesis occurs [6]. Adult hippocampal neurogenesis is therefore 
GH¿QHGDVWKHSURJUHVVLRQIURPQHXUDOVWHPFHOOWRPDWXUHGHQWDWHJUDQXOHQHXURQ
Moreover, while many classes of drugs with antidepressant activity have been developed and 
approved [7], many patients do not respond to treatment [8]. Therefore it is critical for basic research 
to develop animal models that present behavioral, neurochemical and brain morphological phenotypes 
reminiscent of depression and anxiety. Given that anxiety and depression have a high comorbidity 
with co-occurrence rates up to 60% in patients [9, 10], animal models that present signs of both 
diseases could potentially be the most useful.
To fully understand the pathophysiology and treatment of depression, it is essential to delineate 
molecular, cellular and circuit-level determinants of chronic antidepressant action in addition 
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to behavioral models. Of the current leading hypotheses of the pathophysiology and treatment of 
depression, the Neurogenesis Hypothesis of Depression deserves particular attention because it 
allows the characterization because changes in neurogenesis are only seen after chronic, but not 
acute, antidepressant treatment. This review revisits the role of adult hippocampal neurogenesis in 
the pathophysiology of mood disorders, especially anxiety/depression, and also in the antidepressant 
responses, especially in non-stressed and stressed rodents.
HIPPOCAMPAL NEUROGENESIS
Neurogenesis refers to the production of new neurons in the brain. Originally, it was only described 
during development. The dogma of Ramon y Cajal (1913) that the adult brain was unable of generating 
QHZQHXURQVZDV¿UVWTXHVWLRQHGE\WKHZRUNRI$OWPDQLQWKHVZKRUHYHDOHGWKHJHQHVLVRIQHZ
cells in the brain of adult rat and cat by autoradiography with tritiated thymidine [11]. Unfortunately, 
LWZDVXQFHUWDLQZKHWKHUWKHQHZFHOOVZHUHDFWXDOO\QHXURQDOFHOOV7KHZRUNRI.DSODQDQG+LQGV
>@FRQ¿UPHGWKLVE\XVLQJDQXOWUDVWUXFWXUDODQDO\VLVRIWKHODEHOHGFHOOV0DQ\\HDUVODWHU
D FRPELQDWLRQ RI VSHFL¿F QHXURQDOPDUNHUV DQG DQ DQDORJXH RI WK\PLQLGLQH EURPR¶GHR[\
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in two discrete brain regions: the subventricular zone (SVZ) and subgranular zone (SGZ) of dentate 
gyrus of the hippocampus. In this chapter, only the hippocampal neurogenesis and its involvement in 
depression will be presented.
PRODUCTION OF NEW NEURONS IN THE SGZ
Hippocampal neurogenesis is possible in the SGZ of the dentate gyrus of the hippocampus because 
of to the presence of stem cells. These stem cells evolve into neural progenitor cells that can produce 
multiple cell types in the central nervous system such as neurons, astrocytes, oligodendrocytes, 
or microglial cells [14]. In rodents, the duration of the mitotic cycle of proliferating precursors is 
approximately 12 to 24 hours, leading to the production of about 8,000 to 10,000 new neurons per day 
[15] Given that the dentate gyrus consists of approximately one million granule cells, this phenomenon 
is capable of generating a little less than 1% of total granule cells each day. However, the proportion of 
new neurons that survive beyond one month is less than 50%, and the production of new cells is offset 
by the daily loss of mature granule cells. The surviving cells are predominantly a neuronal phenotype 
PDLQO\JOXWDPDWHUJLFJUDQXOHFHOOVEXWDOVRVRPHDUH*$%$HUJLFLQWHUQHXURQEDVNHWFHOOV
A smaller proportion of cells differentiate into astrocytes (15%), oligodendrocytes or microglia [16].
NEUROGENIC NICHE
Adult hippocampal neurogenesis, therefore, mainly refers to the production of a single neuronal type: 
the granule cells of the dentate gyrus. These cells are the principal excitatory neurons of the dentate 
gyrus (DG), receiving connections from the entorhinal cortex and sending projections along mossy 
¿EHUVLQWRWKH&$VXE¿HOGRIWKHKLSSRFDPSXVZKHUHWKH\WHUPLQDWHLQVWUXFWXUHVULFKLQV\QDSVHV
and interneurons. Several projections are also sent into the hilus. The precursors are located between 
the hilus and the granular zone, in a niche called the subgranular zone (SGZ). The SGZ provides a 
microenvironment that promotes neuronal development. This neurogenic niche includes precursors, 
immature neurons, glial and endothelial cells, microglia and some immune cells. The niche is 
surrounded by a basement membrane. Because of the important role of vascularization in this region, 
WKLVQLFKHLVDOVRFDOOHGDYDVFXODUQLFKH>@,QDOOFDVHVWKHQLFKHSURYLGHVDXQLTXHHQYLURQPHQWIRU
QHXURQDOGHYHORSPHQW6WXGLHVVXJJHVWWKDWDVWURF\WHVKDYHDORFDONH\UROHLQQHXURJHQHVLV,QYLYR
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the development of cells has a preferred spatial relationship with astrocytes. Ex vivo, astrocytes and 
astrocyte-derived factors are potent inducers of hippocampal neurogenesis for the precursors [18]. The 
6*=LVDOVRVSHFLDOEHFDXVHLWUHFHLYHVFRQQHFWLRQVIURPVHYHUDOEUDLQUHJLRQVGRSDPLQH¿EHUVLQWKH
ventral tegmental area, projections of serotonergic raphe nuclei, septum acetylcholine connections, 
and connections of GABAergic local interneurons. Manipulations of these neurotransmitter systems 
has also demonstrated regulatory effects on neurogenesis [19] [20]. The fact that these neurotransmitter 
systems regulate neurogenesis is of particular interest because antidepressants mainly act by changing 
monoamine levels [see later section entitled ANTIDEPRESSANTS AND ADULT HIPPOCAMPAL 
1(852*(1(6,6@$SURPLQHQWH[DPSOHLVWKDWPLFHGH¿FLHQWLQWKH6HURWRQLQ$UHFHSWRUGRQRW
VKRZDQHXURJHQLFUHVSRQVHWRFKURQLFÀXR[HWLQHWUHDWPHQW>@
CELLULAR STAGES OF HIPPOCAMPAL NEUROGENESIS
Neurogenesis can be divided into four phases: a step in which precursor cells are dividing, then 
surviving, a post mitotic maturation phase, and a late phase of survival. 
a. The stage of precursor cell
The precursors have properties reminiscent of glial cells, including the morphology of radial glia. The 
cell body is located in the subgranular zone and the dendrites extend into the molecular layer. The 
QDWXUHRIKLSSRFDPSDODVWURF\WHSUHFXUVRUVZDV¿UVWUHYHDOHGE\>@7\SHSUHFXUVRUFHOOV\LHOG
intermediate progenitor cells, or type-2 cells, with a high proliferation activity. A subset of these cells 
FRQWLQXH WRH[SUHVVJOLDOPDUNHUVEXW ODFN WKHPRUSKRORJLFDOFKDUDFWHULVWLFVRI UDGLDOFHOOV W\SH
D7KHW\SHFHOOVWKDWH[SUHVVQHVWLQ¿ODPHQWVVXFKDVFHOOW\SHDOVRH[SUHVVPDUNHUVVXFKDV
NEUROD1 and Prox1. This particular phenotype is used to classify cells as type-2b [16, 23]. Prox1 is 
VSHFL¿FWRWKHGHYHORSPHQWRIJUDQXOHFHOOV,QW\SHFHOOVWKHGHYHORSLQJFHOOVUHFHLYH*$%$HUJLF
innervation [24], and are more sensitive to GABAergic stimulation. Similarly, type-1 cells respond 
WRWKHVHVWLPXOLE\LQFUHDVLQJFHOOSUROLIHUDWLRQ>@$PRQJWKHHDUO\H[SUHVVHGQHXURQDOPDUNHUV
doublecortin (DCX) is expressed on the type-2b cells. The expression of DCX extends from the 
SUROLIHUDWLRQSKDVHWRSRVWPLWRWLFPDWXUDWLRQZKLFKODVWVDERXWZHHNV>@
b. The phase of survival
6RRQDIWHUWKHUHOHDVHRIWKHFHOOF\FOHQHZQHXURQVH[SUHVVPDUNHUVVXFK1HX1>³6SHFL¿FQHXURQDO
QXFOHDU SURWHLQ´@ DQG WKH WUDQVLHQW PDUNHU FDOUHWLQLQ >@ $ PDMRULW\ RI FHOOV IDLO WR HVWDEOLVK
connections with the molecular layer and die. In contrast, cells that establish stable connections 
GHYHORSDVWDEOHGHQGULWLFDUERUL]DWLRQWKDWH[WHQGVLQDVSHFL¿FZD\LQWLPH,QWKHGD\VIROORZLQJ
the exit of the cell cycle, new cells emanate their axons to their target region CA3 to form appropriate 
V\QDSVHV7KLVSHULRGLVPDUNHGE\WKHH[SUHVVLRQRIDSURWHLQPHGLDWRUVXFKDV72$'RU78&
LPSOLFDWHGLQD[RQJXLGDQFH7KH¿UVW*$%$HUJLFLQQHUYDWLRQVDUHH[FLWDWRU\DQGWKHQEHFRPH
inhibitory when glutamatergic connections are established [24]. The GABAergic action leads cells to 
mature into glutamatergic cells and to develop synaptic integration [28] Most regulatory elements and 
processes occur at the stage of neuronal development, and rarely during the expansion phase [27, 29] 
c. The maturation step; from early to late stage
'RXEOHFRUWLQLVH[SUHVVHGLQJUDQXOHFHOOVWKDWUDQJHIURPGD\WRDERXWZHHNVRIDJHZLWK
of its total population being proliferating neuroblasts and the rest being post-mitotic neurons [30]. 
$QRWKHUPDUNHURIPDWXUDWLRQFDOOHGFDOUHWLQLQLVDOVRXVHGDVDPDUNHUIRULPPDWXUH*&VDWWKHHDUO\
SRVWPLWRWLFVWDJH7KHSHULRGRIH[SUHVVLRQRIFDOUHWLQLQZHHNVLVFORVHO\OLQNHGWRGHQGULWLF
maturation. However, using a lentiviral approach expressing the Green Fluorescent protein, it has been 
shown that the axonal growth to CA3 precedes the development of dendritic arborization [14]. After 
full integration to existing circuits, the new cells move from the calcium-binding protein calretinin to 
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FDOELQGLQ>@,WLVVHYHUDOZHHNVEHIRUHWKHFHOOVDUHQRORQJHUGLVWLQJXLVKDEOHHOHFWURSK\VLRORJLFDOO\
from mature neurons of the granule cells [31]. It has been postulated that the time needed to complete 
the functionality of these young neurons is related to the formation and storage of new elements of 
PHPRU\>@)LQDOO\FDOELQGLQOLNH LPPXQRUHDFWLYLW\KDVEHHQGHVFULEHGDVDPDUNHUIRUPDWXUH
granule cells.
QUANTITATIVE ANALYSIS OF PROLIFERATION, SURVIVAL, MATURATION AND 
DIFFERENTIATION, NEWBORN CELLS.
For a full characterization of the neurogenic effects of new compounds, all the steps of neurogenesis, 
including proliferation, survival, maturation, and differentiation have to be completed. So far, 
QR VSHFL¿F DQG H[FOXVLYHPDUNHU KDV EHHQ LGHQWL¿HG WKDWZRXOG DOORZ IRU SURVSHFWLYH VWXGLHV RI
neurogenesis. As a result, detection of neurogenic steps depends on a combination of labeling 
DSSURDFKHV7KXV SUROLIHUDWLRQGLIIHUHQWLDWLRQ DQG VXUYLYDO VWHSV HDFK UHTXLUH D VSHFL¿FSURWRFRO
XVLQJ WKH DGPLQLVWUDWLRQ RI D V\QWKHWLF WK\PLGLQH DQDORJXH ³EURPR¶GHR[\XULGLQH´ %UG8
that substitutes for thymidine incorporation into DNA synthesized during the S phase of the cycle. 
Quantitative analysis of proliferation, differentiation, and survival of newborn cells is made by 
YDU\LQJWKHWLPHLQWHUYDOEHWZHHQWKHSXOVHDGPLQLVWUDWLRQRI%UG8DQGWKHVDFUL¿FHRIDQLPDOV>@
Main methods for a Detection of cell proliferation
)RU WKHTXDQWL¿FDWLRQRI UDWHRIFHOOGLYLVLRQDQLPDOVDUHDGPLQLVWHUHG%UG8>EHWZHHQ WR
PJNJ K EHIRUH VDFUL¿FH >@ 3UROLIHUDWLRQ LV TXDQWL¿HG E\ FRXQWLQJ %UG8SRVLWLYH FHOOV 7R
VLPSOLI\WKHH[SHULPHQWTXDQWL¿FDWLRQRI%UG8SRVLWLYHFOXVWHUVFDQDOVREHSHUIRUPHGWRPHDVXUH
proliferation since a positive correlation exists between BrdU-positive clusters and BrdU-positive 
FHOOV6LQFHWKHTXDQWL¿FDWLRQRI%UG8SRVLWLYHFOXVWHUVLVPXFKOHVVWLPHFRQVXPLQJWKDQFRXQWLQJ
BrdU-positive cells, this method can be used as a rapid indicator of the neurogenic effect of drugs 
or other manipulations [33]. This is important also because BrdU immunostaining has been used not 
only to test whether new drugs affect adult hippocampal neurogenesis, but also whether the anxiety/
GHSUHVVLYHOLNHVWDWHKDVEHHQUHODWHGWRFKDQJHVLQKLSSRFDPSDOQHXURJHQHVLV
Endogenous markers of cell proliferation
Endogenous cell cycle proteins are expressed at different stages of cell cycle progression. For exemple 
WKH³3UROLIHUDWLQJ&HOO1XFOHDU$QWLJHQ3&1$´LVH[SUHVVHGWKURXJKRXWWKHFHOOF\FOHDQGSURYLGH
ORZWHPSRUDOUHVROXWLRQ.LFORVHO\FRUUHVSRQGVWR%UG8DVLWLVH[SUHVVHGERWKGXULQJ6SKDVHDQG
WKURXJKWKHUHPDLQGHURIWKHFHOOF\FOH¿JXUH
Survival and fate of the newly generated cells
8VXDOO\IRUWKHTXDQWL¿FDWLRQRIUDWHRIFHOOVXUYLYDODQLPDOVDUHDGPLQLVWHUHG%UG8WRPJ
NJWZLFHDGD\GXULQJWKUHHGD\VWRZHHNVEHIRUHVDFUL¿FH>@7KHUHDVRQWRZDLWIRUVDFUL¿FH
LVWKDWWKHIDWHRIWKHQHZO\JHQHUDWHGFHOOVFDQRQO\EHGHWHUPLQHGWKUHHWRIRXUZHHNVODWHURQFH
neuronal migration has occurred [13, 36]. Once progenitor cells reach maturity they begin expressing 
QHXURQDOPDUNHUVVXFKDVQHXUR¿ODPHQWV1HX1DQG&DOFLXPELQGLQJSURWHLQVRUDVWURF\WHPDUNHUV
VXFKDVJOLDO¿EULOODU\DFLGLFSURWHLQ*)$3&DOFLXPELQGLQJSURWHLQVVXFKDVFDOELQGLQDUHSURGXFHG
ZKHQFHOOVEHFRPHHOHFWURSK\VLRORJLFDODFWLYH,WLVQRWXQWLOZHHNVDIWHUELUWKWKDWQHZO\JHQHUDWHG
JUDQXOHFHOOVKDYHDFTXLUHGWKHW\SLFDOIHDWXUHVRIPDWXUHJUDQXOHFHOOVDQGFHDVHWRH[SUHVVLPPDWXUH
QHXURQDOPDUNHUV
Markers of maturation
6HYHUDO PDUNHUV KDYH EHHQ XVHG WR DVVHVV PDWXUDWLRQ VXFK DV PLFURWXEXOHDVVRFLDWHG SURWHLQ
[doublecortin]. In the adult dentate gyrus, DCX is exclusively expressed in immature neurons [26, 
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@DQGWKXVKDVEHHQZLGHO\XVHGDVDQLPPDWXUHQHXURQDOPDUNHUWKDWUHOLDEO\UHÀHFWVWKHOHYHORI
neurogenesis and its modulation [26]. To assess the impact of antidepressants on dendritic maturation, 
the morphology of cells that express doublecortin (DCX) are examined. DCX-positive cells with 
tertiary dendrites, which display more complex dendritic arborization, can be distinguished from 
others DCX cells. The ratio of DCX-positive cells with tertiary dendrites over total DCX-positive cells 
is informative of the rate of maturation. The polysialylated form of the neural cell adhesion molecule 
36$1&$0DOVRKDVDWUDQVLHQWH[SUHVVLRQSDWWHUQWKDWPDUNVQHXURQDOSURJHQLWRUV+RZHYHULW
should be noted that, in contrary to DCX, PSA-NCAM has also been detected in glial cells.
METHODS USED TO ABLATE OR INCREASE NEUROGENESIS
The analysis of the causal relationship between neurogenesis and behavior came from the removal 
of progenitor cells. Several methods to date have been developed to reduce or abolish neurogenesis 
(table 1):
$Q;LUUDGLDWLRQRIHLWKHUWKHZKROHEUDLQRUORFDOO\LQWKHKLSSRFDPSXV>@
$V\VWHPLFWUHDWPHQWZLWKDQDQWLPLWRWLFDJHQWVXFKDVPHWK\OD]R[\PHWKDQRODFHWDWH
>0$0@>@
 %\ JHQHWLF PDQLSXODWLRQ VXFK DV *)$37. PLFH LQ ZKLFK WKH
GFAP + progenitor cells die following treatment with ganciclovir [39]. 
In a contrary experiment, Sahay and colleagues [40] developed a genetic gain-of-function strategy 
to inducibly augment the survival of adult-born neurons in a cell-autonomous manner [40]. Because 
60–80% of young adult-born neurons undergo programmed cell death, for which the pro-apoptotic 
JHQH%D[LVUHTXLUHGWKH\XVHGDWUDQVJHQLFPRXVHOLQHLQZKLFKWKHWDPR[LIHQ7$0UHJXODWDEOH
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Figure 1: 6FKHPDUHSUHVHQWLQJWKHHQGRJHQRXVRUH[RJHQRXVPDUNHUVXVHGWRVWXG\DGXOWQHXURJHQHVLV
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UHFRPELQDVH&UH(57LVH[SUHVVHGXQGHUWKHFRQWURORIDNLOREDVHIUDJPHQWRIWKHUDWQHVWLQ
1HVJHQHSURPRWHU>@WRJHWKHUZLWKDÀR[HG%D[PRXVHOLQHWRDEODWH%D[VHOHFWLYHO\LQQHXUDO
stem cells in the adult brain and promote survival.
HIPPOCAMPAL NEUROGENESIS AND MAJOR DEPRESSION AND ITS TREATMENT
THE ANXIETY / DEPRESSION STATE AND HIPPOCAMPAL NEUROGENESIS
The neurogenic hypothesis of depression postulates that decreased production of new granule cells 
LQ WKH GHQWDWH J\UXV RI WKH KLSSRFDPSXV LV OLQNHG WR WKH SDWKRSK\VLRORJ\ RI GHSUHVVLRQ DQG WKDW
WKH LQFUHDVH LQ KLSSRFDPSDO QHXURJHQHVLV LV UHTXLUHG IRU WKH EHKDYLRUDO HIIHFWV RI DQWLGHSUHVVDQW
treatment [42]. The few studies of hippocampal neurogenesis in depressed patients published to date 
have mainly relied on histological examinations of post-mortem brain tissue and studies of magnetic 
resonance imaging. Thus, a reduction in hippocampal volume in depressed patients is somewhat 
HVWDEOLVKHG DQG WKH FRQWULEXWLRQ RI WZR PHWDDQDO\VLV FRQ¿UPHG WKLV UHGXFWLRQ LQ KLSSRFDPSDO
YROXPHLQSDWLHQWVZLWKGHSUHVVLRQ>@7KHIUHTXHQF\RIGHSUHVVLYHHSLVRGHVDQGWKHSHULRGGXULQJ
which they are not treated coincide with the severity of the decline in hippocampal volume. However, 
pathophysiological studies on post-mortem brain tissue indicates that the change in the number of 
neuropil and glial cells may be responsible for reducing the volume of the hippocampus [44]. It is 
KLJKO\XQOLNHO\WKDWORVVRIKLSSRFDPSDOQHXURJHQHVLVFDQDFFRXQWIRUWKHGHFUHDVHGYROXPH7KHVH
imaging results, involving hippocampal neurogenesis in the pathophysiology of major depressive 
episodes, have been challenged by a recent histology study [45]. This study did not actually detect the 
GLIIHUHQFHLQVWHPFHOOSUROLIHUDWLRQ>E\.L@LQWKHKLSSRFDPSXVEHWZHHQSDWLHQWVZLWKGHSUHVVLRQ
and healthy volunteers. The results of this study are limited, however, since the patients were on 
DQWLGHSUHVVDQWPHGLFDWLRQDWWKHWLPHRIGHDWKZKLFKFRXOGPDVNWKHVSHFL¿FHIIHFWVRIGHSUHVVLRQ
on cell proliferation. In addition, in the absence of toxicology studies, it is not clear that the patients 
REVHUYHG WUHDWPHQW0RUHRYHU JLYHQ WKH GLYHUVLW\ LQ WKH VWDJHV RI QHXURJHQHVLV LW LV GLI¿FXOW WR
conclude any involvement of neurogenesis after only observation of cell proliferation. In contrast, 
DPRUH UHFHQW VWXG\ DFWXDOO\ VKRZHG D GHFUHDVH LQ SUROLIHUDWLRQ >E\.L@ LQ SDWLHQWVZLWK
GHSUHVVLRQWKDQLQFRQWUROV>@>@+RZHYHUWKLVGLIIHUHQFHGLGQRWUHDFKVWDWLVWLFDOVLJQL¿FDQFH
3UHFOLQLFDOVWXGLHVDUHXVHIXOWRSURYHFDXVDOOLQNVEHWZHHQKLSSRFDPSDOQHXURJHQHVLVDQGEHKDYLRU
8VLQJ H[SRVXUH WR GLIIHUHQW W\SHV RI VWUHVV OLNH FKURQLF VWUHVV RU VRFLDO VXEPLVVLRQ FDXVHV D
Table 1: Methods used to ablate or increase neurogenesis
Pharmacological 
manipulation Cranial Irradiation Genetic manipulation
ÀXRURXUDFLO>)X@ 
 methylazoxymethanol [MAM], 
 temozolomide [TMZ]
cytosine arabinoside [Ara-C]
X-irradiation, gamma-rays
*)$37.1HVWLQ7.
1HVWLQ%D[7UN%lox/lox-Cre ERT2 
Cyclin D2 transgenic
[38] [96] [115] [21, 39, 52, 69, 73, 97, 116-118] >@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GHFUHDVHLQFHOOSUROLIHUDWLRQLQWKHKLSSRFDPSXV,WLVLPSRUWDQWWRNHHSLQPLQGWKHGLVDGYDQWDJHV
RI WKHVHPHWKRGV VXFK DV QRQVSHFL¿F HIIHFWV RI DEODWLRQ WKDW FDQ LQYROYH VWUXFWXUHV RWKHU WKDQ
the hippocampus, and therefore other functions. Dysfunction of hippocampal neurogenesis is only 
hypothesized to be part of the pathogenesis of major depressive disorders [48], [23]. In reality, the 
VXSSUHVVLRQRIKLSSRFDPSDOQHXURJHQHVLVLQPLFHGRHVQRWDOWHUDQ[LHW\EHKDYLRULQWKHRSHQ¿HOGRU
WKHOLJKWGDUNSDUDGLJPVWKHHOHYDWHGSOXVPD]HRUQRYHOW\VXSSUHVVHGIHHGLQJ>@>@>@7KXV
the X-irradiation in the hippocampus has no effect in the previously mentioned paradigms, suggesting 
WKDW WKH ORVVRIKLSSRFDPSDOQHXURJHQHVLV LVQRWVXI¿FLHQW IRUDEHKDYLRUDOSKHQRW\SHRIDQ[LHW\
depression, and does not exacerbate those induced by stress. Similarly, ablation of neurogenesis by 
0$0DSKDUPDFRORJLFDODJHQWLVQRWVXI¿FLHQWWRLQGXFHDQDQKHGRQLFEHKDYLRULQUDWV>@$LUDQ
HWDO>@H[SORUHGLQPRUHGHWDLOWKHOLQNEHWZHHQGHSUHVVLRQDQGKLSSRFDPSDOQHXURJHQHVLV,WLV
clear from their study that chronic stress in rats is not associated with a decrease in neurogenesis, and 
WKDW WKHUHPRYDORIQHXURJHQHVLVGRHVQRW LQGXFHDGHSUHVVLYHOLNHEHKDYLRU>@+RZHYHURWKHU
studies suggest that the mechanisms are more complex. Recently it was shown that adult hippocampal 
neurogenesis plays an important role in the regulation of affective states [51]. Indeed, transgenic mice 
WKDWRYHUH[SUHVVWKHSURWHLQ%D[LQDSRSWRWLFSURJHQLWRUFHOOVDQGWKXVKDYHDGH¿FLWLQQHXURJHQHVLV
have an anxiety phenotype. In sum, there is evidence indicating that neurogenesis is not a major factor 
in the development of depression, but may be necessary for the behavioral effects of antidepressants 
[2].
ANTIDEPRESSANTS AND ADULT HIPPOCAMPAL NEUROGENESIS
IN PHYSIOLOGICAL CONDITIONS.
To study the effects of antidepressants in unstressed animals, the choice of the strain is essential. It 
should be noted that 129SvEv mice express a low basal level of proliferating cells in the SGZ, and 
therefore are more relevant to study an induced increase in antidepressant treatment in conditions 
without stress than BALB / cJ or C57Bl / 6 mice, which express a higher cell proliferation [52]. 
Instead, the study of the impact of stress on hippocampal neurogenesis is more relevant in these last 
two strains.
(IIHFWVRIDQWLGHSUHVVDQWVRQWKHSUROLIHUDWLRQDQGFHOOVXUYLYDO,QDGGLWLRQWRWKHHIIHFWVRIÀXR[HWLQH
>PJNJ@LQLQFUHDVLQJFHOOSUROLIHUDWLRQLQ6Y(Y7$FPLFH>@>WDEOH@LWDOVRLQFUHDVHVWKH
survival of postmitotic granule cells. These effects of SSRIs on proliferation and cell survival were 
also found in rats [53, 54]. It is important to note that the neurogenic effects of antidepressants are 
only seen with chronic treatment [21, 49, 54-56]. In addition, other treatments such as the atypical 
antidepressant tianeptine, electroconvulsive therapy, mood stabilizers such as lithium, and new 
antidepressants such as agomelatine, increase proliferation and cell survival in the adult hippocampus 
[57]. Furthermore, agomelatine selectively alters neurogenesis in the ventral hippocampus, a region 
more involved in the emotional response [58]. Therefore, it seems that proliferation and survival 
are regulated by distinct mechanisms. For example, an enriched environment increases the survival 
of immature cells without affecting proliferation [59]. In contrast, voluntary exercise increases the 
proliferation and survival, without affecting the maturation [30] or dendritic morphology of newborn 
QHXURQV>@)LQDOO\DUHFHQWVWXG\VKRZHGWKDWÀXR[HWLQHWDUJHWVDFODVVRIQHXUDOSURJHQLWRUFHOOV
by directly increasing symmetric divisions [53]. Effects of antidepressants on the maturation. Until 
recently, it was not clear that SSRIs also targeted immature neurons by affecting their maturation 
DQG IXQFWLRQDO LQWHJUDWLRQ WR WKHQHWZRUN:DQJDQGFROOHDJXHV >@GHPRQVWUDWHG WKDWFKURQLF
WUHDWPHQWZLWKÀXR[HWLQHVWLPXODWHVPDWXUDWLRQRI\RXQJQHXURQV>@,QGHHGWKH\KDYHDGHQGULWLF
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Legend : ÏLQFUHDVHÐGHFUHDVH QRFKDQJHø, not study
Antidepressant Specie
Dose (mg/
kg)
Length of 
Treatment
Prolif. Diff. Survival References
Fluoxetine
S p r a g u e 
Dawley Rat
5
25 days = ø = (120)
21 days Ï ø ø
(121)
7 days = ø ø
1 day = ø ø
(54) 
5 days = ø ø
14 days Ï ø ø
28 days Ï ø ø
0.6 28 days Ï ø ø (122)
Wistar Rat 10 28 days Ï Ï ø (123)
Lister Rat 7 14 days Ï Ï ø (124)
 (BALB/c * 
DBA/2) mice
10
21 days Ï ø ø
(125)10 days Ï ø ø
5 days = ø ø
S129 SvEv 
mice
? ? Ï (126)
10
5 days = ø ø
(21)11 days Ï ø ø
28 days Ï ø Ï
18
5 days = = =
(56)
28 days Ï Ï Ï
129Sl mice 18 21 days Ï ø ø
(127)
A/J mice 18 21 days = ø ø
BALB/cJ mice
18 28 days = = ø (52)
10 28 days = = = (68)
16 24 days = = =
(128)
C57BL/6 mice 16 24 days = = =
CD1 mice 10 28 days Ï = Ï (129)
DBA/2 mice 18 21 days Ï ø ø
(127)
SWR/J mice 18 21 days = ø ø
Agomelatine Wistar Rat 40
21 days Ï Ð Ï
(57)
7 days = ø ø
1 day = ø ø
AMPA Rodents ? ? Ï ø ø (130)
Glutamatergic antagonist Rodents ? ? Ï ø ø (131)
,QWHUOHXNLQHEHWDUHFHSWRU
antagonist
Rodents ? ? Ï ø ø (132)
Citalopram Wistar Rat 10 28 days = = = (133)
ECT Wistar Rat
1 fois par 
jour
5 days Ï Ï ø (134)
Table 2: Effects of chronic antidepressant treatment on hippocampal neurogenesis in rodents
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Antidepressant Species
Dose (mg/
kg)
Length of 
Treatment
Prolif. Diff. Survival References
Fluoxéeine/adolescent
BALB/cJ mice 16 24 days Ï = =
(128)
C57BL/6 mice 16 24 days Ï Ï Ï
Imipramine
Wistar Rat 5 56 days Ï ø ø (135)
 (BALB/c * 
DBA/2) mice
30 21 days Ï ø Ï (125)
129 SvEv mice 20 28 days Ï ø Ï (21)
Lithium
Wistar Rat 2,5 14 days Ï Ï Ï (136)
C57BL/6 mice JNJ 28 days Ï = Ï (137)
Olanzapine
S p r a g u e 
Dawley Rat
2 21 days Ï ø ø
(121) 
2 7 days = ø ø
Reboxétine
Rat Sprague 
Dawley
20 (2/day) 21 days Ï ø ø (54)
Riluzole Rodents ? ? Ï ø ø (138)
Rolipram 129 SvEv mice ? ? Ï ø (139)
Tesofensine Wistar Rat
3 5 days = ø =
(140)
3 14 days Ï ø Ï
Tianeptine Tree Shrews 50 28 days = ø ø (141)
Tranylcypromine
S p r a g u e 
Dawley Rat
7.5, then 
10 (14 last 
days)
21 days Ï ø ø (142)
Venlafaxine Wistar Rat
10 14 days = ø ø
(143) 
40 Ï ø ø
Legend : ÏLQFUHDVHÐGHFUHDVH QRFKDQJHø, not study
arborization more complex than those present in untreated animals, suggesting an accelerating effect 
RIÀXR[HWLQHRQKLSSRFDPSDOQHXURQDOPDWXUDWLRQ>@7KHGXUDWLRQRIRQVHWRIÀXR[HWLQHHIIHFWVRQ
PDWXUDWLRQDOVRFRLQFLGHVZLWKWKHWLPHUHTXLUHGIRUWKHRQVHWRIEHKDYLRUDOHIIHFWVRIWKLVWUHDWPHQW
in mice. Similarly, electroconvulsive therapy (ECT), which provides a very rapid therapeutic 
HIIHFW VWLPXODWHV QHXURJHQHVLV IDVWHU WKDQ ÀXR[HWLQH >@ ,Q DGGLWLRQ (&7 VWLPXODWHV GHQGULWLF
development and maturation [62]. After ECT, young neurons express an increase in dendritic growth, 
and begin to receive glutamatergic synaptic connections early. These results suggest that molecules 
that increase the maturation of new neurons are targets for the development of future treatments. 
a. Effects of antidepressants on the differentiation
)RXUZHHNV DIWHU ELUWK SURJHQLWRU FHOOV DFTXLUH SURSHUWLHV RIPDWXUH JUDQXOH FHOOV )RU H[DPSOH
WKHQHZFHOOVQRORQJHUH[SUHVVWKHLPPDWXUHQHXURQDOPDUNHUV'&;RU36$1&$0DQGUHFHLYH
the same GABAergic and glutamatergic afferents as mature granule cells of the dentate gyrus 
[14, 63, 64]. However, these new cells continue to mature morphologically and physiologically. 
7KH GHQGULWLF VSLQHV RI D QHXURQ DW IRXU ZHHNV ROG DUH PRUH DVVRFLDWHG ZLWK PXOWLSOH V\QDSWLF
ERXWRQV WKDW ROGHU QHXURQV DQG WKH GHQVLW\ FRQWLQXHV WR LQFUHDVH HYHQ DIWHU  ZHHNV >@ ,Q
DGGLWLRQ QHXURQV DJHG WRZHHNV H[KLELW DQ LQFUHDVH LQ H[FLWDELOLW\ DQG D ORZHU WKUHVKROG IRU
LQGXFWLRQ RI ORQJWHUP SRWHQWLDWLRQ >/73@ ZKLOH DW  WR  ZHHNV QHZ QHXURQV H[KLELW JUHDWHU
/73 DPSOLWXGH >@ ,Q DGGLWLRQ D VSHFL¿F IRUP RI /73 >$&6)/73@ UHTXLUHV WKH KLSSRFDPSDO
QHXURJHQHVLVDVWKLVIRUPRI/73LVEORFNHGDIWHUDEODWLRQRIQHXURJHQHVLV>@7KLVFULWLFDOSHULRG
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in young neurons coincides with the development of receptor expression of NMDA NR2B [28]. 
At any given time following differentiation, young neurons can be found across stages of development 
and with distinct morphological and physiological characteristics. Similar to new neurons in the 
developing brain, the newborn granule cells depolarize in response to GABA because of their high 
LQWUDFHOOXODUFRQFHQWUDWLRQRIFKORULGH LRQV >@6RPHZKHUHEHWZHHQ WRZHHNVDIWHUELUWK WKH
response to GABA changes from depolarization to hyperpolarization as the young cells develop their 
GHQGULWLFVSLQHVDQGUHFHLYHJOXWDPDWHUJLFFRQQHFWLRQV,QDGGLWLRQQHZJUDQXOHFHOOVEHJLQWRPDNH
connections with the hilus and CA3 region while synaptic complexity is similar to that of mature 
neurons [67].
b. Dependent and independent neurogenic effects in the action of antidepressants
Recently Boldrini and colleagues [2009] suggested that future studies in humans should determine 
at which level antidepressants should affect neurogenesis to maximize the response [46]. Preclinical 
studies in rodents, using approaches that override functional neurogenesis, are used to establish 
the relationship between neuronal activity and the contribution of hippocampal neurogenesis in 
the behavioral effects of antidepressants in animals that are either stressed or not. The study by 
6DQWDUHOOLDQGFROOHDJXHV>@KDVUDLVHGPDQ\TXHVWLRQVDERXWWKHFRQWULEXWLRQRIKLSSRFDPSDO
neurogenesis in the behavioral improvement induced by antidepressants, unstressed mice [21]. 
From this study it was shown that the behavioral effect of SSRIs is dependent on the presence of 
hippocampal neurogenesis [56]. However, in BALB / cJ mice, abolishing neurogenesis by x-ray 
GRHVQRWEORFNWKHEHKDYLRUDOUHVSRQVHLQGXFHGE\665,VLQGLIIHUHQWEHKDYLRUDOSDUDGLJPVUHODWHG
WRDQ[LHW\GHSUHVVLRQHVSHFLDOO\WKH16)>@)XUWKHUPRUHFKURQLFWUHDWPHQWZLWKÀXR[HWLQHGLG
QRWLQFUHDVHKLSSRFDPSDOQHXURJHQHVLV>@/LNHZLVHWKHEHQH¿FLDOFRQWULEXWLRQVRIDQHQULFKHG
environment, physical exercise, or learning behavior related to anxiety appear to be independent of 
increased neurogenesis in adult mice [69]. 
To examine whether the increase induced by antidepressant treatment may simply be an epiphenomenon, 
the study of animal models of anxiety / depression in which hippocampal neurogenesis is reduced 
appears to be a good alternative. 
ANIMAL MODELS OF DEPRESSIVE PHENOTYPES
6LQFHQRJHQHWLFYDULDQWVZLWKKLJKSHQHWUDQFHWKDWFDXVHGHSUHVVLRQDUHNQRZQDQLPDOPRGHOVKDYH
mainly relied on different means of chronically exposing rodents to stressful experiences, or sensory 
WUDFWOHVLRQVVXFKDVLQROIDFWRU\EXOEHFWRP\WRLQGXFHEHKDYLRUDOVWDWHVWKDWSUHVHQWGHSUHVVLRQOLNH
signs and are responsive to chronic antidepressant treatment.
7KHROGHVWPRVWFRPPRQO\XVHGSDUDGLJPWR LQGXFHDGHSUHVVLRQOLNHVWDWH LVFKURQLFPLOGVWUHVV
(CMS). Initial observations suggested that animals subjected to multiple stressors over a prolonged 
SHULRGRIWLPHUHGXFHGWKHLULQWDNHRIVDFFKDULQHRUVXFURVHDSRWHQWLDOEHKDYLRUDOPRGHORIDQKHGRQLD
[70]. Furthermore, this effect was selectively reversed by chronic treatment with the TCA imipramine 
>@)XUWKHUZRUNZDVDEOHWRUHSHDWWKLVUHVXOWXVLQJPRUHPLOGVWUHVVRUVVXFKDVSHULRGVRIIRRG
and water deprivation, small temperature reductions and changes of cage mates [71, 72]. Following 
WKHVHVWXGLHVWKH&06SURFHGXUHDQGPRGL¿HGYHUVLRQVVXFKDVFKURQLFXQSUHGLFWDEOHVWUHVV&86
RU8&06EHFDPHFRPPRQO\XVHGDQGPXFKZRUNGHPRQVWUDWHGWKDWRWKHUGHSUHVVLRQOLNHFKDQJHV
were induced in animals, such as decreased sexual and aggressive behavior, decreased self-care, and 
altered sleep patterns [71]. Furthermore these behaviors are all reversible by chronic, but not acute, 
treatment using multiple classes of antidepressants [73]. While historically potential pitfalls of the 
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&06SURFHGXUHDUHWKDWLWLVQRWRULRXVO\ODERULQWHQVLYHDQGWKDWWKHUHKDVEHHQVRPHGLI¿FXOW\LQ
JHWWLQJ WKH SURFHGXUH HVWDEOLVKHG DQG WKH UHVXOWV UHSOLFDWHG DFURVV ODERUDWRULHV >@ WKHPRGL¿HG
versions of the CMS have proven more useful.
Recently, there have been some reports using CMS or variants to model treatment resistance in 
URGHQWV,QRQHVWXG\&06VLJQL¿FDQWO\GHFUHDVHGVXFURVHFRQVXPSWLRQDQGWKHSUROLIHUDWLRQRIDGXOW
hippocampal neural progenitors [75]. Following chronic treatment with a SSRI (escitalopram), the 
subjects were retested for sucrose consumption. A bimodal distribution was found where one group 
recovered [increased sucrose consumption] while another refracted treatment [no increase in sucrose 
consumption]. Interestingly, there was a correlation between the animals in the group that recovered 
with a reversal of the decreased proliferation that was absent in the group resistant to treatment 
>@0RUHUHFHQWO\IROORZXSZRUNKDVWDNHQDSURWHRPLFDSSURDFKLQDQDWWHPSWWR¿QGPROHFXODU
differences in the ventral hippocampus between responders and non-responders [76]. Another study 
demonstrated that if animals are on a high fat diet during multiple UCMS procedures they become 
UHVLVWDQWWRWUHDWPHQWZLWKD665,ÀXR[HWLQH>@
A distinct procedure that has gained traction is the usage of a social defeat model. In this paradigm 
a mouse is forced into the territory of a mouse from a larger, more aggressive strain leading to an 
interaction resulting in intruder subordination. Repeated defeats over 10 days can result in a long 
lasting reduced social interaction, sexual dysfunction, sleep dysregulation, anxiety, metabolic 
GH¿FLWV DQG DQKHGRQLD >@ ,QWHUHVWLQJO\ IROORZLQJ WKH VRFLDO GHIHDW SURFHGXUH WKHUH UHPDLQV
a large variance in behavior outcomes in spite of using an inbred mouse strain (C57BL/6). Some 
animals display a resistance to social defeat (resilience) while others are susceptible (determined by 
interaction with a social target relative to an empty enclosure). If animals are separated based on this 
PHDVXUH VXVFHSWLEOHPLFHGHPRQVWUDWHGHFUHDVHG VXFURVH LQWDNH DEOXQWHGFLUFDGLDQ UK\WKPDQG
conditioned place preference to cocaine [80]. Furthermore, phenotypes induced by social defeat in 
susceptible mice can be reversed by antidepressant treatment [79]. Given that molecular mechanisms 
IRUUHVLOLHQFHWRWKHVWUHVVIXOSURFHGXUHDUHQRZEHLQJZRUNHGRXW>@LWZRXOGEHLQWULJXLQJWR
see if similar pathways are necessary for mediating response to antidepressants.
$ WKLUG SURFHGXUH IRU LQGXFLQJ D GHSUHVVLRQOLNH VWDWH LQ DQLPDOV LV DGPLQLVWUDWLRQ RI FKURQLF
JOXFRFRUWLFRLGVLQRUGHUWRPLPLFWKHHIIHFWVRIFKURQLFVWUHVV$VLJQL¿FDQWSURSRUWLRQRIGHSUHVVHG
patients display altered activity of the HPA axis, and stress generally leads to hypersecretion of 
FRUWLFRVWHURLGVZKLFKLPSRVHVDQLQFUHDVHGULVNIRUGHSUHVVLRQ>@&KURQLFWUHDWPHQW
RIURGHQWVZLWKFRUWLFRVWHURQHHIIHFWLYHO\LQGXFHVPXOWLSOHDQ[LHW\DQGGHSUHVVLRQOLNHFKDQJHVLQ
behavior, neurochemistry and brain morphology [89-92]. Behaviorally, depression-related changes 
LQFOXGHVXSSUHVVLRQRIVXFURVHLQWDNHDQGGHFUHDVHGVHOIFDUH>@ZKLOHDQ[LHW\UHODWHGFKDQJHV
LQFOXGHLQFUHDVHGODWHQF\WRHPHUJHLQWRWKHOLJKWFRPSDUWPHQWLQWKHOLJKWGDUNWHVWGHFUHDVHGWLPH
HQWULHVDQGSHUFHQWGLVWDQFHLQWKHFHQWHURIDQRSHQ¿HOGDQGLQFUHDVHGODWHQF\WRWDNHDELWHRIIRRG
in the novelty suppressed feeding (NSF) test [90, 91].
ADULT HIPPOCAMPAL NEUROGENESIS IN PATHOLOGICAL CONDITIONS
2QHRIWKHPDLQ¿QGLQJVRIWKHUROHRIDGXOWKLSSRFDPSDOQHXURJHQHVLVLQGHSUHVVLRQLVWKHREVHUYDWLRQ
that antidepressants confer behavioral effects by stimulating neurogenesis in rodents and humans. A 
UHFHQW VWXG\ VKRZHG IRU WKH¿UVW WLPH LQ WKHGHQWDWHJ\UXV LQKXPDQV WKDW WKHUH DUHPRUHQHVWLQ
expressing progenitor cells, and increased dividing cells after treatment with an SSRI antidepressant 
VHUWUDOLQHÀXR[HWLQHRUWULF\FOLFQRUWULSW\OLQHFORPLSUDPLQHLQSDWLHQWVZLWKGHSUHVVLRQFRPSDUHG
to untreated patients [46]. Another study also showed that antidepressants increase human hippocampal 
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neurogenesis by activating the glucocortiocoid receptor [94]. In nonhuman primates, repeated 
separation stress UHVXOWHGLQGHSUHVVLRQOLNHEHKDYLRUV>DQKHGRQLDDQGVXERUGLQDQFH@DFFRPSDQLHG
E\ UHGXFHGKLSSRFDPSDO QHXURJHQHVLV >@7UHDWPHQW RI WKH QRQKXPDQSULPDWHVZLWKÀXR[HWLQH
VWLPXODWHG QHXURJHQHVLV DQG SUHYHQWHG WKH HPHUJHQFH RI GHSUHVVLRQOLNH EHKDYLRUV )XUWKHUPRUH
ablation of neurogenesis with irradiation of the nonhuman primates abolished the therapeutic effects 
RIÀXR[HWLQH
To address whether altered neurogenesis is important for the treatment of depression, Deisseroth’s group 
XVHGYROWDJHVHQVLWLYHG\HLPDJLQJWRSUREHKLSSRFDPSDODFWLYLW\LQWKH&06LQ5DWDQGVSHFL¿FDOO\
the role of neurogenesis in depression-relevant neurophysiology and behavior [50]. Using irradiation 
WRDEODWHQHXURJHQHVLV$LUDQDQGFROOHDJXHVDOVR IRXQG WKDWDQWLGHSUHVVDQWEHKDYLRUDOHI¿FDF\ LQ
WKH )RUFHG 6ZLP7HVW LQ5DW UHTXLUHG LQWDFW QHXURJHQHVLV2YHUDOO DQWLGHSUHVVDQW WUHDWPHQWZDV
VXI¿FLHQWWRWUDQVLHQWO\LQFUHDVHQHXURJHQHVLVDQGH[HUWEHKDYLRUDOHIIHFWVORQJDIWHUGUXJFOHDUDQFH
IURPWKHV\VWHPDQGWKLVHIIHFWZDVDEVHQWLQDQLPDOVODFNLQJQHXURJHQHVLV;5D\5HFHQWO\DQ
HOHJDQWVWXG\LQ5DWFRQ¿UPHG'HLVVHURWK¶VVWXG\E\VKRZLQJWKDWDQWLGHSUHVVDQWVUHWDLQVRPHEXW
QRWDOO WKHLU WKHUDSHXWLFHI¿FDF\ LQ UHGXFLQJPHDVXUHG LQGLFHVRIDQ[LHW\GHSUHVVLRQOLNHEHKDYLRU
ZKHQKLSSRFDPSDOQHXURJHQHVLVZDVEORFNHGE\DF\WRVWDWLFDJHQW>@,QGHHGXVLQJ&06DQGWKH
antimitotic agent MAM, authors showed that the various antidepressants ameliorated CMS-induced 
behavioral signs of depression to the same extent in vehicle and MAM-treated animals. Conversely, 
XVLQJWKH16)SDUDGLJPWKH\IRXQGWKDWWKHDQWLGHSUHVVDQWGUXJVVWXGLHGLPLSUDPLQHÀXR[HWLQH
UHGXFHGWKHK\SHUDQ[LRXVVWDWHREVHUYHGLQ&06H[SRVHGUDWVHYHQWKRXJKQHXURJHQHLVZDVEORFNHG
Overall, authors concluded that antidepressants re-established neuronal plasticity in hippocampus.  In 
WKH³&257PRGHO´XVLQJ;LUUDGLDWHGPLFHLQZKLFKKLSSRFDPSDOQHXURJHQHVLVZDVDEROLVKHGZH
GHPRQVWUDWHG WKDW DQWLGHSUHVVDQW WUHDWPHQW VWLOO HOLFLWV VRPH DQ[LRO\WLFDQWLGHSUHVVDQWOLNH HIIHFWV
6SHFL¿FDOO\ ZH IRXQG WKDW DQWLGHSUHVVDQW HIIHFWV LQ WKH 2SHQ )LHOG DQG )RUFHG 6ZLP7HVW ZHUH
neurogenesis independent, while effects in the Novelty Suppressed Feeding Test or on coat state 
ZHUHQHXURJHQHVLVGHSHQGHQW$VVXFKRXUVWXG\UHYHDOVWKDWWKHEHKDYLRUDOHIIHFWVRIÀXR[HWLQHDUH
mediated through both neurogenesis-dependent and -independent actions [97]. Previously, Surget 
and colleagues [73] presented important evidence for both neurogenesis-dependent and -independent 
PHFKDQLVPVIRUWKHUHYHUVDORIVWUHVVLQGXFHGEHKDYLRUVE\DQWLGHSUHVVDQWGUXJVLQFOXGLQJÀXR[HWLQH
[73]. Our paper, using a different model of stress, extends this study by utilizing a mechanistic 
approach to propose a neurogenesis-independent pathways for mediating the effects of SSRIs, namely 
WKHȕDUUHVWLQVLJQDOLQJSDWKZD\
ADULT HIPPOCAMPAL NEUROGENESIS IN DIFFERENT GENDERS
7DNLQJLQWRFRQVLGHUDWLRQWKDWGHSUHVVLRQLVWZLFHDVFRPPRQLQZRPHQDVLQPHQLWLVLPSRUWDQW
to also consider sex differences in the effects of depression models and antidepressants on adult 
neurogenesis. In 05/0S-PLFHWUHDWHGZLWKÀXR[HWLQHPJNJELGIRUGD\VFHOOSUROLIHUDWLRQ
was increased in both genders, but females produced more new cells than males [95]. Furthermore, 
ZKLOHÀXR[HWLQHGLGQRWDOWHUVXUYLYDOLQPDOHVPJNJUHGXFHGVXUYLYDOLQIHPDOHV$QRWKHUVWXG\
showed that while acute stress reduced cell proliferation in males, it did not affect proliferation in the 
IHPDOHKLSSRFDPSXV>@5HSHDWHGWUDLQLQJZLWKFRQWUROODEOHVWUHVVGLGQRWLQÀXHQFHSUROLIHUDWLRQ
LQ IHPDOHVDQGXQGHUDOOFRQGLWLRQVPDOHVZHUHPRUH OLNHO\ WKDQ IHPDOHV WRH[SUHVVKHOSOHVVQHVV
behavior. This was true even for males that were not previously stressed. Another study also showed 
WKDWIHPDOHUDWVOHDUQWUDFHPHPRULHVEHWWHUWKDQPDOHUDWVDQGFRQVHTXHQWO\UHWDLQDJUHDWHUSURSRUWLRQ
of new neurons in their hippocampi [99]. Therefore, it is critical to also consider gender when planning 
experiments to study adult neurogenesis.
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POTENTIAL MECHANISMS UNDERLYING THE REQUIREMENT OF NEUROGENESIS 
IN MEDIATING THE ANTIDEPRESSANT RESPONSE
:KLOHPXFKZRUNKDVEHHQGRQHWKDWKDVODLGDIRXQGDWLRQIRUWKHXQGHUVWDQGLQJRIKRZDQWLGHSUHVVDQWV
LQFUHDVHQHXURJHQHVLVPXFKOHVVLVNQRZQDERXWZK\WKHLQFUHDVHLQQHXURJHQHVLVLVUHTXLUHGIRUWKH
DQWLGHSUHVVDQWUHVSRQVH>@2QHOLNHO\PHFKDQLVPZRXOGEHQHJDWLYHIHHGEDFNUHJXODWLRQRIWKH+3$
axis and the stress response. Consistent with this hypothesis, recent studies demonstrated that in mice 
with ablation of neurogenesis there was an increased HPA axis response to an acute stress [100, 101]. 
Since stimulation of the subiculum, CA3 or DG can yield an inhibitory effect on the HPA axis [102, 
103] through well-described circuitry [103-105], it is possible that young neurons may contribute 
WRKLSSRFDPSDOGHSHQGHQWQHJDWLYHIHHGEDFNRIWKH+3$D[LV2QHUHFHQWVWXG\HYHQVXJJHVWVWKDW
chronic stress severely impairs HPA axis activity and the ability of the hippocampus to modulate 
downstream brain areas involved in the stress response [73]. Chronic antidepressant treatment can 
restore the relationship between the hippocampus and the HPA axis, but only in the presence of an 
intact neurogenic niche. Another study also demonstrates that adult-born hippocampal neurons are 
UHTXLUHGIRUQRUPDOH[SUHVVLRQRIWKHHQGRFULQHDQGEHKDYLRUDOFRPSRQHQWVRIWKHVWUHVVUHVSRQVH
[106]. Future studies will need to use genetic methods to more directly determine if young neurons 
LPSDFWWKHQHJDWLYHIHHGEDFNFLUFXLWWRWKH+3$D[LV
Another hypothesis, which is not mutually exclusive, that has gained traction is whether neurogenesis in 
different areas of the SGZ play distinct roles in the regulation of mood. Due to participation in different 
circuitry, it has been suggested that the dorsal and ventral hippocampus may be distinct structures [58]. 
In the hippocampus, the dorsal dentate gyrus receives inputs from lateral and caudomedial entorhinal 
cortex and medially located cells of the medial septal nucleus [107]. Outputs of the dorsal hippocampus 
are to the mammillary complex, dorsal lateral septum and lateral entorhinal cortex. In contrast ventral 
dentate gyrus receives inputs from the rostromedial entorhinal cortex and laterally located cells of 
the medial septal nucleus while ventral hippocampus outputs are to the prefrontal cortex, amygdala, 
nucleus accumbens, hypothalamus, medial entorhinal cortex, bed nucleus of stria terminalis and rostral 
and ventral lateral septum [108]. This different circuitry may suggest that the dorsal hippocampus is 
more important for learning and memory while the ventral hippocampus is more involved in emotion 
>@6RPHOHVLRQVWXGLHVKDYHVXSSRUWHGWKLVK\SRWKHVLV>@%DVHGRQWKLVZRUNLWKDV
been proposed that neurogenesis along the dorsal-ventral axis may also play distinct roles in learning 
and mood [108]. In this idea, the main effect of neurogenesis in the antidepressant response would be 
RQFLUFXLWU\WKURXJKYHQWUDOVWUXFWXUHV*HQHWLFPRGHOVDQGDEODWLRQWHFKQLTXHVWKDWDUHUHVWULFWHGWR
dorsal or ventral SGZ need to be developed in order to test this hypothesis.
0XFKZRUNKDVEHHQGRQHWRDGYDQFHWKHXQGHUVWDQGLQJRIWKHV\QDSWLFDQGSK\VLRORJLFDOSURSHUWLHV
RIWKH\RXQJQHXURQVDQGWKHVHXQLTXHSURSHUWLHVDOORZIRUGLVWLQJXLVKLQJ\RXQJQHXURQVIURPWKHLU
mature granule neuron counterparts [111, 112]. Of particular relevance to antidepressant treatment is 
DIRUPRIORQJWHUPSRWHQWLDWLRQGHULYHGIURPDZHDNVWLPXODWLRQSDUDGLJPLQWKHDEVHQFHRI*$%$
EORFNHUV>$&6)/73@ WKDW LVVHQVLWLYH WRPDQLSXODWLRQV WKDWEORFNKLSSRFDPSDOQHXURJHQHVLV>
@$IWHUFKURQLFEXWQRWDFXWHÀXR[HWLQHWUHDWPHQW$&6)/73LVHQKDQFHGLQVKDPDQLPDOVDQG
FRPSOHWHO\ EORFNHG LQ DQLPDOV VXEMHFWHG WR;LUUDGLDWLRQ >@ VXJJHVWLQJ DQ HIIHFW RI ÀXR[HWLQH
on the electrophysiological properties of young neurons that have integrated into the hippocampal 
circuitry. 
5HODWLYHO\OLWWOHZRUNKDVDGGUHVVHGWKHIXQFWLRQRI\RXQJQHXURQVLQDQLQWDFWKLSSRFDPSDOFLUFXLWLQ
YLYR,QKLSSRFDPSDOVOLFHZRUNLWKDVEHHQGHPRQVWUDWHGWKDWÀXR[HWLQHWUHDWPHQWHQKDQFHVDFWLYLW\
RIWKHGHQWDWHJ\UXVUHODWLYHWR&$LQDQHXURJHQHVLVGHSHQGHQWPDQQHU>@VXJJHVWLQJDQHWZRUN
effect of the young neurons. Furthermore, one very recent study used multiple methods to ablate adult 
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neurogenesis in vivo and assessed hippocampal activity [113]. In anesthetized mice after X-irradiation 
RU WK\PLGLQH NLQDVH PHGLDWHG SKDUPDFRJHQHWLF DEODWLRQ SHUIRUDQWSDWK HYRNHG UHVSRQVHV ZHUH
UHGXFHG LQPDJQLWXGH ,QVWULNLQJFRQWUDVW WKHUHZDVDQ LQFUHDVH LQ WKHDPSOLWXGHRIVSRQWDQHRXV
JDPPDIUHTXHQF\ EXUVWV LQ WKH GHQWDWH J\UXV DQG KLOXV DV ZHOO DV LQFUHDVHG V\QFKURQL]DWLRQ RI
GHQWDWHQHXURQ¿ULQJWRWKHVHEXUVWV7KLVVWULNLQJUHVXOWPD\VXJJHVWWKDWWKH\RXQJQHXURQVFDQVHUYH
to modulate activity in the much larger population of mature granule cells rather than acting solely 
as independent encoding units [113]. One could imagine that antidepressant treatment may modulate 
hippocampal circuitry by enhancing this effect of the young neurons on the mature granule neurons, 
but this possibility remains to be tested.
REVISITING THE NEUROGENESIS HYPOTHESIS OF DEPRESSION
The neurogenesis hypothesis of depression postulated that a decrease in the production of newborn 
granule cells in the dentate gyrus is related to the pathophysiology of depression while enhanced 
KLSSRFDPSDOQHXURJHQHVLVLVUHTXLUHGIRUWKHEHQH¿FLDOHIIHFWVRIDQWLGHSUHVVDQWWUHDWPHQW:LWKIHZ
H[FHSWLRQV>@ LQPRVWVWXGLHVDEODWLRQRIKLSSRFDPSDOQHXURJHQHVLVDORQH LVQRWVXI¿FLHQW
to induce a phenotype reminiscent of either anxiety or depression [14, 21, 39, 50, 52, 69, 73, 107]. 
,W LVDOVRXQOLNHO\ WKDWGHFUHDVHGQHXURJHQHVLVFRXOGDFFRXQW IRU WKHYROXPHWULFGHFUHDVHVVHHQ LQ
the hippocampus of depressed patients, as X-irradiation of mouse hippocampus does not yield a 
VLJQL¿FDQWUHGXFWLRQ>@:KHWKHUVSHFL¿FPDQLSXODWLRQVWKDWLQFUHDVHKLSSRFDPSDOQHXURJHQHVLV
DORQHUHVXOWLQD³QRQGHSUHVVHG´SKHQRW\SHUHPDLQVWREHWHVWHG+RZHYHUHYLGHQFHLVVWURQJWKDW
QHXURJHQHVLVLVUHTXLUHGIRUDWOHDVWVRPHRIWKHEHQH¿FLDOHIIHFWVRIDQWLGHSUHVVDQWWUHDWPHQW,WZLOO
EHFULWLFDOIRUIXWXUHZRUNWRGHWHUPLQHKRZWKHDGGLWLRQRIQHZXQLWVWRWKHGHQWDWHLVLQYROYHGLQ
mediating the effects of antidepressants.
,WZLOODOVREHFULWLFDOIRUIXWXUHZRUNWRYDOLGDWHWKHLPSRUWDQFHRIDQWLGHSUHVVDQWLQGXFHGQHXURJHQHVLV
LQWUDQVODWLRQDOVWXGLHVLQKXPDQV,WZLOOEHLPSRUWDQWWRWHVWLIELRPDUNHUVVXFKDV&%9DQG056
are increased in patients treated with antidepressants. Furthermore, it may be interesting to correlate 
UDWHVRIQHXURJHQHVLVDVPHDVXUHGE\WKHVHELRPDUNHUVZLWKLPSURYHPHQWRIGHSUHVVLYHVLJQVDQG
symptoms.
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L’Article 2 ci-dessous intitulé «Neurogenèse hippocampique adulte: Un acteur dans 
l'action antidépresseur" revisite le rôle de la neurogenèse hippocampique adulte dans des 
modèles animaux physiopathologiques de troubles de l'humeur.  
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Summary  Depression  and  anxiety  are  psychiatric  illnesses  that  are  major  burdens  in  society
and  affect  as  much  as  7%  of  the  world’s  population.  The  heterogeneous  nature  of  depres-
sion  suggests  an  involvement  of  multiple  distinct  brain  regions  including  amygdala,  prefrontal
cortex  and  the  hippocampus,  which  may  be  responsible  for  the  diversity  of  the  symptoms.
Besides  its  critical  role  in  learning  and  memory,  the  hippocampus  is  one  of  only  two  areas
in  mammalian  brain  where  adult  neurogenesis  occurs.  Of  the  current  leading  hypotheses  of
the  pathophysiology  and  treatment  of  depression,  the  neurogenesis  hypothesis  of  depression
deserves  particular  attention  because  changes  in  neurogenesis  are  only  seen  after  chronic,  but
not  acute,  antidepressant  treatment.  This  review  revisits  the  role  of  adult  hippocampal  neu-
rogenesis  in  the  pathophysiology  of  mood  disorders,  especially  anxiety/depression,  and  also  in
the  antidepressant-like  responses,  especially  in  stressed  rodents.
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Résumé  La  dépression  et  l’anxiété  sont  des  maladies  psychiatriques  qui  touchent  plus  de
7  %  de  la  population  mondiale.  Le  caractère  hétérogène  de  la  dépression  suggère  une  impli-
cation  de  plusieurs  régions  cérébrales  distinctes  dans  la  physiopathologie  (comme  l’amygdale,
le  cortex  préfrontral  ou  hippocampe),  qui  peuvent  être  responsables  de  symptômes  divers.
En  plus  de  son  rôle  essentiel  dans  l’apprentissage  et  la  mémoire,  l’hippocampe  est  l’une  des
deux  seules  régions  du  cerveau  des  mammifères  où  se  produit  la  neurogenèse  adulte.  Parmi
les  principales  hypothèses  actuelles  concernant  la  physiopathologie  et  le  traitement  de  la
dépression,  l’hypothèse  neurogénique  mérite  une  attention  particulière  en  raison  des  change-
ments  observés  uniquement  après  un  traitement  chronique  par  antidépresseur,  et  non  pas  après
l’administration  d’une  dose  unique.  Cette  revue  revient  sur  le  rôle  à  proprement  parlé  de  la
neurogenèse  hippocampique  adulte  dans  la  physiopathologie  des  troubles  de  l’humeur,  notam-
ment  l’anxiété/la  dépression,  mais  aussi  dans  les  réponses  antidépressives  à  travers  des  études
précliniques  effectuées  chez  le  rongeur  soumis  à  un  stress  chronique.
© 2013  Publié  par  Elsevier  Masson  SAS.
Introduction
Depressive  and  anxiety  disorders  are  a  major  burden  in
society. Mood  disorders  affect  7%  of  the  world’s  popula-
tion, while  severe  forms  of  depression  impact  2—5%  of  the
US population  [1—3].  Furthermore,  approximately  32—35
million adults  in  the  US  population  (16%)  experience  an
episode of  major  depression  in  their  lifetime  [1].  In  Europe,
a meta-analysis  based  on  27  eligible  studies  including  over
150,000 subjects  from  16  European  countries  estimated  the
prevalence of  depression  between  3  to  10%  during  the  last
12 months  [4].  The  heterogeneous  nature  of  depression  sug-
gests an  involvement  of  multiple  distinct  brain  regions,
which may  be  responsible  for  the  diverse  symptoms.  Human
imaging and  post-mortem  studies  of  the  brain  have  sup-
ported this  hypothesis,  implicating  brain  areas  including  the
prefrontal and  cingulate  cortex,  hippocampus,  ventral  stri-
atum,  amygdala,  and  thalamus  [5].  Together,  these  brain
regions operate  a  series  of  highly  interacting  circuits  that
forms a  neural  circuitry  involved  in  depression  [6].  The  hip-
pocampus is  one  of  several  limbic  structures  that  have  been
extensively studied  in  individuals  with  psychiatric  and  neu-
rologic disorders  in  the  last  decade  [6,7].  Besides  its  critical
role in  learning  and  memory,  the  hippocampus  is  one  of  the
only two  areas  in  mammalian  brain  where  adult  neurogene-
sis occurs  [7].  Adult  hippocampal  neurogenesis  is  therefore
defined as  the  progression  from  neural  stem  cell  to  mature
dentate granule  neuron.
To  fully  understand  the  pathophysiology  and  treatment
of depression,  it  is  essential  to  delineate  molecular,  cellu-
lar and  circuit-level  changes  in  depressive  state  and  also
after chronic  antidepressant  treatment.  Of  the  current
leading hypotheses  of  the  pathophysiology  and  treatment
of depression,  the  neurogenesis  hypothesis  of  depression
deserves particular  attention  because  changes  in  neu-
rogenesis are  only  seen  after  chronic,  but  not  acute,
antidepressant treatment.  This  review  revisits  the  role  of
adult hippocampal  neurogenesis  in  the  pathophysiology  of
mood disorders,  especially  anxiety/depression,  and  also  in
the antidepressant-like  responses  measured  especially  in
stressed rodents.
Hippocampal neurogenesis
Neurogenesis  refers  to  the  production  of  new  neurons  in
the brain.  Originally,  it  was  only  described  during  develop-
ment of  the  central  nervous  system.  Ramon  y  Cajal  (1913)
stated that  the  adult  brain  was  unable  to  generate  new
neurons. This  dogma  was  first  questioned  by  Altman  in
the 1960s,  who  revealed  the  genesis  of  new  cells  in  the
brain of  adult  rat  and  cat  by  autoradiography  with  triti-
ated thymidine  [8].  Unfortunately,  it  was  uncertain  whether
the new  cells  were  actually  neuronal  cells.  Many  years
later, a  combination  of  specific  neuronal  markers  with  an
analogue of  thyminidine,  5-bromo-2′-deoxy-uridine  (BrdU),
confirmed the  neuronal  phenotype  [9].  The  process  of  adult
neurogenesis is  located  in  two  discrete  brain  regions:  the
subventricular zone  (SVZ)  and  subgranular  zone  (SGZ)  of
dentate gyrus  of  the  hippocampus.  In  this  review,  only  the
hippocampal neurogenesis  and  its  involvement  in  depression
will be  presented.
Production of new neurons in the subgranular
zone  of the dentate gyrus
Hippocampal  neurogenesis  is  possible  in  the  SGZ  of  the  den-
tate gyrus  of  the  hippocampus  because  of  the  presence  of
stem cells.  These  stem  cells  evolve  into  neural  progenitor
cells that  can  produce  multiple  cell  types  in  the  central
nervous system  such  as  neurons,  astrocytes,  oligodendro-
cytes, or  microglial  cells.  In  rodents,  the  duration  of  the
mitotic cycle  of  proliferating  precursors  is  approximately
12 to  24  hours,  leading  to  the  production  of  about  8000  to
10,000 new  neurons  per  day  [10].  Given  that  the  dentate
gyrus consists  of  approximately  one  million  granule  cells,
this phenomenon  is  capable  of  generating  a little  less  than
1% of  total  granule  cells  each  day.  However,  the  proportion
of new  neurons  that  survive  beyond  1  month  is  less  than  50%,
and the  production  of  new  cells  is  offset  by  the  daily  loss  of
mature granule  cells.  The  surviving  cells  have  predominantly
a neuronal  phenotype  (75%),  mainly  glutamatergic  granule
cells, while  very  few  are  GABAergic  interneuron  basket  cells.
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Brain-derived neurotrophic factor (BDNF),
depression  and adult hippocampal
neurogenesis
Neurotrophins,  including  brain-derived  neurotrophic  factor
(BDNF), nerve  growth  factor  (NGF),  neurotrophin-3  (NT-3)
and neurotrophin-4/5  (NT-4/5),  are  important  regulators  of
neuronal activity,  influencing  a  plethora  of  events  such  as
neuronal differentiation,  maintenance,  survival,  and  synap-
tic plasticity  throughout  life.  BDNF,  a  secretory  glycoprotein
of the  neurotrophin  family,  is  widely  expressed  in  the  adult
central nervous  system  [11].  Like  other  neurotrophins,  BDNF
is  synthesized  and  released  in  an  activity-dependent  man-
ner. Studies  have  shown  lower  BDNF  levels  in  post-mortem
hippocampus of  depressed  patients,  but  higher  levels  in
patients who  are  taking  antidepressants  at  the  time  of  death
[12]. Stronger  evidence  for  a  causal  role  of  hippocampal
BDNF in  the  action  of  antidepressants  comes  from  animal
studies [13].  Direct  infusion  of  BDNF  into  the  dentate  gyrus
of the  hippocampus  exerted  potent  antidepressant  effects
in rodents.  Furthermore,  animal  studies  indicated  that
stress and  chronic  antidepressant  treatments  have  oppos-
ing actions  on  hippocampal  BDNF  levels  [13].  Specifically,
antidepressants increase  hippocampal  BDNF  mRNA  levels,
and this  increase  is  dependent  upon  chronic  treatment,
which is  consistent  with  the  delayed  onset  of  the  ther-
apeutic effects  of  antidepressants.  Conversely,  numerous
studies have  shown  that  different  forms  of  stress  decrease
hippocampal BDNF  mRNA  levels  [13].  Given  the  key  role
of BDNF/TrkB  in  mood  regulation  and  the  mechanism  of
action of  antidepressants  as  reviewed  earlier,  a  number  of
studies have  investigated  the  role  of  BDNF/TrkB  signaling
in hippocampal  neurogenesis.  Experimental  conditions  that
induce BDNF  expression,  such  as  physical  exercise,  enriched
environment, and  chronic  antidepressant  treatment,  also
increase hippocampal  neurogenesis  [14].  The  survival  of
newborn cells  is  decreased  in  both  BDNF  ±  mice  and  TrkB.
dominant-negative mice.  In  addition,  enriched  environ-
ment failed  to  increase  the  survival  of  newborn  cells  in
BDNF ±  mice  [15].  These  results  suggest  a  role  for  BDNF/TrkB
signaling in  the  survival  of  newborn  hippocampal  neurons.
In contrast,  there  have  been  mixed  results  on  the  role  of
BDNF/TrkB signaling  on  hippocampal  cell  proliferation.
Hippocampal neurogenesis and major
depression
Revisiting the neurogenesis hypothesis of
depression
The  neurogenic  hypothesis  of  depression  postulates  that
decreased production  of  new  granule  cells  in  the  dentate
gyrus of  the  hippocampus  is  linked  to  the  pathophysio-
logy of  depression  and  that  the  increase  in  hippocampal
neurogenesis is  required  for  the  behavioral  effects  of  antide-
pressant treatment  [16,17].  The  few  studies  of  hippocampal
neurogenesis in  depressed  patients  published  to  date  have
mainly relied  on  histological  examinations  of  post-mortem
brain tissue  [18,19].  The  main  findings  in  one  of  these
post-mortem studies  are  that  antidepressant  treatment
results  in  an  increase  in  the  number  of  neural  progeni-
tors in  the  anterior  dentate  gyrus  [18,20].  This  was  not
observed in  another  study  but  these  authors  did  not  examine
specifically the  anterior  hippocampus  [19].  In  both  stud-
ies there  was  no  difference  between  control  and  untreated
depression. A  reduction  in  hippocampal  volume  in  depressed
patients is  somewhat  established,  and  two  meta-analyses
confirmed this  reduction  in  hippocampal  volume  in  patients
with depression  using  magnetic  resonance  imaging  [21].  The
length  of  depressive  episodes  coincides  with  the  severity
of the  decline  in  hippocampal  volume.  However,  patho-
physiological studies  on  post-mortem  brain  tissue  indicate
that changes  in  the  neuropil,  a  possible  consequence  of
a decrease  in  connectivity,  and  glial  cells  may  be  respon-
sible for  reducing  the  volume  of  the  hippocampus  [22].
However, it  is  unlikely  that  such  change  in  hippocam-
pal volume  will  be  difficult  to  determine  according  to
the ratio  between  numbers  of  neuron  provided  by  neu-
rogenesis according  to  the  total  number  of  hippocampal
neurons.
Preclinical studies  in  rodents,  using  approaches  that
manipulate neurogenesis,  are  used  to  establish  the  relation-
ship between  hippocampal  neurogenesis  and  the  behavioral
effects of  antidepressants  in  animals  that  are  either
stressed or  not.  Several  methods  to  date  have  been
developed to  reduce  or  increase  neurogenesis  in  rodents
(Table 1):
• an X-irradiation  of  either  the  whole  brain  or  locally  in  the
hippocampus  [16,23,24];
• asystemic treatment  with  an  anti-mitotic  agent  such  as
methylazoxymethanol  acetate  (MAM)  [25];
• a genetic  manipulation,  such  as  GFAP-TK  mice,  in
which  the  glial  fibrillary  acidic  protein  (GFAP)-positive
progenitor cells  die  following  treatment  with  gan-
ciclovir [23,26]  or  the  inducible  over-expression  of
pro-apoptotic  gene  Bax  specifically  in  neural  precursors
[27].
The suppression  of  hippocampal  neurogenesis  in  mice
does not  alter  anxiety  behavior  in  the  open  field  or  the
light/dark paradigms,  the  elevated  plus  maze,  or  novelty
suppressed feeding  tests  [16,23].  Thus,  except  one  study
[28], the  X-irradiation  in  the  hippocampus  has  no  effect  in
the previously  mentioned  paradigms  suggesting  that  the  loss
of hippocampal  neurogenesis  is  not  sufficient  to  induce  a
behavioral phenotype  of  anxiety/depression  in  mice,  and
does not  exacerbate  those  induced  by  stress.  Similarly,  abla-
tion of  neurogenesis  by  a subchronic  treatment  with  the
toxin MAM,  is  not  sufficient  to  induce  an  anhedonic  behavior
in rats  [25].
Sahay et  al.  [29]  developed  a  genetic  gain  of  function
strategy to  inducibly  augment  the  survival  of  adult-born  neu-
rons in  a  cell-autonomous  manner  [29].  Because  60—80%  of
young adult-born  neurons  undergo  programmed  cell  death,
for which  the  pro-apoptotic  gene  Bax  is  required,  they
used a  transgenic  mouse  line  in  which  the  tamoxifen  (TAM)-
regulatable recombinase  CreERT2  is  expressed  under  the
control of  a  5.26-kilobase  fragment  of  the  rat  nestin  (Nes)
gene promoter  [30]  together  with  a  floxed  Bax  mouse
line to  ablate  Bax  selectively  in  neural  stem  cells  in  the
adult brain  and  promote  survival  of  these  cells.  Using  this
strategy, increasing  adult  hippocampal  neurogenesis  alone
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Table  1  Methods  used  to  ablate  or  increase  neurogenesis.
Méthodes permettant la manipulation de la neurogenèse.
Pharmacological
manipulation
Cranial irradiation  Genetic  manipulation
5-fluorouracil  (5-Fu),
methylazoxymethanol
(MAM),
temozolomide  (TMZ),
cytosine arabinoside
(Ara-C)
X-irradiation,
gamma-rays
GFAP-TK, Nestin-TK,
Nestin-Bax,
Nestin Cre ERT2-Bax,
TrkBlox/lox-Cre ERT2 Cyclin  D2
transgenic
[23,25,35,36]  [16,23,24,37]  [26,27,29]
does  not  produce  an  anxiolytic  or  antidepressant-like
response.  However,  it  is  important  to  note  that  this  induction
of neurogenesis  was  performed  in  ‘‘non-stressed  animals’’.
Further studies  will  be  necessary  to  assess  whether  genetic
strategies designed  to  specifically  increase  adult  hippocam-
pal neurogenesis  are  sufficient  to  reverse  the  effects  of
chronic stress.
In sum,  there  is  evidence  indicating  that  a  decreased
neurogenesis is  not  a  major  factor  in  the  development
of depression,  but  that  an  increase  in  neurogenesis  may
be necessary  for  the  behavioral  effects  of  antidepressants
[3].
Antidepressant and adult hippocampal
neurogenesis  in pathological conditions
Animal models of depressive phenotypes
Since  no  genetic  variants  with  high  penetrance  that  cause
depression are  known,  animal  models  have  mainly  relied  on
different means  of  chronically  exposing  rodents  to  stressful
experiences, or  sensory  tract  lesions  such  as  in  olfac-
tory bulbectomy,  to  induce  behavioral  states  that  present
depression-like symptoms  and  are  responsive  to  chronic
antidepressant treatment.
A  recent  procedure  for  inducing  a  depression-like
state in  animals  is  chronic  glucocorticoid  administra-
tion in  order  to  mimic  the  effects  of  chronic  stress.
A significant  proportion  of  depressed  patients  display
altered activity  of  the  hypothalamic-pituitary-adrenal
(HPA)  axis,  and  stress  generally  leads  to  hypersecre-
tion of  corticosteroids,  which  imposes  an  increased  risk
for depression  [31].  Chronic  treatment  of  rodents  with
corticosterone effectively  induces  multiple  anxiety-  and
depression-like changes  in  behavior,  neurochemistry  and
brain morphology  [24,32,33].  Behaviorally,  depression-
related changes  include  suppression  of  sucrose  intake  and
decreased self-care  [33],  while  anxiety-related  changes
include:
• increased latency  to  emerge  into  the  light  compartment
in  the  light/dark  test;
• decreased time,  entries  and  percent  distance  in  the  cen-
ter  of  an  open  field;
• increased latency  to  take  a  bite  of  food  in  the  novelty
suppressed  feeding  (NSF)  test.
Adult hippocampal neurogenesis in
pathological  conditions
Using  a  model  based  on  the  exogenous  elevation  of  gluco-
corticoids (named  the  ‘‘CORT-model’’),  a  reduction  in  the
proliferation of  progenitor  cells  after  chronic  corticosterone
treatment was  observed,  demonstrating  a  role  for  gluco-
corticoids in  the  regulation  of  the  proliferation  stage  of
the neurogenic  process  [18].  The  effects  of  corticosterone
on neurogenesis  are  limited  to  the  proliferation  stage  and
do not  involve  the  survival  or  maturation  of  newborn  neu-
rons. Interestingly,  the  effects  of  fluoxetine  on  all  stages  of
neurogenesis (proliferation,  differentiation,  maturation  and
survival) were  more  pronounced  in  corticosterone-treated
mice than  in  controls.  It  is  possible  that  our  model  of
corticosterone-induced  stress  may  increase  the  dynamic
range in  which  fluoxetine  exerts  its  effects  on  different
stages of  adult  hippocampal  neurogenesis  [24].
Agomelatine  is  an  antidepressant  drug  that  has  a
different mechanism  of  action  from  currently  avail-
able antidepressants  (melatonergic  agonist  and  5-HT2  C
antagonist  properties).  Thus,  we  assessed  its  effects  on  neu-
rogenesis in  the  ‘‘CORT-model’’  of  anxiety/depression  [34].
Similarly to  fluoxetine,  chronic  administration  of  agome-
latine reversed  the  decrease  in  cell  proliferation  in  the
hippocampus without  any  discrimination  between  the  dorsal
and the  ventral  hippocampus  (Table  2).
Neurogenesis-dependent and independent
effects  of antidepressants
The  most  compelling  evidence  to  link  adult  hippocampal
neurogenesis with  antidepressants  comes  from  our  labora-
tory, in  a  study  demonstrating  that  neurogenesis  is  necessary
for the  effects  of  imipramine,  a  tricyclic  antidepressant,
and fluoxetine,  a  selective  serotonin  reuptake  inhibitor,  in
two mouse  behavioral  screens  for  antidepressant  activity
[16]. To  address  whether  altered  neurogenesis  is  impor-
tant for  the  treatment  of  depression,  Deisseroth’s  group
used voltage  sensitive  dye  imaging  to  probe  hippocampal
activity in  the  Chronic  Mild  Stress  in  Rat.  They  specifi-
cally studied  the  role  of  neurogenesis  in  depression-relevant
neurophysiology  and  behavior  [35].  Using  irradiation  to
ablate neurogenesis,  Airan  et  al.  also  found  that  antide-
pressant behavioral  efficacy  in  the  Forced  Swim  Test  in  Rat
required intact  hippocampal  neurogenesis.  Overall,  antide-
pressant treatment  was  sufficient  to  transiently  increase
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Table  2  Behavioral  and  neurogenic  effects  of  various  chronic  antidepressant  treatments  in  the  ‘‘CORT’’-model  in  mice.
Effets comportementaux et neurogéniques de différents traitements chroniques par antidépresseurs dans le modèle « CORT » chez la
souris.
Drugs  Pharmacological
target
Phenotype  Neurogenic  effects  References
Fluoxetine  Serotonin  reuptake
inhibitors
Reversed
anxiogenic/depressive-like
phenotype
No effect  on  the  flattened
circadian rhythm  induced  by
chronic corticosterone
Reversed the  decrease
in cell  proliferation
induced  by  chronic
corticosterone
Increased all  steps  of
adult hippocampal
neurogenesis
For all  neurogenic
parameters  in  the
hippocampus:  effects
more pronounced  in
corticosterone-treated
mice
[24,34]
Imipramine  Tricyclics  Reversed
anxiogenic/depressive-like
phenotype
Not  tested  [24]
Reboxetine  Norepinephrin
reuptake  inhibitors
Reversed
anxiogenic/depressive-like
phenotype
Not tested  [24]
Agomelatine  MT1/MT2  agonist
and 5-HT2  C
antagonist
Reversed
anxiogenic/depressive-like
phenotype
Reversed  the  flattened
circadian rhythm  induced  by
chronic corticosterone
Reversed the  decrease
in cell  proliferation
induced  by  chronic
corticosterone
Reversed
(ventral effects  for
maturation)
[34]
neurogenesis  and  exert  behavioral  effects  long  after  drug
clearance from  the  system.  This  effect  was  absent  in  animals
lacking neurogenesis  (X-ray).  Recently,  an  elegant  study  in
rat showed  that  antidepressants  retain  some,  but  not  all,  of
their therapeutic  efficacy  in  reducing  indices  of  anxiety  but
not  depression-like  behavior  when  hippocampal  neurogen-
esis was  blocked  by  a  cytostatic  agent  [36].  Indeed,  using
chronic mild  stress  (CMS)  and  the  anti-mitotic  agent  MAM,
authors showed  that  various  antidepressants  ameliorated
CMS-induced behavioral  signs  of  depression  to  the  same
extent in  vehicle  and  MAM-treated  animals.  Conversely,
using the  NSF  paradigm,  they  found  that  the  antidepressant
drugs studied  (imipramine,  fluoxetine)  reduced  the  hyper-
anxious state  observed  in  CMS-exposed  rats  even  though
neurogenesis was  blocked.  Overall,  authors  concluded  that
antidepressants re-established  neuronal  plasticity  in  the
hippocampus [36].  In  the  ‘‘CORT-model’’,  using  X-irradiated
mice, in  which  hippocampal  neurogenesis  was  abolished,
we demonstrated  that  antidepressant  treatment  still  elic-
its some  anxiolytic/antidepressant-like  effects.  Specifically,
we found  that  antidepressant  effects  in  the  Open  Field
and Forced  Swim  Test  were  neurogenesis  independent,
while effects  in  the  Novelty  Suppressed  Feeding  Test
or  on  coat  state  were  neurogenesis-dependent.  As  such,
our study  revealed  that  the  behavioral  effects  of  fluox-
etine are  mediated  through  both  neurogenesis-dependent
and -independent  actions  [24].  Previously,  Surget  et  al.
[37] presented  important  evidence  for  both  neurogenesis-
dependent and  -independent  mechanisms  for  the  reversal  of
stress-induced behaviors  by  antidepressant  drugs,  including
fluoxetine [37].
Potential mechanisms underlying the
requirement  of neurogenesis in mediating
the  antidepressant response
Despite  all  the  work  done  that  has  laid  a foundation  for  the
understanding of  how  antidepressants  increase  adult  hip-
pocampal neurogenesis,  much  less  is  known  about  why  the
increase in  neurogenesis  is  required  for  the  antidepressant
response [3].  One  likely  mechanism  would  be  negative  feed-
back regulation  of  the  HPA  axis  and  the  stress  response.  It  is
possible that  young  neurons  may  contribute  to  hippocampal-
dependent negative  feedback  of  the  HPA  axis.  One  recent
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study  suggests  that  chronic  stress  severely  impairs  HPA  axis
activity and  the  ability  of  the  hippocampus  to  modulate
downstream brain  areas  involved  in  the  stress  response  [37].
Chronic antidepressant  treatment  can  restore  the  relation-
ship between  the  hippocampus  and  the  HPA  axis,  but  only  in
the presence  of  an  intact  neurogenic  niche.  Another  study
also demonstrates  that  adult-born  hippocampal  neurons  are
required for  normal  expression  of  the  endocrine  and  behav-
ioral components  of  the  stress  response  [38].  Future  studies
will need  to  use  genetic  methods  to  determine  more  directly
if young  neurons  impact  the  negative  feedback  circuit  to  the
HPA axis.
Another hypothesis,  which  is  not  mutually  exclusive,  that
has gained  attraction  is  whether  neurogenesis  in  different
areas of  the  SGZ  play  distinct  roles  in  the  regulation  of  mood.
Due to  participation  in  different  circuitries,  it  has  been  sug-
gested that  the  dorsal  and  ventral  hippocampus  may  have
distinct roles  [39,40].  In  the  hippocampus  of  Rodents,  the
dorsal dentate  gyrus  receives  inputs  from  lateral  and  cau-
domedial entorhinal  cortex  and  medially  located  cells  of  the
medial septal  nucleus  [41].  Outputs  of  the  dorsal  hippocam-
pus are  to  the  mammillary  complex,  dorsal  lateral  septum
and lateral  entorhinal  cortex.  In  contrast,  ventral  dentate
gyrus receives  inputs  from  the  rostromedial  entorhinal  cor-
tex and  laterally  located  cells  of  the  medial  septal  nucleus,
while ventral  hippocampus  outputs  are  to  the  prefrontal  cor-
tex, amygdala,  nucleus  accumbens,  hypothalamus,  medial
entorhinal cortex,  bed  nucleus  of  stria  terminalis  and  rostral
and ventral  lateral  septum  [42].  These  different  anatomical
circuitries suggest  that  the  dorsal  hippocampus  is  a  more
important brain  area  for  learning  and  memory,  while  the
ventral hippocampus  is  more  involved  in  emotion  [39,42].  In
this idea,  the  main  effect  of  neurogenesis  in  the  antide-
pressant response  would  be  on  circuitry  through  ventral
structures. Genetic  models  and  ablation  techniques  that  are
restricted to  dorsal  or  ventral  SGZ  need  to  be  developed  in
order to  test  for  this  hypothesis.
Conclusions
The  neurogenic  hypothesis  of  mood  disorders  remains
promising for  conceptualizing  depression  mechanisms,
which may  lead  to  novel  avenues  for  treatments  of  these
psychiatric diseases  [43].  Clinically,  we  need  more  informa-
tion on  the  level  and  regulation  of  human  adult  hippocampal
neurogenesis. Interestingly,  neurogenesis  decreases  with
age in  humans  and  animals  (Gould,  1999),  whereas
depression prevalence  increases  with  age.  As  recently
suggested by  Eisch  et  al.,  more  research  is  warranted
to examine  to  what  extent  the  age-induced  increase  in
depression is  due  to  life  experience,  age-induced  increase
in medical  burden,  or  possibly  age-induced  decrease
in neurogenesis  [4,5,12,25].  Also,  in  vivo  imaging  of
correlates of  human  neurogenesis  is  difficult,  and  greater
technical advances  are  needed  before  we  can  conclude  what
aspects of  neurogenesis  structure  and  function  are  shared
between humans  and  laboratory  animals,  and  modulated  by
stress or  antidepressants.  Thus,  it  will  be  important  to  test
if potential  biomarkers  (such  as  cerebral  blood  volume  and
magnetic resonance  spectroscopy)  [44,45]  are  increased  in
patients treated  with  antidepressants.  Furthermore,  it  will
be  interesting  to  correlate  rates  of  neurogenesis  as  mea-
sured by  these  biomarkers  with  improvement  in  depressive
symptoms.
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67 
4-­‐	   Le	   récepteur	   5-­‐HT4	   et	   son	   implication	  
dans	  la	  dépression	  
The current classification of serotonin receptors reveals multiple subtypes (Filip and 
Bader, 2009; Fink, and Gothert, 2007). Apart from the 5-HT3 receptor which is a ligand-gated 
cation channel, all the other 5-HT receptors  are metabotropic receptors coupled to G proteins 
and containing a predicted seven-transmembrane domain structure. The different subtypes of 
serotonin receptors can be divided in seven families: 5-HT1 (1A, 1B, 1D , 1E, 1F) 5-HT2 (2A, 
2B, 2C), 5-HT3 (3A , 3B, 3C, 3D; 3E), 5-HT4 , 5- HT5 (5A, 5B) , 5-HT6 and 5-HT7 (Figur 4).  
 
 
 
 
 
 
 
 
Figure 4 : Classification of 5-HT receptor (adapted from Hoyer et al., 2002).  
The classification shows the different subtypes or 5-HT receptor and their coupling. 
 
The 5-ht5 receptor is at present not yet functionally identified and its physiological role 
remains to be defined; thus, it can only be provisionally classified retaining its lower case 
appellation (Hannon and Hoyer, 2008) 
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The present study is focused on the 5-HT4 receptor subtype. The 5-HT4 receptor is one of 
14 serotonin receptors in the mammalian nervous system (Barnes and Sharp, 1999). Along 
with 5-HT6 and 5-HT7 receptors, these metabotropic receptors are positively coupled to 
adenylyl cyclase, and thus stimulate the production of the second messenger cAMP (Gerald et 
al., 1995).  
I. Généralités	  
The 5-HT4 receptor was originally identified by its pharmacology that was unique 
among the serotonin receptor subtypes known at the time. Specifically, in the late 1980’s 
there was speculation about a novel 5-HT receptor subtype that was present in neurons of the 
colliculus and hippocampus that stimulated adenylyl cyclase activity and increased cAMP 
production, but was insensitive to known antagonists of the 5-HT1, 5-HT2 and 5-HT3 receptor 
subtypes (Dumuis et al. 1988; Bockaert et al. 1990; Bockaert et al., 2004). For a long time, 
the 5-HT3 and 5-HT4  receptors seemed closely related due to their similar pharmacological 
profile. Indeed, the first ligands discovered for the 5-HT4 receptor had also a high affinity for 
the 5-HT3 receptor (Dumuis et al., 1988; Eglen et al., 1995; Bockaert et al., 2004). In 1992, 
the 5-HT4 receptor was finally recognized as a new serotonergic receptor subtype and 
subsequent development of ligands with affinity and/or selectivity for this receptor has grown 
exponentially throughout the years (Bockaert et al., 2004; Dumuis et al., 1988; Eglen et al., 
1995; Bockaert et al., 2004). In the late 1990’s, the gene coding for the 5-HT4 receptor, which 
is exceptionally large and complex (700kb, 38 exons), was simultaneously cloned in two 
different species mouse and rat (Gerald et al., 1995; Claeysen et al., 1996; Bockaert et al., 
2004).  
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The 5-HT4 receptor possesses three intracellular loops and three extracellular loops. 
The amino terminus is oriented toward the extracellular space, whereas the carboxyl terminus 
(C-terminus) is oriented toward the cytoplasm. Primary sequences of the different isoforms 
are identical throughout the first 358 residues but divergences at their C-terminal end suggest 
differences in G protein coupling (Claeysen et al., 1999; Bockaert et al., 2004) (Figure 5). 
 
 
 
 
 
 
 
 
 
 
Figure 5 : 5-HT4 receptor sequence (Padayatti et al., 2013).  
Two-dimensional representation of the 5-HT4 receptor sequence.  
To date, it is well known that 5-HT4 receptors can exist in multiple isoforms with 
distinct functional properties (Claeysen et al., 1999; Pindon et al., 2002; Ponimaskin et al., 
2002; Bockaert et al 2004). Alternative splice variants of the 5-HT4 receptor have been 
identified in both rodent and human totalling nine identified variants, though all variants do 
not appear in every species. Humans have at least five of these variants, whereas mice only 
have four (Claeysen et al., 1999) (Figure 6). The functional differences in the alternative 
forms have yet to be firmly established, though in general, differences in the intracellular 
loops (i3 in particular) and the carboxyl termini can result in differences in G protein 
coupling. These isoforms can be further modified by phosphorylation and palmitoylation at 
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their carboxyl-terminal or intracellular loops that can influence signaling and regulation 
(Barthet et al., 2005). 
 
Figure 6 : C-terminal amino acid sequences of the 5-HT4 receptor splice variants 
(Claeysen et al., 1999). 
All of the cloned 5-HT4 receptors share the same amino acid sequence up to Leu 358 and differ from 
Leu 358 on (boxed). *Receptors cloned by (Claeysen et al., 1996; Claeysen et al., 1997). †Receptors cloned by 
Gerald et al. (1995). ‡Receptors previously cloned by Blondel et al. (1998). §Receptors cloned by Van den 
Wyngaert et al. (1997); m stands for mouse, r for rat and h for human Note that the amino acid sequences after 
Leu 358 of newly cloned m5-HT4(e) m5-HT4(f), r5-HT4(e), and h5-HT4(e) receptors are shaded. The EMBL 
Nucleotide Sequence Database accession numbers for mouse 5-HT4(a), 5-HT4(b), 5-HT4(e) and 5-HT4(f) 
receptors are Y09587,Y09585, Y09588, and AJ011369, respectively. For r5-HT4(a), r5-HT4(b), and r5-HT4(e) 
receptors, the numbers are U20906, U20907, and AJ011370, respectively, and for h5-HT4(a), h5-HT4(b), h5-
HT4(c), h5-HT4(d) and h5-HT4(e) receptors,Y09586, Y10437, Y12506, Y12507, and AJ011371, respectively. 
 
Through the use of PCR and quantitative analysis of mRNA levels, the researchers 
found a strong expression of isoforms a, b, c, g and n in the central nervous system (CNS) 
(Vilaro et al 2002, 2005; Bockaert et al., 2004). Isoform (a) appears to be highly expressed in 
the amygdala, hippocampus, nucleus accumbens and caudate nucleus; some expression was 
also found in the small intestine, the atrium, and pituitary gland. Isoform (b) appears to be the 
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most predominant form in the CNS and periphery such as the caudate nucleus, putamen, 
amygdala, the pituitary gland and the small intestine. As for isoform (g), it seems to be highly 
expressed in the hypothalamus and cortex; then isoform (c) is highly expressed in the 
pituitary gland and small intestine, but it is also found at some lower levels in the caudate 
nucleus, hippocampus, and putamen. Conversely, isoform (d) was not detected in the CNS 
and is present only in the small intestine (Vilaro et al 2002, 2005 ; Bockaert et al., 2004). 
Alternative splicing of the receptor results in almost identical pharmacological properties, but 
with distinct functional profiles.  
The emergence of functional studies with transfected 5-HT4 receptor splice variants 
showed interesting differences in efficacy and potency as well as sensitivity toward 
homologous agonist-induced desensitization (Mialet et al., 2003; Bockaert et al., 2004; 
Ponimaskin et al., 2005). In addition, several studies indicate that differences between splice 
variants in intrinsic activity suggest a role of the carboxyl terminus in maintaining an inactive 
state of the receptor (Mialet et al., 2003). Further investigations have shown that progressive 
C-terminal deletions resulted in greater constitutive activity, which goes in line with previous 
findings that demonstrated that the shorter variants display greater production of cAMP in the 
absence of ligand (Claeysen et al., 1999).  
The study of signaling and trafficking of 5-HT4 receptors is a relatively new area of 
research when compared to other GPCPR’s such as opioid or dopamine receptors. However, 
numerous studies suggest that isoform-specific difference in 5-HT4 receptors might impact 
the overall coupling and regulation of this receptor and their potential as future targets for 
therapeutic intervention (Barthet et al., 2005; Vilaro et al., 2005; Bohn and Schmid, 2010; 
Marin et al 2012 and Mnie-Filali and Pineyro, 2012). 
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II. Localisation	  et	  fonctionalité	  du	  récepteur	  5-­‐HT4	  	  
The 5-HT4 receptors are expressed in a wide variety of tissues of vertebrates including 
brain, esophagus, ileum, colon, adrenocortical cells, urinary bladder, and heart (Eglen et al., 
1995). 
A. Localisation	  et	  fonctionalité	  du	  récepteur	  5-­‐HT4	  à	  la	  périphérie	  
The 5-HT4 receptor has been shown to play important roles in the heart, 
gastrointestinal tract, adrenal gland, and urinary bladder, as well as in the central nervous 
system (Hegde and Eglen, 1996) (Figure 7). The cardiac effects mediated by 5-HT4 receptors 
are present in the atrium with tachycardia and increased myocardial contractility. In the 
gastrointestinal tract, activation of 5-HT4 receptors has been found to facilitate acetylcholine 
(ACh)-induced motility (Eglen et al., 1990; Kilbinger and Wolf, 1992), to mediate peristalsis 
and secretion of electrolytes (Craig and Clarke, 1991). 5-HT4 receptors have also been shown 
to modulate ACh-induced bladder contractions (Hegde and Eglen, 1996). In the adrenal 
gland, it was shown that secretion of corticosteroids, and regulation of the production of 
aldosterone and cortisol is modulated by 5-HT4 receptor (Lefebvre et al., 1992) and in the 
urinary bladder 5-HT4 receptors modulate cholinergic/purinergic transmission (Boyd & 
Rohan, 1994). Moreover, these receptors are involved in the control of nausea and vomiting 
as well as smooth muscle tone, mucosal electrolyte secretion and peristaltic reflex (Hegde and 
Eglen, 1996).  
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Figure 7: Localization and major effect of 5-HT4 receptors in various peripheral organs 
(adapted from Hedge and Eglen 1996). 
 
B. Localisation	  et	  fonctionalité	  du	  récepteur	  5-­‐HT4	  au	  niveau	  du	  système	  nerveux	  
central	  
1. Localisation	  au	  niveau	  du	  système	  nerveux	  central	  
The development in 1993, of two new specific radioligands of the 5-HT4 receptor, the 
antagonists [3H]-GR 113808 and [125I]-SB 207710, revolutionized the study of this receptor. 
Their use in biochemical assays and autoradiography of different species allowed an accurate 
determination of the regional distribution of 5-HT4 receptor in the brain (Grossman et al., 
1993).  
The vast majority of 5-HT4 receptors are expressed in the hypothalamus, 
hippocampus, nucleus accumbens, the ventral pallidum, amygdala, the basal ganglia, 
olfactory bulbs, frontal cortex, the septal area, the substantia nigra, the fundus striatus (Figure 
8) (Bockaert et al., 2004; Eglen et al, 1995; Vilaro et al, 1996; Vilaro et al., 2005; Waeber et 
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al., 1993). The locatlization of these receptors in the limbic system suggests a role in 
controlling emotions. 
5-HT4 receptors are heteroreceptors, located in the somatodendritic compartment and 
axon terminals of the spiny efferent neurons of the striatum containing γ-aminobutyric acid 
(GABA) (Compan et al., 1996; Cai et al., 2002; Bockaert et al, 2004; King et al., 2008). They 
are also expressed in glutamatergic pyramidal neurons in the medial prefrontal cortex and 
hippocampus (CA1, CA3) and granule cells of the dentate gyrus (Roychowdhury et al., 1994; 
Bockaert et al, 2004 ; Vilaro et al., 2005; King et al., 2008). In the cortex, hippocampus and 
amygdala, 5-HT4 receptors are also localized on cholinergic neurons where they stimulate the 
release of acetylcholine (Waeber et al., 1994; Bockaert et al, 2004; King et al., 2008). 
Recently, it has been shown that 5-HT4 receptors are likely expressed by efferent neurons of 
the nucleus accumbens projecting to the lateral hypothalamus (Jean et al., 2012 and Bockaert 
et al., 2011). 
 
Figure 8: Localization of 5-HT4 receptors in the human brain (Reynolds et al., 1994). 
A large body of evidences has been gathered over the past decades in regard to the 
importance of 5-HT4 receptor isoforms a and b (Vilaro et al, 2002; Pindon et al., 2002; 
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Qanbar and Bouvier, 2003; Ponimaskin et al., 2002, 2005; Mnie-Filali et al., 2010; Bockaert 
et al., 2008; Marin et al. 2012). These isoforms have a high expression in the limbic system 
such as the nucleus accumbens, hippocampus and the striatum, structures which are 
responsible for monitoring responses of motivation and pleasure affected in depression. 
(Vilaro et al., 2002, 2005.) These isoforms have also contributed to potential targets for the 
development of novel, rapid antidepressant (Lucas et al., 2007; Pascual-Brazo 2012).  
However, due to a lack of antibody and specific ligands to each of the two isoforms, it has 
been an arduos task to distinguish and characterize their properties in signaling and regulation 
functions, which are important aspect for the development of antidepressants with an effective 
response and faster onset of action (Lucas et al., 2007; Pascual-Brazo et al., 2012). 
2. Fonctionalité	  au	  niveau	  du	  système	  nerveux	  central	  
Several studies showed that agonist activation of the 5-HT4 receptors, leads to a 
cascade of signaling events such as production of cyclic AMP (CAMP), activation of a protein 
kinase A which results in the phosphorylation of cAMP response element binding protein 
(CREB) and as a consequence the expression of a number of genes involved in cell survival 
(Figure 9) (Bockaert et al., 2006; Bockaert et al., 2008; Ahamad and Nirogi, 2011). In 
addition, all 5-HT4 receptor splice variants are able to stimulate adenylyl cyclase (AC) 
activity and raise intracellular cAMP levels in the presence of 5-HT or agonists. 
Based on a diversity of methodological appoaches such as 5-HT4 receptor binding, 
single cell PCR studies, autodiography, electrophysiology, microdialysis, in situ 
hybridization, and many other techniques, we know the cellular and subcellular localization of 
the 5-HT4 receptors (Waeber et al. 1993, 1994; Compan et al., 1996; Bonaventure et al., 2000; 
Bockaert et al., 2008; Lucas, 2009). Likewise, an impressive number of articles highlighted 
the prominent role of the 5-HT4 receptors in brain functions such as memory and cognition, 
mood disorders and feeding disorder (Bockaert et al, 2004; Compan et al., 2004; King et al., 
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2008; Bockaert et al., 2008; Lucas et al., 2007; Lucas, 2009; Ahamad and Nirogi, 2011; 
Pascua-Brazo et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
Figure 9: 5-HT4 receptor activation leading to various cellular events (adapted and 
modified from Ahamad and Nirogi, 2011). 
Activation of 5-HT4 receptor leads to acetylcholine release, which coupled with the release of BDNF, 
may help in memory/mood. The activation of the receptor is also reported to enhance the release of BDNF-
induced neurogenesis. 
a) Le	  récepteur	  5-­‐HT4	  	  et	  la	  prise	  alimentaire	  
As previously addressed, 5-HT4 receptors expressed in the central nervous system 
have been associated with limbic/affective functions as well as food intake. The first evidence 
that demonstrated the implication of 5-HT4 receptors in food intake was obtained using the 5-
HT4 receptor knockout mice (Compan et al., 2004). Indeed, the defective mutation of the 
mHtr4 gene encoding 5-HT4 receptors reduced hypophagia following restraint stress and 
novelty-induced exploratory activity a possible animal model for anorexia nervosa (Compan 
et al., 2004; Bockaert 2008, 2011). It is also known that 5-HT4 receptors control mRNA 
expression of CART (cocaine- and amphetamine-regulated transcript), an anorectic peptide, 
via a signaling pathway involving cAMP/PKA (Compan et al., 2004; Jean et al., 2007).  
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Further study also showed that the rewarding drug MDMA (3,4-N-
methylenedioxymetham-phetamine) reduces feeding via 5-HT4 receptor activation through 
the same mechanism (Jean et al., 2007). Interestingly, in a recent study, Compan’s group 
demonstrated that when motivation comes into play, the NAc-5-HT4 receptor/5-HT1B 
receptor/CART pathway might prevail over the autonomic nervous control of feeding. The 
NAc-5-HT4 receptor/CART surplus makes the brain “silent” to energy loss (Jean et al., 2012).  
b) Le	  récepteur	  5-­‐HT4	  et	  	  la	  cognition	  
5-HT4 receptors expressed in the central nervous system have been involved in 
memory and cognitive functions. It has been established that activation of CREB protein 
protein is an important mediator of memory formation and pro-cognitive effects (Bockaert et 
al., 2004; Bockaert et al., 2008). Several signaling pathways leading to cAMP accumulation 
in neurons are being investigated as prospective candidates for therapeutic interventions of 
cognitive deficits linked with various neurological disorders (Ahamad and Nirogi, 2011; 
Marin et al., 2012). Additionally, pharmacological and behavioral essays have shown 
improvement in memory acquisition induced by 5-HT4 receptor in rodents and primates (King 
et al., 2008; Bockaert et al., 2008; Marchetti et al., 2008). Indeed, in various animal models, 
partial 5-HT4 receptor agonists were reported to promote learning in a variety of behavioral 
tests (Bockaert et al., 2004, 2008 ; Marchetti et al., 2008) (tables 4, 5, 6 and 7). Activation of 
this receptor inhibits neuronal potassium channels and subsequent mobilization of calcium 
ions, resulting in increased neuronal excitability (Bockaert et al., 2004, 2008). It also 
improves neurotransmission and enhances the release of acetylcholine in the frontal cortex 
and hippocampus and  promotes an increase in Long Term Potentiation (LTP), in 
hippocampus and amygdala.  
Consolo and colleagues were the first to demonstrate by in vivo microdialysis studies 
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that agonists BIMU1 and BIMU8 increase acetylcholine. Further studies confirmed this 
results, but it also demonstrated that 5-HT4 agonists facilitates hippocampal Ach outflow 
(Consolo et al., 1994; Yamaguchi et al., 1997; Letty et al.,1997; Orsetti et al., 2007). Thus, 5-
HT4 receptors may improve learning and memory formation by enhancing the synaptic 
release of acetylcholine in the brain. (Bockaert et al., 2004, 2008; King et al., 2008; Lucas et 
al., 2009). The putative role of 5-HT4 receptors in learning and memory has also been 
investigated in animal studies. Pre-training administration with 5-HT4 agonists BIMU1 or 
BIMU8, has been shown to enhance acquisition, but impair the consolidation of learning in an 
autoshaping paradigm in rats (Meneses and Hong, 1997). In addition, 5-HT4 receptor agonists 
enhanced spatial navigation in rats. Specifically in the Morris Water maze, 5-HT4 receptor 
agonists were also found to reduce escape latency (Fontana et al., 1996), and to reverse 
atropine-induced deficits (Fontana et al., 1997). In the Y Maze, the agonist RS-67333 was 
also able to enhance place recognition as evidenced by increased visits to the novel arm of the 
maze (Orsetti et al., 2003).  
The role of the 5-HT4 receptor in synaptic plasticity was also demonstrated in freely 
moving rats with implanted microelectrodes by agonist stimulation with RS67333, which led 
to increased synaptic transmission in hippocampus (Kulla et al., 2002). Similar effects were 
observed in anesthetized rats using another 5-HT4 selective agonist SC 53116 (Matsumoto et 
al., 2001). Lastly, in both young and old macaques, the agonist RS 17107 induced 
improvements in a delayed matching-to-sample task in which the monkeys had to learn to 
correctly match colors to receive a food reward (Terry et al., 1998). Efficacy of 5-HT4 
receptor agonists in the older monkeys lends further support to the potential use of these 
compounds in the treatment of memory disorders. 
Furthermore, 5-HT4 receptors also activates the exchange factor Epac, which in turn 
stimulates an α-secretase activity and the release of soluble amyloid precursor protein 
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(sAPPα), which has neuroprotective and memory-enhancing properties (Bockaert et al., 2008; 
King et al., 2008; Marin et al., 2012). These findings in correlation with other studies showing 
a loss of 5-HT4 receptor binding sites in cortical and hippocampal regions in the Alzheimer 
brain suggest that 5-HT4 agonists may be used in the treatment of Alzheimer’s disease.  
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c) Le	  récepteur	  5-­‐HT4	  	  et	  la	  régulation	  des	  émotions	  
The expression of the 5-HT4 receptors in the limbic system also suggests a role of this 
receptor in mood regulation. It has been reported that 5-HT4  agonists exert stimulatory effect 
in firing activity on 5-HT neurons in the dorsal raphe nucleus (Lucas and Debonnel 2002), 
suggesting a role for this receptor in depression. It is also well known that activation of 5-HT4 
receptor leads to cAMP formation, which through cAMP Response Element-binding protein 
(CREB) phosphorylation initiates a cascade of signaling such as induction of neurogenesis 
(Lucas et al., 2005; Pascual-Brazo et al., 2012).  
5-HT4 receptor binding in different brain regions, electrophysiology studies and 
behavioral studies support a role of the 5-HT4  receptor in mood disorders (Compan et al., 
2004, Lucas et al 2007; Lucas, 2009; Licht et al., 2009; Bockaert et al., 2011; Pascual Brazo 
et al., 2012). Further explanation will be given in chapter IV. 
III. La	  protéine	  β-­‐arrestin	  1,	  le	  récepteur	  5-­‐HT4	  et	  leurs	  interactions	  	  
A. La	   protein	   β-­‐arrestine	   1,	   un	   exemple	   de	   proteine	   interagissant	   avec	   les	  
récepteurs	  couplés	  aux	  proteins	  G	  
Although coupling to G proteins remains a central event in 5-HT4 receptor-mediated 
signaling, evidence indicates that the regulation of their functional status also depends on 
interactions with a variety of additional protein partners named GPCR interacting proteins 
(GIPs) (Bockaert et al., 2006, 2011). These interactions create additional opportunities for not 
only G-protein-dependent signaling, but also for G-protein-independent signaling (Lefkowitz 
and Whalen, 2004). The GIPs have three main roles: First, they allow receptor targeting to 
appropriate subcellular compartments such as dendrites, axons, spines in which they have 
their specific function. Second, control receptor trafficking in and out of the plasma 
membrane, and third, ensure a fine-tuning of receptor signaling (Bockaert et al., 2004; Barthet 
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et al., 2009; Marin et al., 2012).  
β-arrestins, is a GPCR interacting protein that belong to the arrestin family. They are 
ubiquitously expressed in the brain and interact specifically with GPCRs, including the 5-HT4 
receptor, following their activation by agonists and subsequent phosphorylation by GRKs 
(Bockaert et al., 2004). To date, four members of the arrestin gene family have been cloned 
(Freedman and Lefkowitz, 1996). Arrestin1 and arrestin 4, also known as visual arrestin and 
cone arrestin, which are expressed exclusively in the retina where they regulate 
photoreceptors functions. By contrast, β-arrestin 1 and β-arrestin 2, also known as arrestin 2 
and arrestin 3 respectively, are ubiquitously expressed and regulate GPCRs. 
A growing body of evidences have revealed that β-arrestins play a key role in the 
signaling, desensitization and internalization of GPCR’s, including the majority of 5-HT 
receptors (Vilaro et al., 2005), and are particularly well positioned to play a significant role in 
ligand-directed functional signaling. The role of β-arrestins in the desensitization and 
internalization of certain 5-HT receptors has been intensively investigated (Barthet et al, 
2005; Bohn et al., 2010; Mnie-Filali and Pineyro, 2012). It has been established that β-
arrestins in their inactive form are phosphorylated cytosolic proteins. In many cases, receptor 
phosphorylation on serine and threonine residues present in the carboxyl-terminal domain or 
intracellular loops of the receptor appears to play a major role in initiating the desensitization 
process which can be homologous or heterologous (Mialet et al., 2003). For intance, β-
arrestin 1 undergoes phosphorylation in serine-412 in the carboxyl-terminal (Lin et al., 1997), 
by extracellular signal regulated kinase (ERK1/2). Following agonist stimulation, β-arrestin 1 
is translocated to the plasma membrane where it is dephosphorylated, a process that is not 
required for receptor binding and desensitization but is obligatory for receptor internalization. 
B. La	  protéine	  β-­‐arrestine	  1	  et	  les	  troubles	  anxio/dépressifs	  
Recently, a substantial body of evidence indicates that β-arrestins (β-arrestin-1 and β-
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arrestin-2), proteins that regulate G-protein receptor coupling, play a role in the 
pathophysiology of mood disorders and in the mechanisms underlying antidepressant actions 
(Avissar et al., 2004; Schreiber and Avissar, 2009; Matuzany-Ruban et al., 2005; Beaulieu et 
al., 2008; David et al., 2009; Schreiber et al., 2009; Golan et al., 2010). The β-arrestin-
signaling cascade has recently gained attention as a potential pre-clinical/clinical bridging 
biomarker for depressive states and treatment effects. In naïve rats, SSRI, SNRI and non-
selective reuptake inhibitor antidepressants significantly elevate β-arrestin-1 levels in the 
cortex and the hippocampus (Avissar et al., 2004; Beaulieu and Caron, 2008; Beaulieu et al., 
2008; David et al., 2009). Similarly, β-arrestin 1 expression is decreased in the hypothalamus 
and hippocampus in anxious/depressed mice exposed to glucocorticoid elevation, and is 
restored by chronic fluoxetine treatment (David et al., 2009). Moreover, β-arrestin 1 and 2 
signaling is involved in mediating the response to fluoxetine and lithium (Beaulieu et al., 
2008; David et al., 2009).  
Clinical data from Avissar’s group (Avissar et al., 2004) suggest that β-arrestin-1 
mRNA and protein levels are highest in peripheral blood leukocytes of MDD patients. 
Therefore, β-arrestin-1 may be a putative candidate biochemical marker in clinical practice 
for depressive pathophysiology and the response to antidepressants (for review see (Schreiber 
et al., 2009). β-arrestin mRNA levels and β-arrestin-1 protein levels in mononuclear 
leukocytes of untreated patients with MDD are lower than the levels found in healthy 
subjects. Furthermore, reduced levels of β- arrestin-1 protein and mRNA are significantly 
correlated with the severity of depressive symptoms (Avissar et al., 2004; Schreiber et al., 
2009). However, the low β-arrestin-1 protein and mRNA levels are alleviated by 
antidepressant treatment. Therefore, these low levels may predict clinical improvement 
(Avissar et al., 2004; Golan et al., 2010).  
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C. Le	  récepteur	  5-­‐HT4	  et	  la	  protéine	  β-­‐arrestine	  1	  
In 2005, Barthet and colleagues identified GRK2 as the major GRK responsible for 
the desensitization of the 5-HT4 receptor mediated Gs pathway (Figure 10A). They 
demonstrated by in vitro studies using primary colliculi neurons or HEK293 cells that 
uncoupling of 5-HT4 receptors from Gs proteins and β-arrestins-dependent receptor 
endocytosis are distinct molecular events with different GRK requirements (Figure 10) 
(Barthet et al., 2007; Bohn et al., 2010; Marin et al., 2012). For instance, uncoupling of 5-HT4 
receptors from Gαs proteins required the presence of GRK2 but did not depend on its kinase 
activity (Dumuis et al., 1988; Barthet et al, 2005) (Figure 10A). In contrast, recruitment of β-
arrestins, which allows receptor internalization, required receptor phosphorylation by GRK2 
of a cluster of serines and threonines located in the receptor C-terminus. This mechanism also 
implies that the phosphorylation process of the 5-HT4 receptor C-terminal domain and its 
Serr/thr clusters seems to be absolutely necessary for β-arrestin recruitment (Figure 11).  
 
 
 
 
 
 
Figure 10: A general schema of Gs-dependent (A) and Gs-independent signaling (B) and 
desensitization of 5-HT4 receptors (Bockaert et al. 2008). 
 
A" B"
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Further characterization by Barthet and collegues showed a constitutive interaction of 
5-HT4 receptors and GRK5, and claimed that effect contributes to the basal “constitutive 
activity” of the receptor as previously reported (Figure 10B) (Claeysen et al., 1999; Barthet et 
al., 2009). These studies were based on the role of GRK5 in the desensitization of G-protein-
independent pathway and identified β-arrestin1 as the protein responsible for the negative 
regulation of 5-HT4 receptor-mediated Src/ERK pathway. This desensitization process 
required two complex molecular events such as a recruitment of β-arrestin1 to a 
phosphorylated serine/threonine cluster located in the receptor C-terminal domain (Figure 
11A) and a direct phosphorylation (at Ser412) in which β-arrestin1 phosphorylation at Ser412 
is essential for GRK5-mediated inhibition of the 5-HT4 receptor-operated Src/ERK pathway 
(Figure 11B). 
 
 
 
 
 
 
 
 
 
 
Figure 11: Model of desensitization by GRK5 of 5-HT4 receptor-operated ERK signaling 
(Bockaert et al., 2008). 
 
These studies demonstrated for the first time a role of a GRK family member (GRK5) 
in the desensitization of G protein-independent pathway and identified β- arrestin1 as a novel 
A" B"
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substrate of GRK5 in addition of its well described GPCR substrates. They also showed 
earlier that engagement of the ERK1,2 pathway (implicated in modulation of cognitive 
functions) by 5-HT4 receptors and its regulation are critically dependent of a complex 
“receptosome” including at least Src, GRK5 and β-arrestin1 (Barthet et al 2009; Marin et al., 
2012). As expression of both GRK5 and β-arrestin1 increases considerably during 
development (Gurevich et al, 2004), it is likely that the negative regulation of the 5-HT4 
mediated activation of the G protein-independent Src/ERK pathway will be higher in adult 
neurons. Therefore, GRK5 and β-arrestin1 play a critical role in determing the nature of the 
signaling pathway (Gs or ERK) predominantly engaged upon activation of 5-HT4 receptor 
which could be critical for 5-HT4-dependent synaptic plasticity and memory consolidation 
(Kemp and Manahan-Vaughan, 2004, 2005; Marchetti et al, 2004; Micale et al, 2006).  
D. Les	  variants	  du	  récepteur	  5-­‐HT4	  et	  la	  protéine	  β-­‐arrestine	  1	  
A better understanding of the consequences of the 5-HT4 receptor activation is linked to 
isoforms differences, which seems to play an important part in regard to the coupling of the 
receptor. For instance, the internalization process of the 5-HT4 receptor is dependent on the 
two isoforms of the receptor, 5-HT4a and 5-HT4b. Serotonin-induced internalization of the 5-
HT4a receptor in HEK293 cells was inhibited by expression of dominant negative GRK2 and 
β-arrestin1 (βarr1319-418), while 5-HT4b receptor internalization was only partially 
attenuated by βarr1319-418. This study suggests that although β-arrestins are involved in the 
trafficking of 5-HT4 receptors, there are isoform-specific differences that may impact on the 
overall regulation of these receptors (Mnie-Filali et al., 2010; Bockaert  et al., 2008; Marin et 
al., 2012).  
Furthermore, other studies have shown that isoform 5-HT4a is accumulated in a 
perinuclear compartment location while isoform 5-HT4b is widely distributed in the cytosol of 
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the cell and these differences have an impact in post-endocytic distribution of each isoform, 
which is also consistent with the different requirements GRK2 and β-arrestin for their 
internalization process. The internalization and post-endocytosis distribution of GPCRs 
distribution is determined by several factors including the activity of kinases 
thatphosphorylate Ser / Thr residues intracellular (Ferguson et al, 1996; Ferguson et al., 
1998), and the ability of β-arrestin to interact with the receptor (Lefkowitz, 1998; Lohse et al, 
1990). 
Ponimaskin and colleagues have shown that 5-HT4 receptor contains potential sites for 
posttranslational modifications within their cytoplasmic carboxyl terminal. They identified 
three palmitoylation sites located at the extremity of the C-terminal of the 5-HT4(a) isoform 
and demonstrated that 5-HT4(a) receptor palmitoylation is dynamically regulated upon agonist 
stimulation of the receptor (Ponimaskin et al., 2001). In addition, mutation studies at the 
palmitoylation sites of the 5-HT4(a) isoform have decreased the rate and the extent of β-
arrestin recruitment to this receptor. Likewise, receptor palmitoylation was also found to be 
required for ligand-induced β-arrestin recruitment to the cell membrane and endocytosis of 
the thyrotropin-releasing hormone receptor (Groarke et al., 2001). Further studies also 
demonstrated that mutation of the membrane proximal palmitoylation site facilitates β-
arrestin-mediated internalization of 5-HT4(a) receptors.  
Therefore understanding the consequences of 5-HT4/β-arrestin interaction could aid in 
the development of pharmacotherapies to selectively target the activation or the inhibition of 
specific serotonin receptor signaling cascades.  
IV. Le	  récepteur	  5-­‐HT4	  et	  ses	  ligands	  et	  leurs	  implication	  dans	  la	  dépression	  
Human and animal studies have suggested that receptors 5-HT1 and 5-HT2 receptors 
play a critical role in anxiety/depression and antidepressant response (Barnes and Sharp, 
1999; Zhuang et al 1999; Cryan and Lucki 2000). However, recent evidences also suggested 
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that 5-HT4 receptors may be implicated in depression and in antidepressant treatment (Lucas 
et al., 2005, 2007; Pascual-Brazo et al., 2012). The 5-HT4 receptor has been identified as a 
positive regulator of 5-HT neuron firing in the dorsal raphe nucleus, suggesting a role for this 
receptor in depression and antidepressant treatment (Lucas et al., 2005; Lucas and Debonnel, 
2002). There are two clinical studies, which suggest a role of the 5-HT4 receptor in clinical 
depression. One study reported polymorphisms in the splice variant region of the serotonin 4 
receptor gene, which have been associated with unipolar depression (Ohtsuki et al. 2002). The 
second study revealed alterations of both 5-HT4 receptor binding sites and cAMP 
concentration levels in several brain regions of depressed violent suicide victims (Rosel et al., 
2004).  
A. Les	  ligands	  du	  récepteurs	  5-­‐HT4	  et	  leurs	  conséquences	  neurochimiques	  
By in vivo extracellular recordings in the DRN of rats, where nearly all of the 
serotonergic cell bodies are found in the brain, acute systemic administration of cisapride, a 5-
HT4 receptor agonist, and GR125487, a 5-HT4 receptor antagonist, was found to increase and 
decrease, respectively, the firing rate of dorsal raphe neurons (Lucas and Debonnel, 2002), 
suggesting both a tonic and phasic influence of 5-HT4 receptor activity on serotonergic 
neuron activity. More recently, it has been shown that 5-HT4 agonists increase the firing of 
serotonergic neurons, achieving their maximal effect within about 3 days and these effects 
persist after 21 days in rats (Lucas and Debonnel, 2002; Lucas et al., 2005). For instance, 
SSRIs increase synaptic levels of 5-HT relatively quickly (hours or days), but there is a delay 
in therapeutic response (weeks or months) due to the likely requirement for adaptations at 
both pre- and postsynaptic site (Blier et al., 1990; Blier, 2003; Czachura and Rasmussen, 
2000). Alternatively, 5-HT4 receptor agonists may cause a more rapid desensitization of 5-
HT1A autoreceptors to permit such a fast increase in DRN firing rates. Thus, 5-HT4 receptors 
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may mediate antidepressant-like effects via increased serotonergic release at postsynaptic 
sites.  
In support of a central role of the 5-HT4 receptor in 5-HT system control, 5-HT4 
receptor activation increased the effect of acute SSRI (paroxetine) administration on 5-HT 
levels in the ventral hippocampus, both acutely and after three days of administration with the 
5-HT4 receptor partial agonist RS67333 (Licht et al., 2009). This effect is most likely due to 
the acute stimulation of 5-HT neuron firing rate by 5-HT4 receptor partial agonism, which has 
been reported by others. While acute administration of RS67333 did not affect extracellular 5-
HT levels in the ventral hippocampus, only three days of RS67333 administration was 
required to elevate 5-HT levels. As an increase in extracellular 5-HT levels is associated with 
antidepressant effects of drug treatment, these report suggest that 5-HT4 receptor partial 
agonism have antidepressant potential, in particular in combination with SSRI administration. 
B. Les	  ligands	  du	  récepteurs	  5-­‐HT4	  et	  leurs	  effets	  comportementaux	  
Recent findings indicate that a mental disorders such as anxiety and/or depression 
could benefit from modulation of the 5-HT4 receptor signaling (Compan et al. 2004; Lucas et 
al., 2007; Lucas 2009; Compan et al., 2004; Pascual-Brazo et al.,2012). 
1. Les	  ligands	  du	  récepteurs	  5-­‐HT4	  et	  leurs	  effets	  de	  type	  anxiolytiques	  
Behavioral tests and the use of experimental animals have been very useful for the 
study of pharmacological compounds to investigate the impact of 5-HT4 receptors in anxiety/ 
depression phenotypes. Furthermore, studies have also focused on whether 5-HT4 receptors 
may mediate anxiolytic behavioral effects of SSRIs. From experimental animal studies, the 
role of 5-HT4 receptors in anxiety is unclear. For instance, in the light/dark choice paradigm a 
test to measure anxiolytic activity, mice treated with an anxiolytic (diazepam) spend more 
time in the light compartment than vehicle-treated mice. This effect of diazepam has been 
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shown to be dose-dependently inhibited by antagonists of the 5-HT4 receptor (GR 113808, SB 
204070, and SDZ 205-557) (Costall and Naylor, 1997) suggesting a role of the 5-HT4 
receptor in mediating these anxiolytic effects (table 7). Although a direct effect of the 5-HT4 
receptor antagonists on anxiety-like behavior in the light/dark choice test was not detected 
(Costall and Naylor, 1997), others report an anxiolytic effect of 5-HT4 receptor antagonists 
SB 204070, GR 113808 (Silvestre et al., 1996) and SB 207266A (Silvestre et al., 1996; 
Kennett et al., 1997) in rats in the elevated plus maze, another test of anxiety-like behavior. 
Rats treated with SB 204070 or GR 113808 displayed increases in the percent of total time 
spent in the open arms, which would suggest reduced anxiety-like behavior. However, one 
study did not detect an effect of the antagonists SB 204070 and GR 113808 on the number of 
open arm entries with a 10 minute pre-test injection interval (Silvestre et al., 1996), whereas 
another study reported an increase in percent open arm entries after injections of SB 204070 
or SB 207266A one hour prior to testing (Kennett et al., 1997). Whether 5-HT4 receptor 
antagonists cause anxiolytics effects remains unclear since reports indicate a lack of an effect 
in the light/dark choice paradigm, and anxiety-reducing effects in the elevated plus maze.  
Further investigations have shown that stimulation of 5-HT4 receptor inhibits the 
anxiolytic effect of diazepam (an enhancer of GABA response), particularly under conditions 
of high serotonergic tone (Costall et al., 1993). Since GABAA receptor-mediated inhibition of 
synaptic transmission is highly involved in controlling neuronal excitability, and GABAA 
receptors have been implicated in the pathogenesis of anxiety disorders (Macdonald and 
Olsen, 1994; Cai et al 2002), these lines of evidence prompt the speculation that 5-HT4 
receptors may exert some of their functions by acting on GABAergic signaling in PFC 
neurons. 
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2. Les	  ligands	  du	  récepteurs	  5-­‐HT4	  et	  leurs	  effets	  de	  type	  antidépresseur	  
Studies have investigated whether a 5-HT4 receptor antagonist can exert 
antidepressant-like effects independently, or whether it can alter acute fluoxetine effects in the 
rat forced swimming test (FST) (Cryan and Lucki, 2000). The fluoxetine-induced decreases in 
immobility in the FST were not affected by co-administration of the 5-HT4 receptor 
antagonist SB 204070A, and the antagonist had no independent effects in the FST either 
(Cryan and Lucki, 2000). Conversely, studies by Lucas and colleagues showed that with 5-
HT4 agonists, RS 67333 and prucalopride in the rat forced swimming test (FST) significantly 
reduced the time of immobility by about 50% compared with controls, whereas citalopram 
reduced immobility time by about 23%. (tables 7 and 8). Additional behavioral experiments 
were in agreement with this result showing that 5-HT4 receptor agonist RS 67333, was more 
effective than citalopram (Lucas et al., 2007, 2010). In addition, Lucas and colleagues 
demonstrated that cellular and behavioral responses that require 2–3 weeks of antidepressant 
treatment in rodents would occur after only 1–3 d of treatment with a selective 5-HT4 receptor 
agonist (RS67333) (Lucas et al., 2007). Moreover, signaling molecules that interact with the 
5-HT4 receptor such as P11 (S100A10) (Egeland et al., 2011; Warner-Schmidt et al., 2009) 
may represent novel targets for fast-acting anxiolytic/antidepressant treatments. There is 
indeed recent evidence that cortical neurons that express both P11 and 5-HT4 receptors are 
involved in the behavioral effects of SSRIs (Schmidt et al., 2012) and that chronic treatment 
with fluoxetine results in an increase in 5-HT4 receptor expressions in cortical neurons 
(Schmidt et al., 2012). Finally, in behavioral paradigms such as the FST and the Tail 
Suspension Test (TST), the antidepressant activity of RS67333 was absent in P11 knockout 
mice when compared with wild-type littermate controls (Warner-Schmidt et al., 2009). All 
these studies open the door to the link between the 5-HT4 receptor and depression and provide 
an encouraging pharmacological strategy to obtain a fast antidepressant response. 
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C. Les	   ligands	   du	   récepteurs	   5-­‐HT4	   et	   la	   neurogenèse	   hippocampique	   chez	  
l’adulte	  
In addition to behavioral data, several hippocampal neuroplasticity changes have been 
related to antidepressant efficacy. One of the most remarkable features of 5-HT4 receptor 
agonists is their ability to induce neurogenesis in hippocampus as well as enteric system in 
rodents (Lucas et al., 2007, 2009; Liu et al., 2009; Pascual-Brazo et al., 2012). In addition to 
previous behavioral data, and in agreement with a previous report from Lucas and colleagues, 
a recent study performed in naïve rats confirmed that three days of treatment with the 5-HT4 
agonist (RS67333) significantly promoted neurogenesis in the subgranular zone of the dentate 
gyrus of the hippocampus, an effect normally seen after a minimum of two weeks of 
treatment with classical antidepressants such as SSRIs (Pascual-Brazo et al., 2012). These 
results are interesting because hippocampal neurogenesis has been implicated in some of the 
behavioral effects of antidepressants in adult rodents (David et al., 2009; Santarelli et al., 
2003). However, no direct evidence has yet linked the antidepressant-like effects of 5-HT4 
receptor activation and its neurogenic effects. Further support for an antidepressant-like effect 
of 5-HT4 receptor activation is based on analysis of signal transduction. 5-HT4 receptors are 
G(s)-coupled GPCRs that activate adenylyl cyclase, and thus increase production of cAMP 
(Dumuis et al., 1989; Torres et al., 1995), which could activate protein kinase A, and in turn 
phosphorylate the transcription factor CREB. Interestingly, chronic antidepressant treatment 
has been shown to activate the same signal transduction machinery (Nibuya et al., 1996). It is 
thought that the activation of CREB into pCREB constitutes a key step for the facilitation of 
hippocampal neurogenesis, another characteristic property of antidepressants (Malberg et al 
2000; Duman et al., 2001; Castren, 2004). 
The second-messenger cAMP has also been strongly suggested to be involved in the 
mechanism of action of antidepressants (Donati and Rasenick, 2003). Interestingly, a 
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significant decrease in 5-HT4 receptor-dependent cAMP production has been reported after 
chronic treatment within 3 weeks of fluoxetine, venlafaxine (Vidal et al. 2010) or imipramine 
(Reierson et al. 2009), probably reflecting a desensitization process, due to a less efficient 
coupling to Gs proteins.  A study also reported that 7 days stimulation with the 5-HT4  agonist 
is required to fully desensitize the post-receptor signaling pathway associated to 5-HT4 
receptors, in agreement with the results obtained in behavioral tests predictive of chronic 
response (Pascual-Brazo et al., 2012). 
BDNF has a role in neurite outgrowth and synaptic plasticity (McAllister, 1999). 
Several studies have shown that antidepressants up-regulate hippocampal BDNF (Duman and 
Monteggia, 2006), although the temporal pattern of these changes is a matter of debate. While 
some authors have reported an induction of BDNF expression after subchronic treatment 
(Larsen et al., 2008; Musazzi et al., 2009), other studies only show up-regulation of BDNF 
after chronic antidepressant administration (De Foubert et al., 2004; Nibuya et al., 1995). It 
appears that the long-term effect of antidepressants to modulate behavior and survival of new 
neurons is mediated, at least in part by BDNF. Therefore, since 5-HT4 receptors activation 
could also enhance BDNF expression, its activation can lead to antidepressant-like effects on 
behavior and neuroplasticity. A study by Pascual-Brazo and colleagues reported an increase 
in expression of BDNF after 3 days treatment with the 5-HT4 receptor agonist RS67333, and a 
significant increase in the expression of BDNF protein in whole hippocampal homogenates 
following 7 day treatment (Pascual-Brazo et al., 2012). Another study also reported an 
increase in the expression of BDNF following acute administration of another 5-HT4 agonist 
(SL65.0155) (Tamburella et al. 2009).  
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Problématique	  du	  travail	  de	  thèse	  
Despite side effects, Selective Serotonin Reuptake Inhibitors continue to be leader for 
the treatment of depression and several anxiety disorders. SSRIs such as fluoxetine (Prozac®)  
and paroxetine (Paxil®) are highly prescribed in France for the treatment of mood disorders 
such as depression and anxiety. However, the delayed onset of action (2-4 weeks) is a main 
concern. High suicidal rates among patients combined with a significant amount of patients 
who do not repond to the first treatment demand an urgent need for faster acting and more 
effective antidepressant. Thus, the development of new antidepressants is of considerable 
importance as well as understanding the mechanisms underlying the delayed onset of action. 
Past relevant work discussed in this thesis demonstrated evidence that 5-HT4 receptor 
may be a direct target for treating depression and a new hope for fast acting antidepressant 
treatment. Administration of 5-HT4 agonists induced similar molecular and behavioral 
changes as common antidepressants in rodents. In addition to behavioral data, it has been 
proposed that a short period of treatment with 5-HT4 agonists increased the number of 
newborn cells in the dentate gyrus (DG), one of the steps of adult hippocampal neurogenesis. 
These results are interesting because hippocampal neurogenesis has been implicated in some 
of the behavioral effects of antidepressants in adult rodents. However, no direct evidence has 
yet linked the antidepressant-like effects of 5-HT4 receptor activation and its neurogenic 
effects. 
During my PhD work, I have endeavored to investigate both antidepressant and 
anxiolytic-like effects of either subchronic or chronic administration of a 5-HT4 receptor 
agonist in a model of anxiety/depression based on the elevation of glucocorticoids in mice 
(CORT model). We also assessed whether chronic 5-HT4 receptor stimulation can affect 
proliferation of newborn cells and maturation of newborn neurons. Lastly, using our mouse 
model of anxiety/depression combined with ablation of hippocampal neurogenesis by X-
  
 
100 
irradiation, we assessed whether the anxiolytic/antidepressant action of RS67333 after 7-days 
and 28-days of treatment recruits a neurogenesis-dependent mechanism. 
Another interesting point covered during my thesis work was to investigate whether 
the fast onset of anxiolytic/antidepressant action of 5-HT4 receptor agonist treatment can be 
predicted by measuring  β-arrestin 1 levels in Peripheral Blood Mononuclear Cells (PBMC). I 
was particularly interested in  β-arrestin 1 expression due to its potential as a biochemical 
diagnostic tool. As previously described, β-arrestin 1 is known to mediate receptor 
desensitization, endocytosis and G protein-independent signaling, However, it is also 
recognized as a protein involved in the pathophysiology of depression and in antidepressant 
mechanism of action. Assessing peripheral protein levels in PBMCs is an attractive method 
because PBMCs are circulating cells that can be easily collected and monitored.  
Therefore, I developed a method to screen putative biomarkers of the pathophysiology 
of mood disorders and the response to antidepressants by measuring and assessing circulating 
proteins, especially β-arrestin 1 in PBMCs. First, I was interested in investigating whether 
changes in β-arrestin 1 levels in mouse PBMCs were observed in a model of 
anxiety/depression and secondly, whether these levels could be corrected by chronic treatment 
with the SSRI fluoxetine or/and by a 5-HT4  agonist.  
Lastly, I wanted to investigate the effects of a chronic treatment with RS67333 on the 
β-arrestin 1expression levels in the mouse brain treated with chronic corticosterone in two 
specific regions: the hippocampus and the cortex, two key brain structures possibly involved 
in the antidepressant response. Recent reports previously described showed that chronic 
treatment with various classes of antidepressants induced desensitization and/or 
downregulation of the 5-HT4 receptors in cerebral regions implicated in depression such as 
the hippocampus, probably reflecting a desensitization process, due to a less efficient 
coupling to Gs proteins. Another study showed that a short exposure with the 5-HT4 agonist is 
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required to fully desensitize the signaling pathway associated to 5-HT4 receptors. Therefore, I 
investigated whether in our CORT model there was a restoration of β-arrestin 1 expression in 
the hippocampus and cortex after RS67333 or fluoxetine chronic treatment. 
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1. Abstract 
 Understanding the pathophysiology of affective disorders and their treatment relies 
on the availability of experimental models that accurately mimic aspects of the disease. The 
use of exogenously administered corticosterone (CORT model) has validity as an animal 
model to study chronic stress and depression, displaying some hallmark characteristics of 
anxiety and depression observed in patients.  
 Recently, we have adapted the CORT model protocol to screen a rapid onset drug 
to treat anxiety/depression disorders. In spite of the fact that selective serotonin reuptake 
inhibitors (SSRIs) are the most commonly prescribed drugs for the treatment of depression 
and several anxiety disorders, the onset of action of SSRIs is often delayed by 3 to 6 weeks. 
The existence of this delayed action combined with the fact that one third of patients do not 
respond to treatment emphasizes the need for faster acting and more effective antidepressants. 
This chapter gives laboratory protocols including step-by-step recommendations to explain 
how the CORT model in mice can be used to screen a rapid onset drug to treat 
anxiety/depression. For this purpose we took as an example, the behavioral and cellular 
effects of a 5-HT4 receptor ligand, RS67333 in comparison to the classical Selective Serotonin 
Reuptake Inhibitors, fluoxetine. Likewise, we emphasize how proteins levels, including β-
arrestin 1 measurements, in peripheral blood mononuclear cells (PBMCs) isolated from 
whole blood in corticosterone-treated mice could provide one of the markers of a biological 
signature of treatment response and predict a fast onset action in the mouse CORT model.  
 
Keywords: anxious/depression-model, 5-HT4 receptor, corticosterone, β-arrestin 1 
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2. Background and Historical Overview 
 In order for basic research to provide potential advances, a critical first step is to 
create useful animal models with relevant phenotypic features of the pathophysiology of 
depression and their treatment response[1]. Therefore it is critical for basic research to 
develop animal models that present behavioral, neurochemical and brain morphological 
phenotype reminiscent of depression and anxiety. Given that anxiety and depression have a 
high comorbidity with co-occurrence rates up to 60% in patients [2], animal models that 
present signs of both diseases could potentially be the most useful. Historically, since very 
few genetic variants with high penetrance (Brain Derived Neurotrophic Factor with the 
Val66Met, Serotoninergic transporter with the short and the long variant) that cause 
depression are known, animal models have mainly relied on different means of chronically 
exposing rodents to stressful experiences, or sensory tract lesions such as in olfactory 
bulbectomy, to induce behavioral states that present depression-like signs and are responsive 
to chronic antidepressant treatment. Previously, drugs with putative anxiolytic/antidepressant 
properties were screened in naïve animals using behavioral paradigms predictive to anxiolytic 
(Open Field, Elevated Plus Maze, Light/Dark paradigm) or antidepressant-like activity 
(Forced Swim Test, tail Suspension test) sensitive to acute administration. 
 The oldest most commonly used paradigm to induce a depression-like state is 
chronic mild stress (CMS). Initial observations in 1982 suggested that rats subjected to 
multiple stressors over a prolonged period of time reduced their intake of saccharine or 
sucrose, a potential behavioral model of anhedonia [3]. Furthermore, this effect was 
selectively reversed by chronic treatment with the tricyclic antidepressant drugs (TCA) such 
as imipramine [3]. Further work was able to repeat this result using more mild stressors, such 
as periods of food and water deprivation, small temperature reductions and changes of cage 
mates [4,5]. Following these studies, the CMS procedure, and modified versions such as 
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chronic unpredictable stress (CUS or UCMS), became commonly used and much work 
demonstrated that other depression-like changes were induced in animals, such as decreased 
sexual and aggressive behaviors, decreased self- care, and altered sleep patterns [5]. 
Furthermore, these behaviors were all reversible by chronic, but not acute, treatment using 
multiple classes of antidepressants [6]. While historically potential pitfalls of the CMS 
procedure are that it is notoriously labor intensive, and that there has been some difficulty in 
getting the procedure established in mice of various backgrounds and the results replicated 
across laboratories [7], the modified versions of the CMS have proven more useful.  
 A distinct procedure that has gained traction is the usage of a social defeat model. 
In this paradigm a mouse is forced into the territory of a mouse from a larger, more aggressive 
strain leading to an interaction resulting in intruder subordination. Repeated defeats over 10 
days can result in a long lasting reduced social interaction, sexual dysfunction, sleep 
dysregulation, anxiety, metabolic deficits and anhedonia [8-10]. Interestingly, following the 
social defeat procedure there remains a large variance in behavior outcomes in spite of using 
an inbred mouse strain (C57BL/6). Some animals display a resistance to social defeat 
(resilience) while others are susceptible (determined by interaction with a social target relative 
to an empty enclosure). Similar validity as the social defeat has been established for early life 
stress, such as maternal separation, which induces life-long behavioral and neuroendocrine 
abnormalities in the pups, some of which can be reversed by antidepressant medications 
[11,7] 
 Another procedure for inducing a depression-like state in Rodents is administration 
of chronic glucocorticoids in order to mimic the effects of chronic stress. A significant 
proportion of depressed patients display altered activity of the HPA axis, and chronic stress 
generally leads to hypersecretion of corticosteroids, which imposes an increased risk for 
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depression [12].  
 Among these possibilities to induce depression with co-morbid anxiety in Rodents, 
we choose to set up a model based on chronic corticosterone because the procedure is easy to 
implement compared to the CMS and easy to replicate across laboratories. Previous protocols 
have implemented the administration of corticosterone using pellets [13] or chronic injections 
[14]. The protocol described in this chapter is a method based on chronic corticosterone 
administration in the drinking water. This protocol provides an alternative to chronic 
injections preventing to dissolve CORT in sesame oil or EtOH. Chronic corticosterone 
administration has already been used in both C57BL⁄6 and CD-1 mice [15] but also in Rat 
[16]. It effectively induces multiple anxiety- and depression-like changes in behavior, 
neurochemistry and brain morphology [17,15,18,19]. Behaviorally, depression-related 
changes include suppression of sucrose intake and decreased self-care [15,16], while anxiety- 
related changes include increased latency to emerge into the light compartment in the 
light/dark test, decreased time, entries and percent distance in the center of an open field and 
increased latency to take a bite of food in the novelty suppressed feeding (NSF) test 
[19,15,20]. Furthermore, these effects are reversible by chronic, but not acute, antidepressant 
treatment [19,15,16]. Importantly, using X-irradiation of a restricted region of mouse brain 
containing the hippocampus, we demonstrated that some but not all of the effects of 
antidepressant treatment were neurogenesis-dependent [21]. More specifically, X-irradiation 
prevented the neurogenic and behavioral effects of selective serotonin reuptake inhibitors 
(SSRIs), fluoxetine in the NSF test, which is a neurogenesis-dependent test; conversely, 
fluoxetine-induced reversal of anxiety measures in the open field is neurogenesis-
independent.  Finally, this corticosterone paradigm is a useful paradigm not only to screen 
new antidepressant drugs [19], but also to investigate the mechanism of action of 
antidepressant drugs [15,22]. 
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 Recently, we have adapted the CORT model protocol to screen a rapid onset of 
action of drugs to treat anxiety/depression disorders. In spite of the fact that SSRIs are the 
most commonly prescribed drugs for the treatment of depression and several anxiety 
disorders, the onset of action of these antidepressant drugs is often delayed by 3 to 6 weeks. 
[23]. The existence of this delayed action combined with the fact that one third of patients do 
not respond to treatment emphasizes the need for faster acting and more effective 
antidepressants [1]. This chapter gives a detailed overview of how the CORT model can help, 
at least in part, to solve this problem. For this purpose, we will take as an example, the effect 
of a 5-HT4 receptor ligand, RS67333, in comparison to the classical SSRI, fluoxetine. Indeed, 
past works performed in naïve, non-stressed rats pointed out 5-HT4 receptor agonists as a 
putative class of antidepressants with a rapid onset of action on depression-related behaviors 
and on hippocampal neurogenesis [24]. Indeed, a 3-day regimen with such compounds was 
sufficient to reverse CMS-induced decrease in sucrose intake in rats. Furthermore, several 
pre-clinical [15] and clinical [25-28] studies indicating the role of β-arrestin1, a protein 
involved in G protein receptor coupling, in the pathophysiology of mood disorders as well as 
in the mechanism of action of antidepressant [29,25,30,26,28]. So we also emphasize in this 
chapter how proteins levels, including β-arrestin 1 measurements in peripheral blood 
mononuclear cells (PBMCs) isolated from whole blood in corticosterone-treated mice, could 
provide one of the markers of a biological signature of treatment response.  
3. Procedure 
A classical protocol design to screen a rapid onset of action of drugs to treat 
anxiety/depression phenotype requires a 12 weeks study from the reception of the animals to 
their sacrifice (table 1). The corticosterone treatment will begin a week after animals are 
identified (the method used ear punch). The drug treatment will follow 4-weeks after the start 
of corticosterone treatment. Interestingly, in comparison to our original work [15], animals 
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are tested at two different time points throughout the protocol to compare subchronic (7 days) 
effects to chronic (28days) effects of drugs. The behavioral sequences are determined from 
the least to the most stressful events (i.e., from the open field to the FST). In addition, to 
address inherent difficulties in behavioral phenotyping in mice over time and to summarize 
results over tests and studies results, we use a method based on z-normalization principles 
also know as the emotionality score [31]. This test allowed the quantification of our behaviors 
results in an integrative manner along coherent dimensions, such as shown here for 
emotionality. Indeed, it is often difficult to reconcile positive or intermediate findings across 
tests, especially for behavioral measures that are subject to known variability in Rodents [31]. 
Thus, it is crucial to keep a record of behavioral data related to each animal across paradigm. 
It will allow calculating the emotionality score and/or performing correlation between 
behavior responses in anxiety/depression tests and changes in putative biomarkers. Blood 
collection and PBMCs isolation occurs the day after the last behavioral test is performed 
(table 1). 
 
3.1. Subjects 
 Historically we have been using adult male C57BL/6Ntac mice purchased from 
Taconic Farms (Lille Skensved, Denmark and Germantown, NY, USA. The choice of the 
adult male C57BL/6Ntac mice is based on the fact that most of C57BL/6Ntac, and more 
generally C57BL⁄6 mice, are non-responders at baseline, i.e., chronic antidepressant treatment 
has little effect on neurogenesis or behavioral tests in this mouse background. However, when 
C57BL⁄6 mice are exposed to chronic corticosterone paradigms, a depression-like state is 
induced as determined by multiple behavioral tests [15]. Chronically stressed adult C57BL⁄6 
mice also display a reduction in proliferation of progenitor cells[15,19]. Subsequent chronic 
antidepressant treatment will rescue the behavioral and neurogenesis effects of chronic stress 
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in C57BL⁄6 mice [15]. In other words, chronic stress paradigms can convert C57BL/6 mice 
from non-responders to responders (for review see [32]).  
 For a classical screening of a compound, experimenters should consider using 15 
animals per group. A classical study includes a corticosterone-treated group, a corticosterone-
treated group in the presence of fluoxetine and the corticosterone-treated group with the tested 
drugs at 2-3 different doses. A control group (without CORT) should also be included. It will 
allow the comparison with the corticosterone-treated group, pointing out the 
anxiety/depression-like state in this latest group.  
 Thus, to screen a putative rapid onset of action of a drug to treat anxiety/depression, 
at least 60 animals should be included in an experiment. All mice are 7-8 weeks old, weighed 
23-25g at the beginning of the treatment, and are maintained on a 12L:12 D schedule (lights 
on at 0600). They are housed in groups of five (table 1). Food and water are provided ad 
libitum. A week after their reception, animals are identified by ear punch. This identification 
is crucial and will allow a monitoring of each animal across time and across behavioral 
paradigms. We recommend monitoring body weights once a week during all the experiment. 
In our hands, male C57BL/6Ntac exposed to chronic corticosterone (5 mg/kg/day for 4 
weeks) might gain weight in comparison to controls animals (table 1). All testings must be 
conducted in compliance with the laboratory animal care guidelines and with protocols 
approved by the Institutional Animal Care and Use Committee.  
3.2. Corticosterone preparation 
Our designed protocol consists in chronic administration of corticosterone in the drinking 
water. For this purpose, corticosterone (4-pregnen-11b-DIOL-3 20-DIONE 21-hemisuccinate 
(Sigma-Aldrich Saint-Quentin Fallavier, France) is dissolved in vehicle (0.45% 
hydroxypropyl-β-cyclodextrin, Sigma-Aldrich Saint-Quentin Fallavier, France). The dose and 
duration of corticosterone treatment are selected based on previous studies [15,33]. For a 
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cohort of 60 animals corticosterone (35 µg/ml/d, equivalent to about 5 mg/kg/d) is available 
ad libitum in the drinking water in (table 2). Corticosterone powder begins to degrade once in 
solution (table 1). Thus, to protect corticosterone from light, opaque bottles should be used. 
Control animals (vehicle group) should receive the vehicle (0.45 % β-cyclodextrin, β-CD).  
3.3. Drugs treatment to assess rapid onset of action of 5-HT4 receptor 
agonist, RS67333 
While administration with β-CD or corticosterone continued, mice are treated with vehicle 
(0.45% β-CD), fluoxetine hydrochloride (Anawa Trading, Zurich, Switzerland), RS67333 
hydrochloride (1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-butyl-4piperidinyl)-1-propanone 
hydrochloride) (Tocris Bioscience, Bristol, United Kinkdom) (Fig. 1). RS67333 is delivered 
by osmotic mini-pumps at a dose of 1.5 mg/kg/day [34]. Fluoxetine (18 mg/kg per day) is 
delivered in the drinking water as previously described [15]. Osmotic minipumps (42 days 
mini-pumps, 2006 model, Alzet, Cupertino, CA) is implanted subcutaneously under light 
anesthesia (ketamine/xylazine; (75/20 mg/kg) from Sigma Aldrich (Sigma-Aldrich Saint-
Quentin Fallavier, France). Treatment is always maintained until the end of the experiments 
(figure 1). 
3.4. Behavioral tests 
The same cohort of animals is tested in five different behavioral tests of anxiety and 
depression. The originality of our protocol consists of successively testing after 7 days and 28 
days of treatment, each animal, over a week in the Open Field (OF), Elevated Plus Maze 
(EPM), Novelty Suppressed Feeding (NSF), Splash Test (ST) and Tail Suspension Test (Fig 
1). Behavioral testing occurred during the light phase between 07:00 a.m. and 07:00 p.m.. 
Behavioral paradigms occur after 7 or 28 days of drug treatment. Other behavioral paradigms 
could also be processed such as the light/dark paradigm for anxiety or the sucrose preference 
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for depression. Experimenters should keep in minds that they should always start behavioral 
analyses from the less to the most stressful paradigm, i.e., Open Field, Elevated Plus Maze, 
Novelty Suppressed Feeding, Forced Swim Test/Tail Suspension Test, Splash Test). 
3.1.1. Open Field (OF) 
This test was initially described by Hall and Ballachey (1932) [35] and is performed in 
our laboratory as described by David and colleagues [15]. Motor activity is quantified in four 
43 x 43 cm2 Plexiglas open field boxes (MED Associates, Georgia, VT). Two sets of 16 
pulse-modulated infrared photo beams are placed on opposite walls 2.5-cm apart to record x–
y ambulatory movements. Activity chambers are computer interfaced for data sampling at 
100-ms resolution. The computer defines grid lines dividing each open field into center and 
surround regions, with each of four lines being 11 cm from each wall. Dependent measures in 
the center are the total time and the number of entries over a 30-min test period. The activity 
in the center is quantified as distance traveled in the center divided by total distance traveled.  
3.1.2. Elevated Plus Maze (EPM) 
This test was initially described by Pellow and colleagues (1985) [36] and is 
performed in our laboratory as described by David and colleagues [15]. The maze is a plus-
cross-shaped apparatus, with two open arms and two arms closed by walls linked by a central 
platform 50 cm above the floor. Mice are individually placed in the center of the maze facing 
an open arm and are allowed to explore the maze during 5 min. The time spent in the open 
arms as well as the numbers of entries into the open arms are used as an anxiety index. All 
parameters are measured using a video tracker (EPM3C, Bioseb, Vitrolles, France). 
3.1.3. Novelty-Suppressed-Feeding (NSF) 
The NSF in mice was initially described by Santarelli and colleagues (2003) [21]. It is 
a conflict test that elicits competing motivations: the drive to eat and the fear of venturing into 
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the center of a brightly lit arena. The latency to begin eating is used as an index of 
anxiety/depression-like behavior, because classical anxiolytic drugs as well as chronic 
antidepressants decrease this measure. The NSF test is carried out during a 10-min period as 
previously described in René Hen’s laboratory [15]. Briefly, the testing apparatus consisted of 
a plastic box (50x50x20 cm), the floor of which is covered with approximately 2 cm of 
wooden bedding. Twenty-four hours prior to behavioral testing, all food is removed from the 
home cage. At the time of testing, a single pellet of food (regular chow) is placed on a white 
paper platform positioned in the center of the box. Each animal is placed in a corner of the 
box, and a stopwatch is immediately started. The latency to eat (defined as the mouse sitting 
on its haunches and biting the pellet with the use of forepaws) is timed. Immediately 
afterwards, the animal is transferred to its home cage, and the amount of food consumed by 
the mouse in the subsequent 5 min is measured, serving as a control for change in appetite as 
a possible confounding factor. 
3.1.4. Tail Suspension Test (TST) 
The TST was initially described by Steru et al., (1985) [37] as an antidepressant 
activity screening test [37] often used to test compounds that are expected to affect depression 
related behaviors. Mice are suspended by their tails with tape:, in such a position that they 
cannot escape or hold on to nearby surfaces. During this test, typically 6 minutes in duration, 
the resulting escape oriented behaviors are quantified using an automated tail suspension test 
apparatus (Bioseb, Vitrolles, France). A specific strain gauge linked to a computer quantifies 
the time spent by the animal trying to escape from this uncomfortable position. 
3.1.5. Splash Test (ST) 
This test was initially described by Surget and colleagues [6] and it consists of 
squirting 200 µl of a 10% sucrose solution on the mouse’s snout. The grooming duration is 
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assessed at the end of the corticosterone regimen following (or not) by 4 weeks of drug 
treatment according to a protocol used elsewhere [15]. 
3.5. Emotionality Score 
To address behavioral variability and obtain comprehensive and integrated measures 
in each group, emotionality-related data are normalized using a Z-score methodology 
previously described [31]. Z-scores for behavioral measures are first averaged within a test, 
then across tests to ensure equal weighting of the four tests comprising the final Z-score 
(Table 3). The TST as the FST, is excluded from the emotionality score analysis since it is 
primarily recognized as a screening test for antidepressant drug action. In the Z-score 
analysis, the vehicle/vehicle group is used as control. Increased emotionality in mice is 
revealed by decreased values of dependent variables in some tests (OF and EPM) and by 
increased values in other tests (NSF), and thus all measures indicative of increased 
emotionality should be reflected by positive numbers of standard deviations from the control 
group mean [31]. 
3.6. Collection of mouse blood and isolation of peripheral blood 
mononuclear cells 
Candidate biomarkers that can accurately predict antidepressant-like responses must 
be identified. While there are currently no specific markers that are considered “gold 
standards”, a few candidates have emerged. Recently, we showed that PBMCs from 
anxious/depressed mice showed significantly reduced β-arrestin 1 levels [38]. These 
decreased β-arrestin 1 expression levels in PBMCs were restored to normal levels with 
chronic fluoxetine treatment. Blood is collected from anaesthetized mice as previously 
described [39,40]. In compliance with the laboratory animal care guidelines, approximately 
0.4 ml of blood per mouse is collected in K3EDTA tubes with a submandibular bleeding 
procedure [30]. 5 mm point size sterile lancets (MediPoint, Mineola, NY) are used to 
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puncture the location where the orbital vein and the submandibular vein join to form the 
jugular vein [40]. A light pressure with dry gauze is applied to the punctured area for 
hemostasis. Separation and extraction of peripheral blood mononuclear cells (PBMCs) are 
performed using an iodixanol mixer technique [41]. Mouse PBMCs are purified from whole 
blood by density centrifugation (300 g at 20°C for 30 min) using solution B of the 
OptiPrepTMgradient solution (Sigma-Aldrich Saint-Quentin Fallavier, France). Specifically, 
the OptiPrepTMgradient solution is used to separate blood into PBMC and plasma layers with 
centrifugation. The PBMC layers are then carefully removed from the tube and transferred to 
a new 50 ml conical tube. The PBMCs are then washed twice with solution B (1 min each). 
After another centrifugation (150 g at 20°C for 7 min) and 2 washing steps (1 min each), 
mouse PBMCs are recovered with a final centrifugation (1,000 g at 4°C for 5 min) and are 
stored at -80°C.  
Equal amounts of proteins are separated by 10% sodium dodecyl sulfate–
polyacrylamide electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride 
membranes (PVDF), (Amersham Biosciences, Les Ulis, France). The membranes are then 
incubated overnight with a primary mouse monoclonal anti-β-Arrestin 1 antibody (#610551, 
BD Bioscience Pharmigen, France; 1:100). In order to ensure that equal amounts of total 
protein (30 μg) are loaded in each lane, β-actin protein levels were also assessed (β-actin (C4) 
HRP, Santa Cruz Biotechnology, Germany, 1:10,000). Immune complexes are detected using 
appropriate peroxide-conjugated secondary antibodies and a Chemiluminescent reagent kit 
(Pierce Biotechnology). Immunoblot quantifications are performed by densitometric scanning 
with Image lab software (Bio-Rad). Signals are in the linear range. The densitometry values 
are normalized against the β-actin values. 
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3.7. Statistical Analysis 
Results from data analyses are classically expressed as mean ± SEM. Data are 
analyzed using StatView 5.0 software (SAS Institute, Cary, NC). One-way ANOVAs is 
applied to the behavioral and neurochemical data as appropriate. Significant main effects 
and/or interactions are followed by Fisher’s PLSD post hoc analysis. In the NSF test, the 
Kaplan-Meier survival analysis is used due to the lack of normal distribution of the data. 
Mantel-Cox log-rank test is used to evaluate differences between experimental groups. 
Statistical significance is set at P<0.05.  
4. Data Analysis and Anticipated Results  
Behavioral data can be analyzed and presented separately using classical parameters 
such as time or entries in the center in the Open Field, time or entries in the opened arm in the 
Elevated Plus Maze, the latency to feed in the Novelty Suppressed Feeding, the grooming 
duration in the Splash test and the immobility duration in the Tail Suspension/Forced Swim 
Test (table 4), Excluding the TST/FST, chronic corticosterone treatment affects all the 
behavioral parameters by inducing an anxiety/depressive-like phenotype. For example, long-
term corticosterone exposure does not change immobility duration in the mouse FST, which 
might imply that this test is more appropriate to identify antidepressant-like activity of a 
molecule than a depressive-like state, as originally described by Porsolt (1977) [42].  
Classical monoaminergic antidepressants such as fluoxetine, reboxetine, imipramine 
or agomelatine, a novel antidepressant drug with melatonergic agonist and 5-HT2C receptor 
antagonist properties, display antidepressant/anxiolytic-like properties in the CORT model 
[15,33], correcting behavioral deficits in the OF, EPM, NSF or ST. Applying z-normalization 
across complementary measures in different behavioral tests after chronic corticosterone 
increases emotionality score [31]. The emotionality score (z-score) is easy-to-apply and 
“generalizable”. Z-score methodology can increase the reliability and comprehensiveness of 
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behavioral testing from a variety of non-exclusive tasks, but along cohesive behavioral 
dimensions. An important feature of its application to behavioral data is to ensure conformity 
with the direction of effects. Thus, chronic corticosterone is producing a persistent 
anxiety/depressive-like phenotype in mice, as measured by an increase in emotionality score.  
It is extremely interesting to note that, unlike fluoxetine, a 5-HT4 receptor agonist, 
such as RS67333, is able to correct the increase in the emotionality score induced by chronic 
corticosterone after a week of treatment. A longer duration of treatment (28 days) is required 
for fluoxetine to exert anxiolytic-like effects comparable to 7 days of RS67333 treatment. 
Data from pre-clinical [15,25][19] and clinical [25,28,27] studies performed by 
Avissar’s group support the importance of measuring β-arrestin 1 levels as a peripheral 
biomarker of the pathophysiology of mood disorders and predicting the antidepressant-like 
response [30,25,27]. We recently found that β-arrestin 1 protein levels in leukocytes were 
reduced when mice were treated by chronic corticosterone [30,35]. The reduced β-arrestin 1 
levels exposed to chronic corticosterone were alleviated by fluoxetine treatment after chronic, 
but not subchronic treatment (Fig 3). In contrast, RS67333 treatment was able to correct this 
decrease in β-arrestin 1 expression in CORT-treated mice as early as 7 days of treatment. The 
rapid onset of anxiolytic/antidepressant-like activity observed after a subchronic treatment 
with RS67333 is predicted by a change in β-arrestin 1 levels in PBMC isolated from 
anxious/depressive-like mice. The relationship between changes in β-arrestin 1 levels at the 
periphery, as well as in various brain tissues and the anxiolytic/antidepressant-like activity of 
5-HT4 receptor agonists is still unknown and requires further investigation.  
5. Troubleshooting  
Several practical recommendations, summarized here, may help the researchers to 
obtain more reliable and reproducible behavioral data. 
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1-The CORT model in mice has been developed in adult male C57BL/6Ntac mice. 
Strains differences may occur. The researchers may need to re-assess the strain’s sensitivity to 
long-term corticosterone treatment for their experiment, e.g. re-examine the dose of 
corticosterone.  
2-Experimenters should keep in mind that the emotionality score should be used only 
for screening purposes and not for mechanistic approaches. Indeed, antidepressant-like 
activity of monoaminergic drugs at least, required neurogenesis-dependent and independent 
action in the mouse CORT model [15]. For example, in the NSF test, both fluoxetine and a 5-
HT4 receptor agonist had an anxiolytic/antidepressant-like effect only after chronic treatment, 
suggesting that the neurobiological mechanisms involved in this paradigm are different from 
those underlying the other behavioral tests (OF, EPM, TST, ST). If after a subchronic 
treatment, the emotionality score for a 5-HT4 receptor agonist can reverse/block the increase 
in z-score induced by chronic corticosterone treatment, it only reflects a part of its activity, 
the neurogenesis-independent one.  
3- Measuring protein levels in mouse PBMCs at several time points is a powerful 
technique that can be used to reveal potential biomarkers for the pathophysiology of 
depression and the antidepressant response. Our study focused on β-arrestin 1 level, however, 
disease conditions are most often signified by the dysregulation of complex biological 
pathways involving multiple key factors. Experimenter should keep in mind that several 
factors may influence the outcome of PBMC separation. Factors such as addition of medium 
to whole blood before centrifugation, PBMC separation, medium temperature, separation 
media from different sources, centrifugation speed and frequency and addition of serum are 
likely to have an impact on cell quality and quantity recover and therefore a low yield in 
protein levels. 
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6. Conclusions  
We believe the CORT model described in this chapter is ideally suited to address the 
basic molecular mechanisms of anxiety/depression and screening drugs with innovative 
targets. The present study is encouraging for the development of 5HT4 receptor agonist or 
signaling molecules that interact with its receptor leading to a fast anxiolytic/antidepressant 
activity for the benefit of patients. Finally, we also demonstrated that PBMCs isolated from a 
small volume of whole blood in unanesthetized mice using a submandibular bleeding method 
might provide a useful biological tool to assess circulating proteins including β-arrestin 1. 
Likewise, we confirmed that measurements of β-arrestin 1 level in PBMCs may serve as a 
biochemical marker of depression in humans and can predict fast onset of action of drugs 
such as 5-HT4 receptor agonist. Overall, with the CORT model associated with an 
emotionality score analysis and a β-arrestin 1 measure in PBMC, we developed powerful 
tools to predict the effectiveness of antidepressant drugs. 
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Legend 
 
Figure 1: Protocol to assess fast onset of action of new drugs in anxio/depressive mouse 
model 
(A) In place of normal drinking water, grouped-housed male C57BL/6Ntac mice are 
presented with vehicle (0.45% hydroxypropyl-β-cyclodextrin) or corticosterone (35 µg/ml) in 
the presence or absence of a 5-HT4 agonist (RS67333, 1.5 mg/kg/day, Alzet® mini pump 
model 2006 implanted subcutaneously) or fluoxetine, 18 mg/kg/day.  
(B) The anxiety/depressive-like phenotype of chronic corticosterone is assessed by comparing 
a chronic corticosterone/vehicle group versus a vehicle/vehicle group. The same animals are 
successively tested in the OF paradigm, the EPM, the NSF, the ST, and the TST after 
subchronic (days 7 to 11) or chronic (days 28 to 33) drug treatment. 
 
Figure 2: Classical behavioral paradigms used to screen anxiolytic/antidepressant-like 
activity in mice 
The Open Field (OF) and the Elevated plus maze (EPM) paradigms are used to screen 
anxiolytic-like activity. The Splash test (ST), the Forced Swim test (FST) and the Tail 
Suspension Test are useful paradigm to predict antidepressant-like activity.  
 
Figure 3: Rapid onset of action of 5-HT4 agonist treatment in a mouse model of 
anxiety/depression  
Effects of a subchronic and a chronic 5-HT4 ligand, RS67333, or fluoxetine treatment on 
anxiety- and depression-like behaviors on the Emotionality score after subchronic (A) or 
chronic treatment (B). Test z-values (Open-Field, Elevated Plus maze, Novelty Supressed 
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Feeding and Splash Test) are then calculated by averaging individual z-scores and averaged to 
obtain emotionality z-score after subchronic (A) and chronic treatment (B). One-factor 
ANOVA with Fisher’s PLSD post hoc analysis against the control group (vehicle/vehicle) 
revealed that only chronic RS67333 treatment reversed increase in emotionality score induced 
by corticosterone after subchronic treatment (F(3,56)=4.9, p<0.01) while it takes 28 days for 
fluoxetine treatment (F(3,56)=9.25, p<0.01). Values plotted are mean ± SEM (n= 15 per 
group). **p<0.01, ##p<0.01, versus vehicle/vehicle group and corticosterone/vehicle group, 
respectively. 
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Table 1: Weekly procedure to assess rapid onset therapeutic activity in a model of 
anxiety/depression 
	  
Week Days Procedures 
0 0 Reception of animals, housed by 5 
1 7 Mouse Identification (ear punch) 
2 
14  
(day 0 of the treatment) 
Start of Corticosterone treatment 
Weigh animals 
17 Change Corticosterone 
3  
(week 1 of the treatment) 
21 
(day 7 of the corticosterone treatment) 
Change Corticosterone 
Weigh animals 
24 Change Corticosterone 
4 
(week 2 of the treatment) 
28 
(day 14 of the corticosterone treatment) 
Change Corticosterone 
Weigh animals 
31 Change Corticosterone 
5 
(week 3 of the treatment) 
35 
(day 21 of the corticosterone treatment) 
Change Corticosterone 
Weigh animals 
38 Change Corticosterone 
6 
(week 4 of the treatment) 
42 
(day 28 of the corticosterone treatment) 
Change Corticosterone 
Weigh animals 
45 Change Corticosterone 
7 
(week 5 of the treatment) 
49 
(day 35 of the corticosterone treatment) 
Start fluoxetine and drug treatment (5-
HT4 receptor agonist RS67333, mini-pump) 
Change Corticosterone 
Weigh animals 
52 Change Corticosterone 
8 
(week 6 of the treatment) 
56 
(day 42 of the corticosterone treatment, day 7 
of drugs treatment) 
Change Corticosterone and fluoxetine 
Weigh animals 
Open Field Paradigm 
57 Elevated Plus Maze 
58 Food Deprivation 
59 Change Corticosterone Novelty Suppressed Feeding 
60 Splash Test 
61 Tail Suspension Test 
62 Blood collection 
9 
(week 7 of the treatment) 
63 
(day 49 of the corticosterone treatment, day 14 
of drugs treatment) 
Change Corticosterone and fluoxetine 
Weigh animals 
66 Change Corticosterone 
10 
(week 8 of the treatment) 
70 
(day 56 of the corticosterone treatment, day 21 
of drugs treatment) 
Change Corticosterone and fluoxetine 
Weigh animals 
73 Change Corticosterone 
11 
(week 9 of the treatment) 
77 
(day 63 of the corticosterone treatment, day 28 
of drugs treatment) 
Change Corticosterone and fluoxetine 
Weigh animals 
Open Field Paradigm 
78 Elevated Plus Maze 
79 Food Deprivation 
80 Change Corticosterone Novelty Suppressed Feeding 
81 Splash Test 
82 Tail Suspension Test 
83 Blood collection 
12 
(week 10 of the treatment) 84 Sacrifice of animals (perfusion) !
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Table 2: Method to prepare chronic corticosterone 
 
Chronic Corticosterone administration (mice) in the drinking water 
§ Dissolving Corticosterone  
§ Dissolve corticosterone in 20% β-cyclodextrin  
§ Protect corticosterone from excessive light exposure. 
 
 Preparation of the solution of 100 ml of a 20% β-cyclodextrin solution (β-
cyclodextrin can be prepare weekly and stored at 4°C) 
§ Weigh 20g of β-cyclodextrin  
§ Raise volume to 100 ml with water. 
§ Stir 30 min at room temperature  
 
Preparation of the solution of 35µg/ml/day of corticosterone 
§ To 37.5 ml 20% β-cyclodextrin add 58.34 mg corticosterone 
§ Sonicate circa 30 min 
§ Raise volume to 1666 ml with water. 
§ Compounds used: 
§ Corticosterone:  Sigma-C2505 
§ β-cyclodextrin:  Sigma H107 
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Table 4: Example of table used to calculate the emotionality score 
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Résultats	  Expérimentaux	  
	  
Article	  4:	  	  
Rapid	   anxiolytic	   effects	   of	   a	   5-­‐HT4	   receptor	   agonist	   are	   mediated	   by	   a	   neurogenesis-­‐
independent	   mechanism.	   Accepted	   for	   publication	   in	   Neuropsychopharmacology,	  
manuscript	  NPP-­‐13-­‐1008RR	  
	  
Article	  5:	  	  
A	  method	  for	  biomarker	  measurements	  in	  peripheral	  blood	  mononuclear	  cells	  isolated	  from	  
anxious	   and	   depressed	   mice:	   β-­‐arrestin	   1	   protein	   levels	   in	   depression	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Introduction	  of	  the	  study	  
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed drugs 
for the treatment of depression and several anxiety disorders. Unfortunately, the onset of action 
of SSRIs is often delayed by 3 to 6 weeks (Artigas, 2013). The existence of this delayed action 
combined with the fact that one third of patients do not respond to treatment emphasizes the 
need for faster acting and more effective antidepressants (Samuels et al., 2011).  
It has been proposed that 5-HT4 receptor agonists such as RS67333 may bring new 
hope for treating depression (Lucas, 2009; Lucas et al., 2005; Lucas and Debonnel, 2002; 
Lucas et al., 2010; Lucas et al., 2007). 
While a number of studies have assessed the antidepressant-like activity of 5-HT4 
receptor agonists, none have so far evaluated their anxiolytic-like profile. We also assessed 
whether chronic 5-HT4 receptor stimulation can affect proliferation of newborn cells and 
maturation of newborn neurons. Finally, using our mouse model of anxiety/depression 
combined with ablation of hippocampal neurogenesis by X-irradiation, we assessed whether 
the anxiolytic/antidepressant action of RS67333 after 7-days and 28-days of treatment recruits 
a neurogenesis-dependent mechanism. 
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ABSTRACT 
Selective serotonin reuptake inhibitors (SSRIs) display a delayed onset of action of several 
weeks. Past work in naïve rats showed that 5-HT4 receptor agonists had rapid effects on 
depression-related behaviors and on hippocampal neurogenesis. We decided to investigate 
whether 5-HT4 receptor stimulation was necessary for the effects of SSRIs in a mouse model 
of anxiety/depression and whether hippocampal neurogenesis contributed to these effects. 
Using the mouse corticosterone model of anxiety/depression, we assessed whether chronic 
treatment with a 5-HT4 receptor agonist (RS67333, 1.5 mg/kg/day) had effects on anxiety and 
depression-related behaviors as well as on hippocampal neurogenesis in comparison to 
chronic fluoxetine treatment (18 mg/kg/day). Then, using our anxiety/depression model 
combined with ablation of hippocampal neurogenesis, we investigated whether neurogenesis 
was necessary for the behavioral effects of subchronic (7-days) or chronic (28-days) RS67333 
treatment. We also assessed whether a 5-HT4 receptor antagonist, (GR125487, 1 mg/kg/day) 
could prevent the behavioral and neurogenic effects of fluoxetine. Chronic treatment with 
RS67333, similar to fluoxetine, induced anxiolytic/antidepressant-like activity and stimulated 
adult hippocampal neurogenesis, specifically facilitating maturation of newborn neurons. 
However, unlike fluoxetine, anxiolytic effects of RS67333 were already present after 7 days 
and did not require hippocampal neurogenesis. Chronic treatment with GR125487 prevented 
both anxiolytic/antidepressant-like and neurogenic effects of fluoxetine, indicating that 5-HT4 
receptor activation is necessary for these effects of SSRIs. 5-HT4 receptor stimulation could 
represent an innovative and rapid onset therapeutic approach to treat depression with 
comorbid anxiety.  
Key words: 5-HT4 receptor, anxiolytic, neurogenesis, fast onset 
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INTRODUCTION 
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed drugs 
for the treatment of depression and several anxiety disorders. Unfortunately, the onset of action 
of SSRIs is often delayed by 3 to 6 weeks (Artigas, 2013). The existence of this delayed action 
combined with the fact that one third of patients do not respond to treatment emphasizes the 
need for faster acting and more effective antidepressants (Samuels et al, 2011).  
It has been proposed that 5-HT4 receptor agonists such as RS67333 may bring new hope 
for treating depression (Lucas, 2009; Lucas et al, 2005; Lucas and Debonnel, 2002; Lucas et al, 
2010; Lucas et al, 2007). Indeed, administration of 5-HT4 agonists induced similar molecular 
and behavioral changes as common antidepressants in rodents (Bockaert et al, 2008; Lucas et 
al, 2007; Pascual-Brazo et al, 2012). Depressed-like state in the olfactory bulbectomy or 
chronic mild stress model was completely abolished after 10-14 days of RS67333 treatment in 
rats, suggesting a more rapid response mechanism in comparison to classical antidepressants 
(Lucas et al, 2007). A positive behavioral response in the novelty suppressed feeding (NSF) test 
in rat, a complete reversion of anhedonic-like state (sucrose consumption), and an increase in 
swimming behavior in defeated mice in the forced swim test (FST) were also observed after a 
short period of RS67333 treatment (Gomez-Lazaro et al, 2012; Pascual-Brazo et al, 2012). In 
addition to behavioral data, and in agreement with a previous report from Lucas and colleagues, 
a recent study performed in naïve rats confirmed that a short period of treatment with RS67333 
increased the number of newborn cells in the dentate gyrus (DG) (Pascual-Brazo et al, 2012). 
These results are interesting because hippocampal neurogenesis has been implicated in some of 
the behavioral effects of antidepressants in adult rodents (David et al, 2009; Santarelli et al, 
2003). However, no direct evidence has yet linked the antidepressant-like effects of 5-HT4 
receptor activation and its neurogenic effects. Lastly, it has been suggested that SSRIs and 5-
HT4 receptor agonists share common mechanisms of action. Indeed, the 5-HT4 receptor agonist, 
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RS67333, augmented the acute effect of paroxetine on extracellular 5-HT levels in rat ventral 
hippocampus, and after only 3 days of administration increased basal hippocampal 5-HT levels 
(Licht et al, 2010). The coadministration of the SSRI citalopram and RS67333 strongly 
potentiated the antidepressant-like properties of the latter in several electrophysiological, 
molecular, and behavioral paradigms (Lucas et al, 2010). 
While a number of studies have assessed the antidepressant-like activity of 5-HT4 
receptor agonists, none have so far evaluated their anxiolytic-like profile. It is noteworthy that 
some SSRIs are often prescribed for the treatment of anxiety disorders (Burghardt and Bauer, 
2013). Anxiety disorders have a lifetime prevalence of over 25% making them the most 
common psychiatric disorders (Kheirbek et al, 2012). Moreover, a co-morbidity between 
depression and anxiety disorders is commonly observed. Thus, this study aimed to investigate 
both antidepressant and anxiolytic-like effects of either subchronic or chronic administration 
of a 5-HT4 receptor agonist in a model of anxiety/depression based on the elevation of 
glucocorticoids in mice (CORT model) (David et al, 2009). “Standard models of depression 
that rely on environmental stress manipulations, such as learned helplessness or the chronic 
mild stress (CMS) are hampered by protocol variability and reported difficulties in 
replication, thus highlighted the need for a reliable, easily replicable depression model 
(Nestler et al, 2002). The corticosterone model is a chronic exposure method optimized for 
use in modeling the persistent anxiety/depression-like state in rodents, allowing for multiple 
behavioral tests in the same animals using an etiologically relevant model of depression that is 
easily replicable between and within laboratories (David et al, 2009; David et al, 2010; 
Gould, 2011; Mendez-David et al, 2013). 
We also assessed whether chronic 5-HT4 receptor stimulation can affect proliferation 
of newborn cells and maturation of newborn neurons. Finally, using our mouse model of 
anxiety/depression combined with ablation of hippocampal neurogenesis by X-irradiation, we 
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assessed whether the anxiolytic/antidepressant action of RS67333 after 7-days and 28-days of 
treatment recruits a neurogenesis-dependent mechanism. 
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MATERIALS and METHODS: 
The supplemental data for this article include supplemental experimental procedures, six 
tables, and four figures. 
 
Subjects 
Adult male C57BL/6Ntac mice were purchased from Taconic Farms (Lille Skensved, 
Denmark and Germantown, NY, USA for the pharmacological and the X irradiation studies 
respectively). All mice were 7-8 weeks old, weighed 23-25g at the beginning of the treatment, 
and were maintained on a 12L:12 D schedule (lights on at 0600). They were housed in groups 
of five. Food and water were provided ad libitum. All testing was conducted in compliance 
with the laboratory animal care guidelines and with protocols approved by the Institutional 
Animal Care and Use Committee (Council directive # 87-848, October 19, 1987, Ministère de 
l'Agriculture et de la Forêt, Service Vétérinaire de la Santé et de la Protection Animale, 
permissions # 92-256B to D.J.D.).  
 
Drugs 
Corticosterone (4-pregnen-11b-DIOL-3 20-DIONE 21-hemisuccinate (35µg/mL) from 
Sigma Aldrich (Saint-Quentin Fallavier, France) was dissolved in vehicle (0.45% 
hydroxypropyl-β-cyclodextrin, (β-CD), Sigma-Aldrich Saint-Quentin Fallavier, France). 
Fluoxetine hydrochloride (160 mg/mL, equivalent to 18mg/kg/day) was purchased from 
Anawa Trading, (Zurich, Switzerland) and dissolved in 0.45% β-CD/corticosterone solution. 
Hydrochloride(1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-butyl-4piperidinyl)-1-propanone 
hydrochloride) (RS67333), and (5-Fluoro-2-methoxy-[1-[2-[(methylsulfonyl)amino]ethyl]-4-
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piperidinyl]-1H-indole-3-methylcarboxylate sulfamate) (GR125487) were purchased from 
Tocris Bioscience (Bristol, United Kingdom) and dissolved in 0.9% saline solution. RS67333 
and GR125487 were chosen based on previous work (Cachard-Chastel et al, 2007; Lucas et 
al, 2007).  
RS67333 shows high binding affinity for the 5-HT4 receptor with a pKi of 8.7 
(Bockaert et al, 2004; Eglen et al, 1995).  Except for the sigma receptors, which are bound at 
affinities comparable to 5-HT4 (sigma 1: pKi = 8.9; and sigma 2: pKi = 8.0), RS67333 has a 
pKi of less than 6.7 for other neurotransmitter receptors including 5-HT1A, 5-HT1D, 5-HT2A, 
5-HT2C, dopamine D1, D2 and muscarinic M1-M3 receptors. However little is known about the 
function of sigma receptors”. However little is known about the function of sigma receptors.  
GR125487 is the most selective 5-HT4 receptor antagonist with a pKi = 10.6 (Schiavi 
et al, 1994) presenting a selectivity more than 1000 fold over other 5-HT receptor (Gale et al, 
1994). The dose of RS67333 and GR125487 used in this study were chosen based on previous 
works (Cachard-Chastel et al, 2007; Lucas et al, 2007). 
 
Corticosterone model and treatment 
 Our model of elevated glucocorticoids (also named CORT model) is able to blunt 
the response of the hypothalamic-pituitary-adrenal axis (HPA) as shown by the markedly 
attenuated stress-induced corticosterone levels observed in these mice (David et al, 2009). 
This is probably a consequence of the negative feedback exerted by corticosterone on the 
HPA axis. This model displays hallmark characteristics of anxiety and depression.  
The dose and duration of corticosterone treatment was selected based on previous 
studies (David et al, 2009; Rainer et al, 2011). Corticosterone (35 µg/ml, equivalent to about 
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5 mg/kg/d) or vehicle (0.45 % β-cyclodextrin, β-CD) was available ad libitum in the drinking 
water in opaque bottles to protect it from light. Corticosterone-treated water was changed 
every 3 d to prevent any possible degradation. Thereafter, while administration with β-CD or 
corticosterone continued, mice were treated with vehicle (0.45% β-CD), fluoxetine, RS67333, 
GR125487 alone, or GR125487 in the presence of fluoxetine (Supplementary Fig. 1). Both 
RS67333 and GR125487 were delivered by osmotic mini-pumps at a dose of 1.5 mg/kg/day 
and 1mg/kg/day respectively (Lucas et al, 2005). Fluoxetine (18 mg/kg per day) was 
delivered in the drinking water as previously described (David et al, 2009). Osmotic 
minipumps (42 days mini-pumps, 2006 model, Alzet, Cupertino, CA) were implanted 
subcutaneously under light anesthesia (ketamine/xylazine; (75/20 mg/kg) from Sigma Aldrich 
(Sigma-Aldrich Saint-Quentin Fallavier, France). Controls animals (Vehicle/Vehicle or 
Corticosterone/Vehicle groups) were also implanted with a mini-pump containing 0.9% saline 
(2006 model, Alzet, Cupertino, CA). Treatment was always maintained until the end of the 
experiments. Corticosterone and fluoxetine dosages were calculated assuming an average 
fluid intake of about 5mL per day (David et al, 2009). 
 
Behavioral tests 
The same cohort of animals was tested in five different behavioral models of anxiety 
and depression. Each animal, over a week, was successively tested in the Open Field (OF), 
Elevated Plus Maze (EPM), Novelty Suppressed Feeding (NSF), Splash Test (ST) and Tail 
Suspension Test (see supplemental material). Behavioral testing occurred during the light 
phase between 0700 and 1900. Behavioral paradigms occurred after 7 or 28 days of drug 
treatment depending on the study (Figure S1A, S1B). 
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Immunohistochemistry 
The effects of chronic RS67333 treatment on cell proliferation or maturation of 
newborn neurons was assessed in corticosterone-treated animals. After anesthesia with 
ketamine and xylazine (100 mg/ml ketamine; 20mg/ml xylazine), mice were perfused 
transcardially (cold saline for 2 min, followed by 4% cold paraformaldehyde at 4°C). The 
brains were then removed and cryoprotected in 30% sucrose and stored at 4°C. Serial sections 
(35 µm) were cryosectioned through the entire hippocampus and stored in PBS with 0.1% 
NaN3. 
 
Proliferation of newborn cells 
We first looked at proliferation of newborn cells using Ki-67 immunohistochemistry 
as described previously (Xia et al, 2012). Sections were washed in PBS, blocked (PBS 
containing 0.3% triton and 10% NDS) and incubated with primary antibody overnight at 4° C 
(Ki67 rabbit, 1:100, Vector, Burlingame, CA). Following washes in PBS, sections were 
incubated with fluorescence coupled rabbit secondary antibody (Jackson ImmunoResearch, 
Beckman, France). Stereological quantification of Ki-67 labeling was performed using an 
Olympus BX51 microscope (Germany).  
 
Maturation of newborn neurons 
For doublecortin staining, the procedure consisted of the following steps: 1 hr 
incubation in 0.1M TBS with 0.5% Triton X-100 and 10% normal donkey serum (NDS), 
followed by goat anti-doublecortin primary antibody (1:100) in TBS/Tx/NDS for 24 hrs at 
4°C. The secondary antibody was biotinylated donkey anti-goat (1:500) in TBS/NDS for 1 hr 
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at room temperature, followed by a 1hr amplification step using an avidin-biotin complex 
(Vector, USA). The immunohistochemistry protocol was adapted from David et al. (David et 
al, 2009). DCX-positive (DCX+) cells were subcategorized according to their dendritic 
morphology: DCX+ cells without and DCX+ cells with tertiary (or higher order) dendrites. 
The maturation index was defined as the ratio of DCX+ cells possessing tertiary dendrites to 
the total number of DCX+ cells. 
 
Sholl analysis 
Sholl analysis was performed as described elsewhere (Guilloux et al, 2013). DCX+ 
cells with tertiary or higher order dendrites were traced using Neurolucida software 
(MicroBrightField, Williston, VT) on an Olympus BX51 microscope equipped with a 
motorized stage device and x100 immersion oil objective. Sholl analysis for dendritic 
complexity was performed using the accompanying software (NeuroExplorer; 
MicroBrightField, version 10), to determine dendritic length and number of intersections 
(branch points). One DCX+ cell was traced for each 35 µm hippocampal slice; n = 6 cells per 
brain for DAB-stained sections). 
 
X-irradiation 
A separate batch of mice mice were anesthetized with ketamine and xylazine (75/20 
mg/kg), placed in a stereotaxic frame, and exposed to cranial irradiation using a PXI X-RAD 
320 X-ray system operated at 300 kV and 12 mA with a 2 mm Al filter. Animals were 
protected with a lead shield that covered the entire body, but left unshielded a 3.22 X 11-mm 
treatment field above the hippocampus (interaural 3.00 to 0.00) exposed to X-ray, thus 
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effectively preventing irradiation from targeting the rest of the brain (Santarelli et al, 2003). 
The corrected dose rate was approximately 0.95 Gy per min at a source to skin distance of 36 
cm. The procedure lasted 2 min and 39 sec, delivering a total of 2.5 Gy. Three 2.5 Gy doses 
were delivered on days 1, 4, and 7 as previously described (Quesseveur et al, 2013). This 7.5 
Gy cumulative dose was determined from prior pilot experiments to be the minimum dosage 
necessary to result in permanent ablation of adult-born neurons in the dentate gyrus as 
assessed by expression of the immature neuronal marker doublecortin. The reason for using a 
fractionated paradigm rather than a single high dose of 7.5Gy is that the ablation is not 
permanent after a single high dose. Histological staining for CD68 as a marker of 
inflammation throughout the brain revealed that irradiated mice were indistinguishable from 
sham animals eight weeks post-irradiation, indicating minimal non-specific side effects of 
irradiation at time of behavioral testing (Meshi et al, 2006). Immunohistochemistry confirmed 
the ablation of adult hippocampal neurogenesis (Supplementary Fig. 4). 
 
Data Analysis and Statistics 
Results from data analyses were expressed as mean ± SEM. Data were analyzed using 
StatView 5.0 software (SAS Institute, Cary, NC). For all experiments, one-way or two-way 
ANOVAs with repeated-measures were applied to the data as appropriate. Significant main 
effects and/or interactions were followed by Fisher’s PLSD post hoc analysis, unpaired t tests. 
In the NSF test, we used the Kaplan-Meier survival analysis due to the lack of normal 
distribution of the data. Mantel-Cox log-rank test was used to evaluate differences between 
experimental groups. Statistical significance was set at P<0.05. A summary of statistical 
measures is included in Tables S1-S6, available online. 
 
  
 
151 
RESULTS 
5-HT4 receptor stimulation produces anxiolytic-like and antidepressant-like effects in a 
model of anxiety/depression. 
To induce an anxious/depressed-like state in C57BL/6Ntac mice we administered a 
low dose of corticosterone (35 µg/ml) for 4 weeks as described in (David et al, 2009) 
(“CORT model”). After chronic corticosterone, we tested the effects of a 4-week treatment 
with the 5-HT4 agonist RS67333 (1.5 mg/kg/day) in comparison to fluoxetine (18 mg/kg/day). 
To assess the selectivity of these effects, we also tested whether the 5-HT4 antagonist 
GR125487 (1mg/kg/day), alone or in combination with fluoxetine, affected the behavioral 
phenotype (see experimental design, Figure S1). In the open field (OF), the anxiety-like 
phenotype induced by chronic corticosterone was reversed by chronic fluoxetine and by the 5-
HT4 agonist RS67333 (One-way ANOVA, *p<0.05, Figure 1A). Indeed, chronic fluoxetine 
and RS67333 treatment increased time spent in the center (Figure 1A). A trend for an increase 
in the number of entries in the center was also observed with both compounds (Figure S2A-
B). It is unlikely that this effect was the consequence of a change in locomotor activity since 
the total ambulatory distance was not affected and the ratio of ambulatory distance in the 
center divided by total distance was increased for both treatments (One-way ANOVA, 
*p<0.05, Figure 1B). Interestingly, while the 5-HT4 antagonist GR125487 by itself did not 
affect any anxiety parameters, it prevented fluoxetine induced-anxiolytic-like effects. Indeed, 
the fluoxetine-induced increase in time spent in the center was prevented by chronic 
GR125487 administration. These data indicate that 5-HT4 stimulation induces an anxiolytic-
like effect, and is necessary for the anxiolytic effect of chronic fluoxetine treatment. 
To further validate these results, we next tested the effects of RS67333 and fluoxetine 
alone or in the presence of GR125487 in the same animals in another anxiety-related test, the 
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elevated plus maze (EPM). We found that chronic RS67333 and fluoxetine induced a trend 
for an increase in time spent in and number of entries into the open arms, (Figure 1C and 1D). 
This anxiolytic-like effect of fluoxetine was completely abolished by treatment with the 5-
HT4 antagonist, GR125487. 
We next assessed whether chronic treatment with the 5-HT4 agonist RS67333 could 
also produce antidepressant-like effects. Thus the same mice were tested in the splash test and 
the tail suspension test. We observed that after squirting a 10% sucrose solution on the 
mouse’s snout, increased grooming duration was observed in both the fluoxetine and the 
RS67333 groups (One-way ANOVA, **p<0.01, Figure 1E). Chronic treatment with the 5-
HT4 antagonist GR125487 prevented the antidepressant-like activity of chronic fluoxetine. 
Similarly, in the tail suspension test both fluoxetine and RS67333 had antidepressant-like 
effects and these effects of fluoxetine were blocked by GR125487 (One-way ANOVA, 
**p<0.01, Figure 1F).  
 Finally, we tested these mice in the NSF test, which is sensitive to both acute 
anxiolytics and chronic antidepressants (Guilloux et al, 2013) (Figure 1G, 1H). Like chronic 
fluoxetine, chronic RS67333 decreased the latency to feed (Kaplan-Meier survival analysis, 
Mantel-Cox log-rank test, **p<0.01) without affecting the home-cage food consumption 
(Figure S2C). Chronic treatment with the 5-HT4 antagonist (GR125487) prevented the effect 
of fluoxetine. Altogether, these data indicate that 5-HT4 receptor activation produces both 
anxiolytic-like and antidepressant-like effects comparable to those of fluoxetine in the chronic 
corticosterone model of anxiety/depression. Furthermore we show that 5-HT4 activation is 
necessary for the anxiolytic and antidepressant effects of fluoxetine in this model. 
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5-HT4 receptor activation facilitates the maturation of newborn neurons in the adult 
hippocampus. 
To investigate the potential cellular mechanisms underlying the behavioral effects of 
the 5-HT4 agonist RS67333, we next evaluated changes in adult hippocampal neurogenesis 
that may be relevant to antidepressant action (Surget et al, 2011). 
In agreement with previous observations (David et al, 2009; Rainer et al, 2011), 
chronic fluoxetine exposure resulted in an increase in the number of dividing neural 
precursors as assessed by the number of Ki67-positive cells in the subgranular zone of the 
dentate gyrus (One-way ANOVA, *p<0.05, Figure 2A). The 5-HT4 agonist, RS67333 also 
increased the number of neural precursors, but to a lesser extent than fluoxetine (+51% versus 
+170%). The 5-HT4 antagonist partially blocked the effect of chronic fluoxetine. These results 
suggest that 5-HT4 receptors contribute to the effects of fluoxetine on proliferation, but that 
other 5-HT receptors are likely to be also involved.   
We next assessed the number of young adult-born neurons in the dentate gyrus that 
express doublecortin (DCX), a protein that is expressed for about a month after the birth of 
adult-born neurons (Couillard-Despres et al, 2005) (Figure S3). We also subcategorized the 
DCX+ cells according to their dendritic morphology: total number of DCX+ cells and DCX+ 
cells with complex, tertiary dendrites (Figure 2B-2G). As previously described, chronic 
fluoxetine increased the number of doublecortin-positive cells with tertiary dendrites and the 
maturation index, defined as the ratio of DCX+ cells possessing tertiary dendrites over the 
total DCX+ cells in control animals (David et al, 2009) (One-way ANOVA, **p<0.01, Figure 
2B, 2C and 2D). Chronic treatment with RS67333 affected modestly both the total number of 
DCX positive cells and also the number of DCX cells with tertiary dendrites. 
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The 5-HT4 antagonist, GR125487, partially blocked the neurogenic effects of 
fluoxetine. However, while the effects of chronic fluoxetine on the number of doublecortin-
positive cells with tertiary dendrites are larger than those of chronic 5-HT4 receptor activation, 
the effect of these compounds on the maturation index is similar (+51% and 44% for 
fluoxetine and RS67333, respectively).  
The dendrites of adult-born granule cells become progressively more complex during 
the first 4 weeks after their birth, a stage when the cells express DCX (Couillard-Despres et 
al, 2005). To further examine the effect of 5-HT4 receptor activation on the dendritic 
morphology of newborn cells, we performed Sholl analyses on DCX+ cells with tertiary 
dendrites. DCX+ cells in chronic fluoxetine-treated and RS67333-treated animals displayed 
an increase in dendritic length (One-way ANOVA, **p<0.01, Figure 2E and 2F) and in 
number of dendritic intersections (One-way ANOVA, **p<0.01, Figure 2E and 2G). 
Fluoxetine-induced increase in dendritic complexity was abolished by a chronic treatment 
with the 5-HT4 antagonist, GR125487. 
Overall, these results suggest that 5-HT4 receptor activation facilitates the maturation 
of newborn neurons in the adult hippocampus. 
 
An assessment of causality between the neurogenic and behavioral effects of short and 
long term treatments with the 5-HT4 agonist in the chronic CORT model. 
Since we have shown that long-term 5-HT4 activation induced 
anxiolytic/antidepressant-like effects and facilitated maturation of newborn neurons, we 
decided to test the requirement of hippocampal neurogenesis for the emergence of behavioral 
changes after 5-HT4 receptor activation in our CORT model. Moreover, a recent study in rats 
reported that the behavioral and neurogenic (proliferation of newborn cells) effects of the 5-
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HT4 receptor agonist RS67333 occur after short-term administration (3 to 7 days depending 
on the paradigm) (Pascual-Brazo et al, 2012). Thus, we also investigated whether subchronic 
RS67333 treatment induced a rapid onset of behavioral effects. To address these points, mice 
were submitted to focal hippocampal X-irradiation before the start of chronic corticosterone 
treatment alone or in combination with the 5-HT4 agonist RS67333 (1.5 mg/kg/day) or 
fluoxetine (18 mg/kg/day) (Figure S1B). These animals were tested in anxiety and depression 
related tests first after 7 days of treatment and again after 28 days of treatment.  
 As previously described (David et al, 2009; Rainer et al, 2011), the chronic CORT 
paradigm resulted in an anxious/depressed-like phenotype. The efficacy of corticosterone 
model was assessed by comparing the behavioral phenotype of controls to corticosterone-
treated mice (Figure 3). In anxiety-related tests, chronic corticosterone treatment had a 
marked effect on all anxiety parameters, resulting in decreased time spent in center and ratio 
of distance in center divided by total distance in the OF (One-way ANOVA, *p<0.05 or 
**p<0.01, Figure 3A, 3I, 3J), and in decreased time and entries in the open arms in the EPM 
(One-way ANOVA, **p<0.01, Figure 3C, 3K, 3L). In the Splash test, which is a depression-
related test, chronic CORT resulted in a decrease in grooming (One-way ANOVA, **p<0.01, 
Figure 3O), and in the NSF test, which is related to both anxiety and depression, chronic 
CORT increased the latency to feed (Kaplan-Meier survival analysis, Mantel-Cox log-rank 
test, **p<0.01, Figure 3E, 3F, 3M, 3N). As previously observed in a similar paradigm, the 
FST (David et al, 2009; Rainer et al, 2011), chronic corticosterone treatment did not affect the 
immobility duration in the TST (Figure 3H, 3P), suggesting distinct underlying mechanisms 
between these tests and the OF, EPM, NSF or ST. 
The rapid anxiolytic and antidepressant-like effects of a subchronic 5-HT4 agonist 
treatment do not require hippocampal neurogenesis.  
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A 7-day treatment with RS67333 produced anxiolytic and antidepressant-like effects 
in a battery of behavioral tests (Figure 3A to 3H). In the OF and EPM paradigms, all anxiety-
related parameters were impacted. The time spent in the center (Figure 3A), the number of 
entries in the center (Figure S5A), the ratio of center distance/total distance traveled (Figure 
3B), the time spent in open arms (Figure 3C) and the number of entries in the open arms 
(Figure 3D) were increased after subchronic treatment with RS67333, regardless of whether 
the mice were exposed to X-irradiation or not (two-way ANOVA with significant treatment 
factor, **p<0.01, Figures 3A-C). In contrast, subchronic treatment with fluoxetine did not 
have an anxiolytic effect in the OF and EPM paradigms (Figures 3A-B and 3C-D). These 
results indicate that the anxiolytic effects of RS67333 have a faster onset than those of 
fluoxetine and that these effects do not require adult hippocampal neurogenesis. 
Interestingly, in the NSF test, neither subchronic RS67333 nor subchronic fluoxetine 
had an effect on latency to feed in both sham and X-irradiated groups (Figures 3E-F) 
indicating that in this test, the anxiolytic/antidepressant activity of RS67333 and fluoxetine 
require a longer treatment. 
In the ST and TST (Figures 3G-H), after 11 and 12 days of administration, both 
RS67333 and fluoxetine increased grooming duration and decreased immobility duration, 
respectively (two-way ANOVA with significant treatment factor, **p<0.01). These 
antidepressant-like effects were not affected by focal hippocampal X-irradiation. 
Altogether, these results demonstrate that, unlike fluoxetine, the 5-HT4 agonist 
RS67333 elicits a rapid anxiolytic and antidepressant-like effect in all the paradigms tested 
(OF, EPM, ST and TST) except the NSF. However, hippocampal neurogenesis is not required 
for these effects of RS67333.  
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In this study we assessed the behavioral activity of RS67333 after both subchronic and 
chronic treatments. Thus, the same animals were tested after 7 and 28 days of treatment. It is 
therefore not surprising to observe changes in the basal values in control animals since they 
have been exposed twice to behavioral tests. We have seen these effects of repeated testing 
routinely. For example, in the Novelty Suppressed Feeding paradigm, the latency to feed was 
decreased after a second exposure to the test (Wang et al., 2008). In the present study, we 
observed a decrease in the time spent in the center of the arena, due to the re-exposure to the 
test in all treated groups. However, the size of the anxiolytic-like effect of RS67333, remains 
the same between the first and the second exposure to the open field. 
The behavioral effects of long term 5-HT4 agonist treatment are mediated by both 
neurogenesis-dependent and -independent mechanisms.  
Since we previously demonstrated that chronic 5-HT4 activation produced 
anxiolytic/antidepressant-like activity in the CORT model, we proceeded to investigate 
whether these behavioral effects require adult hippocampal neurogenesis. 
The same battery of behavioral tests was performed again after 28 days of treatment 
with fluoxetine or RS67333 (Figures 3I-P). In the OF (Figures 3I-J) and the EPM (Figures 
3K-L) paradigms, chronic RS67333 maintained the anxiolytic-like effect observed 
subchronically (two-way ANOVA with significant treatment factor, *p<0.05, Figures 3I-3L). 
Chronic fluoxetine also elicited an anxiolytic-like effect while it had no effect after 
subchronic treatment (two-way ANOVA with significant treatment factor, *p<0.05, Figures 
3I-3J) Moreover, these anxiolytic-like effects of RS67333 and fluoxetine were not affected by 
the ablation of adult hippocampal neurogenesis by X-irradiation.  
In contrast, the anxiolytic/antidepressant-like effects of RS67333 and fluoxetine in the 
NSF paradigm were completely abolished by hippocampal X-irradiation (Figures 3M and 3N; 
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Kaplan-Meier survival analysis, Mantel-Cox log-rank test, **p<0.01, two-way ANOVA with 
significant interaction between irradiation and treatment **p<0.01) indicating that these 
effects require adult hippocampal neurogenesis. Home cage food consumption was not 
affected by drug treatment or irradiation (Figure S5D).  
In the splash test and TST, long-term administration of RS67333 and fluoxetine 
induced an increase in grooming duration and a decrease in immobility duration that were not 
affected by focal X-irradiation (two-way ANOVA with significant treatment factor, **p<0.01 
for both tests, Figures 3O-3P).  
Altogether these results indicate that the effects of chronic treatment with RS67333 
and fluoxetine in the OF, EPM, ST, and TST are independent of hippocampal neurogenesis. 
In contrast, the anxiolytic/antidepressant-like effects of these compounds in the NSF test 
require neurogenesis. 
DISCUSSION  
Fast anxiolytic action of a 5-HT4 agonist. 
Most current antidepressant treatments are limited by a significant degree of non 
responsiveness among patients (Trivedi et al, 2006), delayed onset of therapeutic efficacy, 
and a number of side effects (Kato and Serretti, 2010). The development of new 
antidepressants is therefore of considerable importance (Wong et al, 2010), and understanding 
the mechanisms underlying the delayed onset should offer insights into new approaches. 
Recent studies as well as our present results indicate that 5-HT4 receptor agonists are faster 
acting than SSRIs (Lucas et al, 2007; Pascual-Brazo et al, 2012; Tamburella et al, 2009).  
While a 7-day treatment with fluoxetine or RS67333 induced antidepressant-like activity 
in the TST and ST, only the 5-HT4 agonist RS67333 resulted in anxiolytic-like activity in the 
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OF and the EPM. A longer duration of treatment (28 days) is required for fluoxetine to exert 
anxiolytic-like effects comparable to 7 days of RS67333 treatment. While recent evidence 
indicates that 5-HT4 receptors may represent a new target for antidepressant drugs (Bockaert et 
al, 2004; Lucas et al, 2007; Pascual-Brazo et al, 2012; Tamburella et al, 2009), the role of 5-
HT4 receptor ligands in anxiety is unclear. Discrepancies in results observed with 5-HT4 
receptor antagonists have been observed. In one study, the 5-HT4 receptor antagonists, SDZ205-
557, GR113808, and SB204070, administered acutely, failed to induce anxiolytic-like behavior 
in the light/dark choice test in mice (Costall and Naylor, 1997), while in two other studies, acute 
administration of the 5-HT4 receptor antagonists, SB204070, GR113808 (Silvestre et al, 1996), 
and SB207266A (Kennett et al, 1997; Silvestre et al, 1996), had an anxiolytic-like effect in rats 
in the elevated plus maze. 5-HT4 receptor knock-out mice do not display an anxious or 
depressed-like phenotype, though an attenuated response to novelty may be relevant to mood 
disorders (Compan et al, 2004). In our hands, chronic treatment with GR125487 did not affect 
the anxiety-like phenotype induced by chronic corticosterone treatment. 5-HT4 receptor agonists 
have mainly been tested in behavioral tests of antidepressant-like activity (see (Lucas, 2009) for 
review). Only one study investigated the effects of RS67333 in the OF paradigm over a 5-min 
period (Lucas et al, 2007). The authors showed that hyperlocomotion induced by olfactory 
bulbectomy was totally abolished after 14 days of RS67333 treatment in rats. To our 
knowledge, the present study is the first to clearly demonstrate fast anxiolytic-like activity of a 
5-HT4 receptor agonist in a mouse model of anxiety/depression. Our data in regards to the 
literature support a direct effect of RS67333 on the 5-HT4 receptor. There is considerable 
evidence that RS67333 is a specific agonist of the 5-HT4 receptor. Indeed, three studies have 
evaluated the effects of RS67333 in the presence of the selective 5-HT4 antagonist GR125487, 
and shown that the effects of RS67333 are blocked by GR125487. Lucas and colleagues showed 
that the increase in 5-HT firing induced by RS67333 (1.5 mg/kg, acutely, during 3 days or 21 
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days) is prevented by GR125487 administration (Lucas et al, 2005). This effect of RS67333 on 
the firing of 5-HT neurons is likely to contribute to the phenotype we observe in the current 
study. Enhanced cognition induced by RS67333 was blocked by the 5-HT4 receptor antagonist 
GR 125487 (1mg/kg, intravenous [i.v.]) (Freret et al, 2012; Lamirault and Simon, 2001). Both 
studies tested the specificity of the effects of RS67333 in the Novel Object Recognition test by 
using the highly potent and selective 5-HT4 receptor antagonist, GR125487. They found that 1 
mg/kg of GR125487, which had no effect per se on the discrimination index, totally reversed 
the beneficial effects of RS67333, arguing thus that these effects of RS67333 are mediated by 5-
HT4 receptor. 
Interestingly, in the NSF test, both fluoxetine and RS67333 had an 
anxiolytic/antidepressant-like effect only after chronic treatment, suggesting that the 
neurobiological mechanisms involved in this paradigm are different from those underlying the 
other tests (OF, EPM, TST, ST). Indeed, we show that the effects of RS67333 and fluoxetine 
in the OF, EPM, TST, and ST are independent of hippocampal neurogenesis, while the effects 
of these compounds in the NSF test require neurogenesis. This is in agreement with our 
previous study showing both neurogenesis-dependent (NSF) and independent (OF, FST) 
effects of fluoxetine in the CORT model (David et al, 2009). It is also noteworthy that the 
only test (NSF) that requires neurogenesis is also the one that requires a chronic 
administration. This observation is likely related to the fact that young adult-born neurons 
take several weeks to mature and that the critical period during which adult-born neurons 
contribute to behavior extends from 4 to 6 weeks after their birth (Denny et al, 2012). 
Interestingly, the effect of the 5-HT4 agonist RS67333 on proliferation of neural precursors 
are weaker than those of fluoxetine, while the effects of RS67333 on the maturation of young 
neurons are similar to those of fluoxetine. Newborn neurons undergo an accelerated 
maturation after chronic fluoxetine treatment (Wang et al, 2008) and possibly also after 5-HT4 
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receptor activation. These results suggest that the neurogenesis-dependent effect of RS67333 
and fluoxetine in the NSF test is more likely to result from increased maturation than from 
increased proliferation.  
The fast onset of action of the 5-HT4 receptor agonist could be a consequence of an 
increase in serotonergic output to projection areas (Lucas et al, 2005; Lucas et al, 2002). 
Indeed, by measuring spontaneous electrical activity in mice lacking 5-HT4 receptors, 
Conductier et al demonstrated that 5-HT4 receptors exert a tonic positive influence on the 
firing activity of DRN (dorsal raphe nucleus) 5-HT neurons (Conductier et al, 2006) and 
previous studies have shown that 5-HT4 receptor activation by selective agonists modulates 
central 5-HT neurotransmission, increasing the firing of DRN 5-HT neurons (Lucas et al, 
2002). There is also accumulating evidence that cortical regions are involved in 5-HT4-
induced anxiolytic/antidepressant-like activities (Lucas et al, 2005) (for review see also 
(Lucas, 2009)). 5-HT4 receptors in the prefrontal cortex control the firing rate of midbrain 
serotonergic neurons via descending inputs (Lucas et al, 2005) and their activation leads to 
increases in serotonin release in projection sites including the hippocampus (Ge and Barnes, 
1996).  
Requirement of 5-HT4 receptors for the behavioral and neurogenic effects of 
SSRIs. 
A blockade of 5-HT4 receptors with the antagonist GR125487 prevented the anxiolytic 
and antidepressant-like effects of fluoxetine. These results show that 5-HT4 receptor 
activation is necessary for the behavioral effects of SSRIs. Our results are consistent with a 
previous study showing a specific induction of 5-HT4 expression after SSRI treatment 
(Schmidt et al, 2012). Moreover, using the NIMH Psychoactive Drug Screening Program 
database, we did not find any study looking at the binding affinity of fluoxetine at the mouse 
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5-HT4 receptor. The only study looking at binding affinities of fluoxetine for serotoninergic 
receptor demonstrated negligible binding of fluoxetine to the 5-HT4 receptor in pig striatal 
membranes (Lucchelli et al, 1995). In addition, quantitative autoradiography revealed that the 
binding of the 5-HT₄ receptor ligand [³H]GR113808 was not significantly changed in 
fluoxetine-treated mice (Kobayashi et al, 2012). Thus, in the present study, the 
anxiolytic/antidepressant-like effects of fluoxetine likely resulted from an indirect activation 
of the 5-HT4 receptor through an increase in endogenous 5-HT levels in the synaptic cleft 
following the blockade of the selective serotonin transporter. However, it is unlikely that 5-
HT4 receptor activation alone can be responsible for all SSRIs-mediated 
anxiolytic/antidepressant-like activity. Among the 14 known 5-HT receptor subtypes, the 5-
HT1A receptor has been prominently implicated in the modulation of mood and anxiety-
related behaviors (Santarelli et al, 2003). 5-HT1A receptor knockout (KO) mice were 
insensitive to the behavioral effects of chronic fluoxetine, suggesting that activation of 5-
HT1A receptors is also a critical component in the mechanism of action of SSRIs. Recent data 
also suggest a potential non-cell autonomous mechanism by which serotonin regulates 
neurogenesis and the response to antidepressants through 5-HT1A receptor (Samuels, personal 
communication). However, we cannot rule out adaptive changes in the serotoninergic system, 
including variations in 5-HT4 receptor levels, which could explain the absence of behavioral 
effects of fluoxetine in 5-HT1A receptor knock-out mice. Indeed, decreases in the density of 
the serotonin transporter (5-HTT) were measured in several brain regions of these 5-HT1A 
mutant mice (Ase et al, 2001), and a recent study described that variation in serotonin 
transporter expression could cause adaptive changes in 5-HT4 receptor levels in serotonin 
transporter overexpressing mice (Jennings et al, 2012).  
SSRIs are potent stimulators of adult hippocampal neurogenesis (Klempin et al, 2010; 
Santarelli et al, 2003). However, the role of each serotoninergic receptor in the neurogenic 
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effects of SSRIs is still a matter of investigation. We have showed that the 5-HT4 agonist, 
RS67333, increased neurogenesis (proliferation and maturation) to a lesser extent than 
fluoxetine and that the 5-HT4 antagonist, GR125487, partially blocked neurogenic effects of 
chronic fluoxetine. These results suggest that 5-HT4 receptors contribute to the effects of 
fluoxetine on proliferation and maturation of newborn neurons, but that other 5-HT receptors 
are likely to be involved. Pharmacological manipulations suggested that 5-HT1A receptors are 
involved in proliferation of precursor cells, whereas 5-HT2 receptors affect both proliferation 
and promote neuronal differentiation (Klempin et al, 2010). Moreover, fluoxetine had no 
effect on neurogenesis (proliferation and survival) in 5-HT1A KO mice (Santarelli et al, 2003).  
These results suggest that both 5-HT4 and 5-HT1A receptors contribute to the effects of 
SSRIs on behavior and neurogenesis. Interestingly, both receptors are expressed in the dentate 
gyrus, which may be the site responsible for their effects on neurogenesis. Recently, it has 
been suggested that 5-HT4 receptor activation may also be involved in antidepressant-induced 
dematuration of mature dentate granule cells (Kobayashi et al, 2010). The exact mechanisms 
underlying in this phenomenon still needs further investigations. However, our results also 
show that most effects of SSRIs and 5-HT4 agonists do not require hippocampal neurogenesis. 
Examining effects of tissue-specific manipulations of these receptors will be important to 
identify the circuits responsible for their fast acting anxiolytic and antidepressant actions.  
Conclusions 
Taken together, our results show, for the first time, in a mouse model of 
anxiety/depression, that a 5-HT4 receptor agonist may be a fast-acting anxiolytic agent, and 
that 5-HT4 stimulation is necessary for the behavioral and neurogenic effects (proliferation 
and maturation) of fluoxetine, a classic SSRI antidepressant. Furthermore, we showed that, 
with the exception of the NSF test, the anxiolytic and antidepressant-like effects of the 5-HT4 
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agonist were independent of hippocampal neurogenesis (Table 1). The present study is 
encouraging for the development of RS-67333 as an anxiolytic/antidepressant compound for 
use in patients. However, the use of the 5-HT4 receptor as a novel antidepressant target may 
be hampered by the fact that it also plays important roles outside the central nervous system, 
e.g., in the heart, gastrointestinal tract, adrenal gland, and urinary bladder (Tonini and Pace, 
2006), which may prevent its development as an effective anxiolytic/antidepressant drug 
(Bockaert et al, 2004, 2008). Thus, signaling molecules that interact with the 5-HT4 receptor 
such as P11 (Egeland et al, 2011; Warner-Schmidt et al, 2009) may represent novel targets 
for fast-acting anxiolytic/antidepressant treatments. There is indeed recent evidence that 
cortical neurons that express both P11 and 5-HT4 receptors are involved in the behavioral 
effects of SSRIs (Schmidt et al, 2012) and that chronic treatment with fluoxetine results in an 
increase in 5-HT4 receptor expressions in cortical neurons (Schmidt et al, 2012). 
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Legend 
Figure 1: Effects of chronic 5-HT4 receptor stimulation (28-days) on the 
anxious/depressed-like phenotype induced by chronic corticosterone exposure. 
(A and B) Effects of chronic treatment with 5-HT4 ligands or fluoxetine, starting after 4 
weeks of corticosterone (35 µg/ml), on anxiety behaviors in the open field test. Anxiety is 
measured as mean time spent in the center in seconds (A) or the ratio of ambulatory distance 
in the center/total ambulatory distance (B). Values plotted are mean ± SEM (n= 10–15 per 
group). *p<0.05,**p<0.01, versus corticosterone/vehicle group. 
(C and D) Effects of chronic treatment with 5-HT4 ligands or fluoxetine, starting after 4 
weeks of corticosterone (35 µg/ml), on anxiety behaviors in the elevated plus maze. Anxiety 
is expressed as mean time in (C) or entries into (D) the open arms. Values plotted are mean ± 
SEM (n= 10–15 per group). #p<0.05 versus corticosterone/fluoxetine group. 
(E) Effect of chronic treatment with 5-HT4 ligands or fluoxetine on corticosterone-induced 
depression-related behaviors in the splash test. Results are expressed as mean duration of 
grooming after receiving a 10% sucrose solution on the snout. Values plotted are mean ± 
SEM (n = 10–15 per group). **p<0.01, ##p<0.01, versus corticosterone/vehicle group and 
corticosterone/fluoxetine group, respectively. 
(F) Effect of chronic treatment with 5-HT4 ligands or fluoxetine in the tail suspension test 
following chronic corticosterone. Results are expressed as mean of immobility duration in 
seconds. Values plotted are mean ± SEM (n= 10–15 per group). **p<0.01, ##p<0.01, versus 
corticosterone/vehicle group and corticosterone/fluoxetine group, respectively. 
(G and H) Effects of chronic treatment with 5-HT4 ligands or fluoxetine on anxiety- and 
depression-like behaviors in the novelty suppressed feeding paradigm after chronic 
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corticosterone. Values plotted are cumulative survival of animals that have not eaten over 10 
min (n= 10–15 per group) (G) or mean of latency to feed in seconds ± SEM (H). **p<0.01, 
##p< 0.01, versus corticosterone/vehicle group and corticosterone/fluoxetine group, 
respectively. 
 
Figure 2: Effects of chronic 5-HT4 receptor stimulation (28 days) on proliferation and 
dendritic maturation of young neurons in the dentate gyrus of the adult hippocampus.  
(A) Effect of chronic treatment with 5-HT4 ligands or fluoxetine, starting after 4 weeks of 
corticosterone (35 µg/ml), on cell proliferation. Cell proliferation is measured as mean 
number of Ki-67 positive cells (A). Values plotted are mean ± SEM (n= 3–5 per group). 
*p<0.05, **p<0.01, ##p<0.01, versus corticosterone/vehicle group and 
corticosterone/fluoxetine group, respectively. 
(B) Effect of chronic treatment with 5-HT4 ligands or fluoxetine on total number of 
doublecortin-positive cells (mean ± SEM; n= 4-5 per group) was measured after chronic 
corticosterone. **p<0.01, ##p<0.01 versus corticosterone/vehicle group, and 
corticosterone/fluoxetine group, respectively. 
(C and D) Doublecortin-positive cells were categorized as to whether they exhibited tertiary 
dendrites. Effects of fluoxetine treatment on the doublecortin-positive cells with tertiary 
dendrites (C) and maturation (D) of newborn granule cells were measured after chronic 
corticosterone. Values are mean ± SEM (n= 4-5 per group). **p<0.01, #p<0.05, ##p<0.01, 
versus corticosterone/vehicle group, and corticosterone/fluoxetine group, respectively. 
(E) Representative image and traces from Sholl analyses of doublecortin-positive cells with 
tertiary branches after vehicle, chronic fluoxetine, chronic RS67333, GR125487 in presence 
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or not of fluoxetine in corticosterone-treated animals (n = 3-4 mice per group, 6 cells per 
mouse).  
(F and G) Effects of chronic treatment with the 5-HT4 ligands RS67333 or fluoxetine on the 
dendritic length (F) or the number of intersections (G) following a Sholl analysis. Values are 
mean ± SEM (n = 4-5 per group). **p<0.01 versus corticosterone/vehicle group. 
 
Figure 3. Neurogenesis-dependent and -independent effects of subchronic (7-days) or 
chronic (28-days) 5-HT4 agonist treatment on corticosterone-induced behavioral 
changes in mice. 
(A–B/I-J) Effects of subchronic (A-B) or chronic (I-J) treatment with RS67333, a 5-HT4 
agonist, after focal X-irradiation of the mouse hippocampus on corticosterone-induced 
anxiety-like behaviors in the open field test. Anxiety is expressed as mean time spent in the 
center, in seconds, for the entire session (A or I), and also as the mean of percentage 
ambulatory distance in the center over total ambulatory distance traveled (B or J). Values are 
mean ± SEM (n = 9–15 per group for corticosterone-treated animals and n=5 for 
vehicle/vehicle). **p<0.01, #p<0.05, ##p<0.01, versus control vehicle/vehicle group and 
corticosterone/RS67333 or corticosterone/vehicle group, respectively. 
(C–D/K-L) Effects of subchronic (C-D) or chronic (K-L) treatment with RS67333, a 5-HT4 
agonist, after focal X-irradiation of the mouse hippocampus on corticosterone-induced 
anxiety-like behaviors in the elevated plus maze paradigm. Anxiety is expressed as mean time 
in the open arms (C or K), and also as the mean entries in the open arms (D or L). Values are 
mean ± SEM (n = 9–15 per group for corticosterone-treated animals and n=5 for 
vehicle/vehicle). **p<0.01, #p<0.05, versus control vehicle/vehicle group and 
corticosterone/RS67333 or corticosterone/vehicle group, respectively. 
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(E–F/M-N) Effects of subchronic (E-F) or chronic (M-N) treatment with RS67333, a 5-HT4 
agonist, after focal X-irradiation on corticosterone-induced anxiety- and depression-related 
behaviors in the novelty suppressed feeding paradigm. Results are cumulative survival of 
animals that have not eaten over 10 min (E or M) or mean ± SEM of latency to feed in 
seconds (F or N) (n = 9–15 per group for corticosterone-treated animals and n=5 for 
vehicle/vehicle). **p<0.01, ##p<0.01, versus control vehicle/vehicle group and 
corticosterone/RS67333 or corticosterone/vehicle group, respectively. 
(G–O) Effects of subchronic (G) or chronic (O) treatment with RS67333, a 5-HT4 agonist, 
after X-irradiation on behavior in the splash test. Results are expressed as mean ± SEM 
duration of grooming after receiving a 10% sucrose solution on the snout (n = 9–15 per group 
for corticosterone-treated animals and n=5 for vehicle/vehicle). *p<0.05, #p<0.05, versus 
control vehicle/vehicle group and corticosterone/vehicle group, respectively. 
(H–P) Effects of subchronic (H) or chronic (P) treatment with RS67333, a 5-HT4 agonist, 
after X-irradiation on behavior in the tail suspension test. Results are expressed as mean ± 
SEM immobility duration (in seconds) (n = 9–15 per group for corticosterone-treated animals 
and n=5 for vehicle/vehicle). **p<0.01, #p<0.05, versus control vehicle/vehicle group and 
corticosterone/vehicle group, respectively. 
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SUPPLEMENTAL DATA 
 
Rapid anxiolytic effects of a 5-HT4 receptor agonist are mediated by a neurogenesis-
independent mechanism 
Authors: Indira Mendez-David1*, Denis J. David1*, Flavie Darcet1, Melody V. Wu3, Saadia 
Kerdine-Romer2, Alain M. Gardier1, René Hen3,§ 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Behavioral tests 
Open Field (OF) 
This test was performed as described by David and colleagues (David et al, 2009). Motor 
activity was quantified in four 43 x 43 cm2 Plexiglas open field boxes (MED Associates, 
Georgia, VT). Two sets of 16 pulse-modulated infrared photobeams were placed on opposite 
walls 2.5-cm apart to record x–y ambulatory movements. Activity chambers were computer 
interfaced for data sampling at 100-ms resolution. The computer defined grid lines that 
divided each open field into center and surround regions, with each of four lines being 11 cm 
from each wall. Dependent measures in the center were the total time and the number of 
entries over a 30-min test period. The activity in the center was quantified as distance traveled 
in the center divided by total distance traveled.  
 
Elevated Plus Maze (EPM) 
This test was performed as described by David and colleagues (David et al, 2009). The maze 
is a plus-cross-shaped apparatus, with two open arms and two arms closed by walls linked by 
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a central platform 50 cm above the floor. Mice were individually put in the center of the maze 
facing an open arm and were allowed to explore the maze during 5 min. The time spent in and 
the number of entries into the open arms were used as an anxiety index. All parameters were 
measured using a videotracker (EPM3C, Bioseb, Vitrolles, France). 
 
Novelty-Suppressed-Feeding (NSF) 
The NSF is a conflict test that elicits competing motivations: the drive to eat and the fear of 
venturing into the center of a brightly lit arena. The latency to begin eating is used as an index 
of anxiety/depression-like behavior, because classical anxiolytic drugs as well as chronic 
antidepressants decrease this measure. The NSF test was carried out during a 10-min period 
as previously described (David et al, 2009). Briefly, the testing apparatus consisted of a 
plastic box (50x50x20 cm), the floor of which was covered with approximately 2 cm of 
wooden bedding. Twenty-four hours prior to behavioral testing, all food was removed from 
the home cage. At the time of testing, a single pellet of food (regular chow) was placed on a 
white paper platform positioned in the center of the box. Each animal was placed in a corner 
of the box, and a stopwatch was immediately started. The latency to eat (defined as the mouse 
sitting on its haunches and biting the pellet with the use of forepaws) was timed. Immediately 
afterwards, the animal was transferred to its home cage, and the amount of food consumed by 
the mouse in the subsequent 5 min was measured, serving as a control for change in appetite 
as a possible confounding factor. 
 
Tail Suspension Test (TST) 
The TST is an antidepressant activity screening test (Steru et al, 1985) often used to test 
compounds that are expected to affect depression related behaviors. Mice are suspended by 
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their tails with tape, in such a position that they cannot escape or hold on to nearby surfaces. 
During this test, typically 6 minutes in duration, the resulting escape oriented behaviors are 
quantified using an automated tail suspension test apparatus (Bioseb, Vitrolles, France). A 
specific strain gauge linked to a computer quantifies the time spent by the animal trying to 
escape. 
 
Splash Test 
This test consisted of squirting 200 µl of a 10% sucrose solution on the mouse’s snout. The 
grooming duration was assessed at the end of the corticosterone regimen in the presence or 
absence of 4-weeks of drug treatment according to a protocol used elsewhere (David et al, 
2009).  
 
Immunohistochemistry 
Doublecortin-immunostaining consisted of the following steps: slices were washed with 3 
times with PBST (PBS 1X + 0.3% triton) for 15 min, blocked with 10%NDS (normal donkey 
serum) + PBST during 2hrs and incubated with by goat anti-doublecortin primary antibody 
(1:100) in PBS/Triton/NDS for 24 hrs at 4°C. After secondary antibody incubation, sections 
were developed using CY2 (Donkey anti-rabbit) 1/250 diluted (dilute in PBS) for 2hrs. 
 
References 
David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, et al (2009). 
Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of 
anxiety/depression. Neuron 62(4): 479-493. 
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SUPPLEMENTAL FIGURES 
Supplemental figure 1: Experimental timeline. 
(A) In a first set of experiments, in place of normal drinking water, grouped-housed male 
C57BL/6Ntac mice were presented with vehicle (0.45% hydroxypropyl-β-cyclodextrin) or 
corticosterone (35 µg/ml) in the presence or absence of a 5-HT4 agonist (RS67333, 1.5 
mg/kg/day, Alzet® mini pump model 2006 implanted subcutaneously), fluoxetine, 18 
mg/kg/day, or a 5-HT4 antagonist alone (GR125487, 1 mg/kg/day, Alzet® mini pump model 
2006 implanted subcutaneously) or in combination with fluoxetine. We investigated whether 
the behavioral changes induced by chronic corticosterone were reversed by chronic 5-HT4 
ligands, fluoxetine alone, or fluoxetine in combination with 5-HT4 receptor antagonist 
treatment. The same animal was successively tested in the OF paradigm, the EPM, the NSF, 
the ST, and the TST and then sacrificed for neurogenesis  
(B) In another set of experiments, focal X-irradiation of the hippocampus was employed to 
assess whether the mechanisms underlying RS67333 mediated rescue of corticosterone-
induced anxiety/depressive-like behavior were neurogenesis-dependent. X-irradiation (2.5 
Gy) was delivered five weeks before the start of corticosterone treatment. All animals (Sham 
or X-irradiated) received corticosterone (35 µg /ml) in the presence of vehicle, RS67333 (1.5 
mg/kg/day), or fluoxetine (18 mg/kg/day). The anxiety/depressive-like phenotype of chronic 
corticosterone was assessed by comparing a chronic corticosterone/vehicle group versus a 
vehicle/vehicle group. The same animals were successively tested in the OF paradigm, the 
EPM, the NSF, the ST, and the TST after subchronic (days 7 to 11) or chronic (days 28 to 33) 
drug treatment. 
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Supplemental figure 2: Effects of chronic 5-HT4 receptor stimulation on entries in the 
center in the open field paradigm and home food consumption in the NSF test in 
anxious/depressive mice. 
 
(A-B) Effect of chronic 5-HT4 ligands or fluoxetine treatment, started after 4 weeks of 
corticosterone (35 µg/ml), on the number of entries in the center (A) and on total ambulatory 
distance in the open field test (B). Values plotted are mean ± SEM (n= 10–15 per group).  
(C) Effect of chronic 5-HT4 ligands or fluoxetine treatment, started after 4 weeks of 
corticosterone (35 µg/ml), on home food consumption in the NSF test. Values plotted are 
mean ± SEM (n= 10–15 per group).  
 
Supplemental figure 3: Images of doublecortin staining following corticosterone for 8 
weeks ± chronic RS67333 (1.5 mg/kg/day), GR125487 (1 mg/kg/day), or fluoxetine (18 
mg/kg/day) alone or in combination with GR125487 treatment.  
Images of coronal sections of mouse hippocampal dentate gyrus stained for doublecortin (10x 
magnification).  
 
Supplemental figure 4: Images of doublecortin staining following corticosterone for 8 
weeks in Sham/vehicle or X-irradiated/vehicle animals.  
Images of coronal sections of mouse hippocampal dentate gyrus stained for doublecortin (10x 
magnification) in sham/vehicle (A) or in Xray/vehicle–treated animals (B).  
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Supplemental figure 5: Effects of subchronic or chronic 5-HT4 receptor stimulation on 
entries in the center in the open field paradigm and home food consumption in the NSF 
test in anxious/depressive X-irradiated mice. 
(A) Effect of subchronic 5-HT4 agonist or fluoxetine treatment, started after 4 weeks of 
corticosterone (35 µg/ml), on entries in the center in the open field test in X-irradiated mice. 
Values plotted are mean ± SEM (n = 9–15 per group for corticosterone-treated animals and 
n=5 for vehicle/vehicle). **p<0.01, #p<0.05, versus control vehicle/vehicle group and 
corticosterone/vehicle group, respectively. 
(B) Effect of chronic 5-HT4 agonist or fluoxetine treatment, started after 4 weeks of 
corticosterone (35 µg/ml), on home food consumption in the NSF test in X-irradiated mice. 
Values plotted are mean ± SEM (n = 9–15 per group for corticosterone-treated animals and 
n=5 for vehicle/vehicle). **p<0.01, #p<0.05, versus control vehicle/vehicle group and 
corticosterone/vehicle group, respectively. 
(C) Effect of subchronic 5-HT4 agonist or fluoxetine treatment, started after 4 weeks of 
corticosterone (35 µg/ml), on food consumption in the novelty suppressed feeding test in X-
irradiated mice. Values plotted are mean ± SEM (n = 9–15 per group for corticosterone-
treated animals and n=5 for vehicle/vehicle).  
(D) Effect of chronic 5-HT4 agonist or fluoxetine treatment, started after 4 weeks of 
corticosterone (35 µg/ml), on food consumption in the novelty suppressed feeding test in X-
irradiated mice. Values plotted are mean ± SEM (n = 9–15 per group for corticosterone-
treated animals and n=5 for vehicle/vehicle). 
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SUPPLEMENTAL DATA 
Supplemental Table 1: complete statistical summary analysis for behavioral data after chronic 
treatment  
 
Behavioral 
paradigm Measurement 
Statistical 
Test Comparison Statistics 
Degrees of 
freedom p Fig. 
Open Field 
Total Time in the 
center 
One-way 
ANOVA Factor treatment F=2.48 4,59 <0.05* 1A PLSD  
Post-hoc test 
Cort/Veh vs Cort/Flx   <0.05* 
Cort/Veh vs Cort/RS   <0.01** 
Ratio Amb. Dist 
Cter/Total Amb 
Dist. 
One-way 
ANOVA Factor treatment F=2.70 4,59 <0.05* 1B PLSD  
Post-hoc test 
Cort/Veh vs Cort/Flx   <0.01** 
Cort/Veh vs Cort/RS   <0.01** 
Entries in the 
center 
One-way 
ANOVA Factor treatment F=0.70 4,59 >0.5 
Supp 
2A 
Total Am One-way ANOVA Factor treatment F=0.66 4,59 >0.5 
Supp 
2B 
Elevated Plus 
Maze 
Total Time in the 
open arms 
One-way 
ANOVA Factor treatment F=1.6 4,59 >0.05 1C PLSD  
Post-hoc test 
Cort/Flx vs 
Cort/FLX+GR   <0.05# 
Entries in the open 
arms 
One-way 
ANOVA Factor treatment F=1.78 4,59 >0.05 1D 
Splash Test Grooming duration 
One-way 
ANOVA Factor treatment F=4.95 4,59 <0.01** 
1E PLSD  
Post-hoc test 
Cort/Veh vs Cort/Flx   <0.01** 
Cort/Veh vs Cort/RS   <0.01** 
Cort/Flx vs 
Cort/FLX+GR   <0.01## 
Tail 
Suspension 
Test 
Immobility 
duration 
One-way 
ANOVA Factor treatment F=3.76 4,59 <0.01** 
1F PLSD  
Post-hoc test 
Cort/Veh vs Cort/Flx   <0.01** 
Cort/Veh vs Cort/RS   <0.01** 
Cort/Flx vs 
Cort/FLX+GR   <0.01## 
Novelty 
Suppressed 
Feeding 
Latency to Feed 
Kaplan-Meier 
Survival analysis    <0.01** 1G 
One-way 
ANOVA Factor treatment F=2.83 4,59 <0.05* 
1H PLSD  
Post-hoc test 
Cort/Veh vs Cort/Flx   <0.01** 
Cort/Veh vs Cort/RS   <0.01** 
Cort/Flx vs 
Cort/FLX+GR   <0.01## 
Food Cons. One-way ANOVA Factor treatment F=1.18 4,59 >0.05 
Supp 
2B 
Legend: CORT:corticosterone; Flx:fluoxetine; Veh:Vehicle; RS:RS67333; GR:GR125487   
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Supplemental table 2: complete statistical summary analysis for neurogenic data after chronic 
treatment  
Behavioral 
paradigm Measurement 
Statistical 
Test Comparison Statistics 
Degrees 
of 
freedom 
p Fig. 
Proliferation KI-67 positive 
cells 
One-way 
ANOVA Factor treatment F=20.07 4,13 <0.05* 
2A 
PLSD  
Post-hoc test 
CORT/Veh vs 
CORT/Flx   <0.01** 
CORT/Veh vs 
CORT/RS   <0.05* 
CORT/Flx vs 
CORT/RS   <0.01## 
Maturation 
DCX-positive 
cells 
One-way 
ANOVA Factor treatment F=9.36 4,13 <0.01** 
2B 
PLSD  
Post-hoc test 
CORT/Veh vs 
CORT/Flx   <0.01** 
CORT/Veh vs 
CORT/FLX+GR   <0.01** 
CORT/Flx vs 
CORT/FLX+GR   <0.01## 
CORT/Flx vs 
CORT/RS   <0.01## 
DCX-positive 
cells with 
tertiary 
dendrites 
One-way 
ANOVA Factor treatment F=12.90 4,13 <0.01** 
2C 
PLSD  
Post-hoc test 
CORT/Veh vs 
CORT/Flx   <0.01** 
CORT/Veh vs 
CORT/FLX+GR   <0.01** 
Cort/Flx vs 
Cort/FLX+GR   <0.01## 
CORT/Flx vs 
CORT/RS   <0.08 
Maturation 
Index 
One-way 
ANOVA Factor treatment F=34.95 4,13 <0.01** 
2D 
PLSD  
Post-hoc test 
CORT/Veh vs 
CORT/Flx   <0.01** 
CORT/Veh vs 
CORT/RS   <0.01** 
CORT/Veh vs 
CORT/FLX+GR   <0.01** 
CORT/Flx vs 
CORT/FLX+GR   <0.01# 
Dendritic length 
One-way 
ANOVA Factor treatment F=8.94 4,91 <0.01** 
2F 
PLSD  
Post-hoc test 
CORT/Veh vs CORT 
FLX (50, 60,70, 80, 
90, 100 µm) 
  <0.01** 
CORT/Veh vs 
CORT/RS (70 µm)   <0.01** 
CORT/Flx vs CORT 
Flx+GR (50, 60,70, 
80, 90, 100 µm) 
  <0.01## 
Dendritic 
intersection 
One-way 
ANOVA Factor treatment F=7.49 4,91 <0.01** 
2G 
PLSD  
Post-hoc test 
CORT/Veh vs CORT 
Flx (60,70, 80, 90 
µm) 
  <0.01** 
CORT/Veh vs 
CORT/RS (70, 80µm)   <0.01** 
CORT/Flx vs CORT 
Flx+GR (60,70, 80, 
90, 100 µm) 
  <0.01## 
Legend: CORT:corticosterone; Flx:fluoxetine; Veh:Vehicle; RS:RS67333; GR:GR125487   
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Supplemental Table 3: complete statistical summary analysis for behavioral data after subchronic 
treatment in sham or X-irradiated mice 
 
Behavioral 
paradigm Measurement Statistical Test Comparison Statistics 
Degrees of 
freedom p Fig. 
Open Field 
Total Time in the 
center 
One-way ANOVA Factor treatment F=6.33 6,65 <0.01** 
3A 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
SHAM/CORT/Flx   <0.01** 
SHAM/Veh/Veh vs 
SHAM/CORT/RS   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Flx   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/RS   <0.01** 
Entries in the center 
One-way ANOVA Factor treatment F=3.90 6,65 <0.01** 
Supp 
4A PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
SHAM/CORT/Flx   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Flx   <0.01** 
Elevated Plus Maze Total Time in the 
open arms 
One-way ANOVA Factor treatment F=3.35 6,65 <0.01** 
3C 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
SHAM/CORT/Flx   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Flx   <0.01** 
Novelty 
Suppressed 
Feeding 
Latency to feed 
Kaplan-Meier Survival 
analysis    <0.01** 
3E 
One-way ANOVA Factor treatment F=3.79 6,65 <0.01** 
3F 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
SHAM/CORT/Flx   <0.01** 
SHAM/Veh/Veh vs 
SHAM/CORT/RS   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Flx   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/RS   <0.01** 
Food cons. One-way ANOVA Factor treatment F=2.20  <0.06 
Supp 
4C 
Tail Suspension 
Test 
Immobility duration 
One-way ANOVA 
Factor treatment F=2.38 6,65 <0.05* 
3H 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Flx 
  <0.01** 
SHAM/Veh/Veh vs 
SHAM/CORT/RS 
  <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Flx 
  <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/RS 
  <0.01** 
Legend : CORT:corticosterone; Flx:fluoxetine; Veh:Vehicle; RS:RS67333; XRAY:X-irradiated 
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Supplemental table 4: complete statistical summary analysis for behavioral data after 
subchronic treatment in sham or X-irradiated mice (two-way ANOVA) 
Behavioral 
paradigm 
Measurement Statistical 
Test 
Comparison Statistics Degrees of 
freedom 
p Fig. 
Open Field 
Total Time in 
the center 
2-way ANOVA 
Factor 1 Pre-
treatment F=0.38 1,61 >0.5 
3A 
Factor 2 Treatment F=8.0 2,61 <0.01** 
Interaction 
(F1 x F2) F=0.039 2,61 >0.5 
PLSD 
Post-hoc test 
  
SHAM/CORT/RS vs  
SHAM/CORT/Veh     <0.05# 
SHAM/CORT/RS vs  
SHAM/CORT/Flx     <0.05# 
XRAY/CORT/RS  vs 
XRAY/CORT/Veh       <0.05# 
XRAY/CORT/RS  vs  
XRAY/CORT/Flx       <0.05# 
Ratio Amb. 
Dist Cter/Total 
Amb Dist. 
2-way ANOVA 
Factor 1 Pre-
treatment F< 0.0001 1,61 >0.5 
3B 
Factor 2 Treatment F=4.91 2,61 <0.05* 
Interaction 
(F1 x F2) F=0.005 2,61 >0.5 
PLSD 
Post-hoc test 
  
  
SHAM/CORT/RS vs  
SHAM/CORT/Veh     <0.05# 
SHAM/CORT/RS vs  
SHAM/CORT/Flx     <0.05# 
XRAY/CORT/RS  vs 
XRAY/CORT/Veh       <0.05# 
XRAY/CORT/RS  vs  
XRAY/CORT/Flx       <0.05# 
Entries in the 
center 
2-way ANOVA 
Factor 1 Pre-
treatment F=0.27 1,61 >0.5 
Supp 4A 
Factor 2 Treatment F=10.41 2,61 <0.01** 
Interaction 
(F1 x F2) F=0.120 2,61 >0.5 
PLSD 
Post-hoc test 
  
  
SHAM/CORT/RS vs  
SHAM/CORT/Veh     <0.05# 
SHAM/CORT/RS vs  
SHAM/CORT/Flx     <0.05# 
XRAY/CORT/RS  vs 
XRAY/CORT/Veh       <0.13 
XRAY/CORT/RS  vs  
XRAY/CORT/Flx       <0.13 
Elevated 
Plus Maze Total Time in the open arms 
2-way ANOVA 
Factor 1 Pre-
treatment F=0.86 1,61 >0.3 
3C 
  
Factor 2 Treatment F=4.96 2,61 <0.01** 
Interaction 
(F1 x F2) F=0.28 2,61 >0.5 
PLSD 
Post-hoc test 
SHAM/CORT/RS vs  
SHAM/CORT/Veh     <0.05# 
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SHAM/CORT/RS vs  
SHAM/CORT/Veh   <0.05# 
XRAY/CORT/RS  vs 
XRAY/CORT/Veh       <0.09 
Entries in the 
open arms 
2-way ANOVA 
Factor 1 Pre-
treatment F=0.14 1,61 >0.5 
3D 
Factor 2 Treatment F=3.09 2,61 <0.053 
Interaction 
(F1 x F2) F=0.92 2,61 <0.41 
PLSD 
Post-hoc test 
SHAM/CORT/RS vs  
SHAM/CORT/Veh     <0.05# 
XRAY/CORT/RS  vs 
XRAY/CORT/Veh       <0.05# 
Splash test Grooming 
duration 
2-way ANOVA 
Factor 1 Pre-
treatment F=2.28 1,61 >0.5 
3G 
 Factor 2 Treatment F=7.16 2,61 <0.01** 
Interaction 
(F1 x F2) F=0.022 2,61 >0.5 
PLSD 
Post-hoc test 
 
SHAM/CORT/Flx vs 
SHAM/CORT/Veh     <0.05# 
SHAM/CORT/RS vs 
SHAM/CORT/Veh     <0.05# 
XRAY/CORT/Flx  vs 
XRAY/CORT/Veh       <0.05# 
XRAY/CORT/RS  vs 
XRAY/CORT/Veh       <0.05# 
Tail 
Suspension 
Test 
Immobility 
duration 
2-way ANOVA 
Factor 1 Pre-
treatment F=2.28 1,61 <0.14 
3H 
Factor 2 Treatment F=7.16 2,61 <0.01** 
Interaction 
(F1 x F2) F=0.02 2,61 >0.5 
PLSD 
Post-hoc test 
  
  
SHAM/CORT/Veh vs  
SHAM/CORT/Flx     <0.05# 
SHAM/CORT/Veh  
vs  SHAM/CORT/RS     <0.05# 
XRAY/CORT/Veh  
vs  XRAY/CORT/Flx     <0.05# 
XRAY/CORT/Veh  
vs  XRAY/CORT/RS     <0.01## 
Factor 1 Pre-treatment: Sham or X-irradiation; Factor 2 Treatment: Vehicle or Corticosterone; CORT:corticosterone; 
Flx:fluoxetine; Veh:Vehicle; RS:RS67333; XRAY:X-irradiated 
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Supplemental Table 5: complete statistical summary analysis for behavioral data after chronic 
treatment 
Behavioral 
paradigm Measurement 
Statistical 
Test Comparison Statistics 
Degrees of 
freedom p Fig. 
Open Field 
Total Time in 
the center 
One-way 
ANOVA Factor treatment F=3.94 6,59 <0.01** 
3I 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
Amb. Dist 
Center/Total 
Amb. Dist 
One-way 
ANOVA Factor treatment F=2.48 6,59 <0.05* 
3J 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
Entries in the 
center 
One-way 
ANOVA Factor treatment F=2.94 6,59 <0.05* 
Supp 
4B PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
Elevated Plus 
Maze 
Total Time in 
the open arms 
One-way 
ANOVA Factor treatment F=5.32 6,59 <0.01** 
3K 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
Entries in the 
open arms 
One-way 
ANOVA Factor treatment F=3.91 6,50 <0.01** 
3L 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
Novelty 
Suppressed 
Feeding 
Latency to feed 
Kaplan-
Meier 
Survival 
analysis 
   <0.01** 3M 
One-way 
ANOVA Factor treatment F=7.31 6,59 <0.01** 
3N 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/Flx   <0.01** 
SHAM/Veh/Veh vs 
XRAY/CORT/RS   <0.05* 
Food cons. One-way ANOVA Factor treatment F=1.28 6,59 <0.3 
Supp 
4D 
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Splash Test Grooming 
duration 
One-way 
ANOVA Factor treatment F=3.40 6,59 <0.01** 
3O 
PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Veh   <0.05* 
SHAM/Veh/Veh vs 
XRAY/CORT/Veh   
 
<0.26 
 
Tail 
Suspension 
Test 
Immobility 
duration 
One-way 
ANOVA Factor treatment F=2.36 6,59 <0.05* 
3P 
 PLSD  
Post-hoc test 
SHAM/Veh/Veh vs 
SHAM/CORT/Flx   <0.05* 
SHAM/Veh/Veh vs 
XRAY/CORT/Flx   <0.05* 
SHAM/Veh/Veh vs 
SHAM/CORT/RS   <0.06 
SHAM/Veh/Veh vs 
XRAY/CORT/RS   <0.07 
Legend: Factor 1 Pre-treatment: Sham or X-irradiation; Factor 2 Treatment: Vehicle or Corticosterone; CORT:corticosterone; 
Flx:fluoxetine; Veh:Vehicle; RS:RS67333; XRAY:X-irradiated 
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Supplemental Table 6: complete statistical summary analysis for behavioral data after chronic 
treatment in sham or X-irradiated mice (two-way ANOVA) 
Behavioral 
paradigm Measurement 
Statistical 
Test Comparison Statistics 
Degrees of 
freedom p 
Fig. 
Open Field 
Total Time in the 
center 
2-way 
ANOVA 
Factor 1 Pre-
treatment F=0.64 1,55 >0.4 
3I 
Factor 2 Treatment F=5.37 2,55 <0.01** 
Interaction 
(F1 x F2) F=0.32 2,55 >0.5 
PLSD 
Post-hoc test 
  
SHAM/CORT/Veh vs 
SHAM/CORT/Flx     <0.01## 
SHAM/CORT/Veh vs  
SHAM/CORT/RS     <0.01## 
XRAY/CORT/Veh  
vs XRAY/CORT/Flx     <0.1 
XRAY/CORT/Veh  
vs  XRAY/CORT/RS     <0.05# 
Ratio Amb. Dist 
Cter/Total Amb 
Dist. 
2-way 
ANOVA 
Factor 1 Pre-
treatment F=0.24 1,55 >0.5 
3J 
Factor 2 Treatment F=3.17 2,55 <0.05* 
Interaction 
(F1 x F2) F=0.60 2,55 >0.5 
PLSD 
Post-hoc test 
SHAM/CORT/Veh vs 
SHAM/CORT/Flx     <0.01## 
SHAM/CORT/Veh vs  
SHAM/CORT/RS     <0.05# 
XRAY/CORT/Veh  
vs XRAY/CORT/Flx     <0.2 
Entries in the 
center 
2-way 
ANOVA 
Factor 1 Pre-
treatment F=0.052 1,55 >0.5 
Supp 4B 
Factor 2 Treatment F=5.47 2,55 <0.01** 
Interaction 
(F1 x F2) F=0.40 2,55 >0.5 
PLSD 
Post-hoc test 
SHAM/CORT/Veh vs 
SHAM/CORT/Flx     <0.05# 
SHAM/CORT/Veh vs  
SHAM/CORT/RS     <0.05# 
XRAY/CORT/Veh  
vs XRAY/CORT/Flx     <0.07 
XRAY/CORT/Veh  
vs  XRAY/CORT/RS     <0.01## 
Elevated 
Plus Maze Total Time in the open arms 
2-way 
ANOVA 
Factor 1 Pre-
treatment F=3.45 1,55 <0.07 
3K 
Factor 2 Treatment F=9.28 2,55 <0.01** 
Interaction 
(F1 x F2) F=0.56 2,55 >0.5 
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PLSD 
Post-hoc test 
  
SHAM/CORT/Veh vs 
SHAM/CORT/Flx     <0.06 
SHAM/CORT/Veh vs  
SHAM/CORT/RS     <0.05# 
XRAY/CORT/Veh  
vs XRAY/CORT/Flx     <0.09 
XRAY/CORT/Veh  
vs  XRAY/CORT/RS     <0.01## 
Entries in the open 
arms 
2-way 
ANOVA 
Factor 1 Pre-
treatment F=2.98 1,55 <0.09 
3L 
Factor 2 Treatment F=7.91 2,55 <0.001*** 
Interaction 
(F1 x F2) F=0.27 2,55 >0.5 
PLSD 
Post-hoc test 
  
SHAM/CORT/Veh vs 
SHAM/CORT/Flx     <0.05# 
SHAM/CORT/Veh vs  
SHAM/CORT/RS     <0.01## 
XRAY/CORT/Veh  
vs XRAY/CORT/Flx     <0.13 
XRAY/CORT/Veh  
vs  XRAY/CORT/RS     <0.042# 
Novelty 
Suppressed 
Feeding 
Latency to feed 
2-way 
ANOVA 
Factor 1 Pre-
treatment F=14.42 1,55 <0.01** 
3N 
  
Factor 2 Treatment F=2.73 2,55 <0.08 
Interaction 
(F1 x F2) F=6.86 2,55 <0.01** 
PLSD SHAM/CORT/Veh vs SHAM/CORT/Flx     <0.05# 
Post-hoc test SHAM/CORT/Veh vs  SHAM/CORT/RS     <0.01## 
Food Cons. 2-way ANOVA 
Factor 1 Pre-
treatment F=1.48 1,55 >0.2 
Supp 4D 
 Factor 2 Treatment F=0.67 2,55 >0.5 
Interaction 
(F1 x F2) F=1.42 2,55 >0.2 
Splash test Grooming duration 
2-way 
ANOVA 
Factor 1 Pre-
treatment F=2.22 1,55 >0.1 
3O 
Factor 2 treatment F=8.85 2,55 <0.01** 
Interaction 
(F1 x F2) F=0.35 2,55 >0.5 
PLSD 
Post-hoc test 
 
SHAM/CORT/Veh vs 
SHAM/CORT/Flx     <0.05# 
SHAM/CORT/Veh vs  
SHAM/CORT/RS     <0.01## 
XRAY/CORT/Veh  
vs XRAY/CORT/Flx     <0.07 
XRAY/CORT/Veh  
vs  XRAY/CORT/RS     <0.01## 
Tail 
Suspension 
Immobility 
duration 
2-way 
ANOVA 
Factor 1 Pre-
treatment F=0.055 1,55 >0.5 3P 
 Factor 2 Treatment F=5.43 2,55 <0.01** 
  
 
192 
Test Interaction 
(F1 x F2) F=0.18 2,55 >0.5 
PLSD 
Post-hoc test 
SHAM/CORT/Veh vs 
SHAM/CORT/Flx     <0.05# 
SHAM/CORT/Veh vs  
SHAM/CORT/RS     <0.06 
XRAY/CORT/Veh  
vs XRAY/CORT/Flx     <0.07 
XRAY/CORT/Veh  
vs  XRAY/CORT/RS     <0.05# 
Legend: Factor 1 Pre-treatment: Sham or X-irradiation; Factor 2 Treatment: Vehicle or Corticosterone; CORT:corticosterone; 
Flx=fluoxetine; Veh:Vehicle; RS:RS67333; XRAY:X-irradiated	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Supplemental Figure 4
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Conclusion	  of	  the	  study	  
Our study shows, for the first time, in a mouse model of anxiety/depression, that a 5-
HT4 receptor agonist may be a fast-acting anxiolytic agent, and that 5-HT4 stimulation is 
necessary for the behavioral and neurogenic effects (proliferation and maturation) of 
fluoxetine, a classic SSRI antidepressant. Furthermore, we showed that, with the exception of 
the NSF test, the anxiolytic and antidepressant-like effects of the 5-HT4 agonist were 
independent of hippocampal neurogenesis.  
The present study is encouraging for the development of RS-67333 as an 
anxiolytic/antidepressant compound for use in patients. However, the use of the 5-HT4 
receptor as a novel antidepressant target may be hampered by the fact that it also plays 
important roles outside the central nervous system (Tonini and Pace, 2006), which may 
prevent its development as an effective anxiolytic/antidepressant drug (Bockaert et al., 2004, 
2008). Thus, signaling molecules that interact with the 5-HT4 receptor such as P11 (Egeland 
et al., 2011; Warner-Schmidt et al., 2009) may represent novel targets for fast-acting 
anxiolytic/antidepressant treatments.  
We next wanted to investigate whether the fast onset of anxiolytic/antidepressant 
action of 5-HT4 receptor agonist treatment can be predict by measuring in Peripheral Blood 
Mononuclear Cells, β-arrestin 1 levels, a protein known to play a role in the pathophysiology 
of depression and in antidepressant mechanism of action (Avissar et al., 2004; Schreiber and 
Avissar, 2004; Matuzany-Ruban et al., 2005; Beaulieu et al., 2008; David et al., 2009; 
Schreiber et al., 2009; Golan et al., 2010).  
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Article	   5:	   A	   method	   for	   biomarker	   measurements	   in	   peripheral	   blood	  
mononuclear	   cells	   isolated	   from	   anxious	   and	   depressed	   mice:	   β-­‐arrestin	   1	  
protein	  levels	  in	  depression	  and	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Introduction	  of	  the	  study	  
A recent review from Duman’s group highlighted the need to develop a biomarker 
panel for depression. This biomarker panel should profile diverse peripheral factors that 
together will provide a biological signature of depressive disorders subtypes and predict 
treatment response (Schmidt et al., 2011). Assessing peripheral protein levels in PBMCs is an 
attractive method because PBMCs are circulating cells that can be easily collected and 
monitored. Previous studies demonstrated that PBMCs can be isolated from mouse blood to 
assess immunological responses (Fuss et al., 2009).  
In this study we developed a method to screen putative biomarkers of the 
pathophysiology of mood disorders and the response to Ads, measuring and assessing 
circulating proteins, espically β-arrestin 1 in PBMCs. If β-arrestin 1 is know as a protein to 
mediate receptor desensitization, endocytosis and G protein-independent signaling, it also 
recognized as a protein involved in the pathophysiology of depression and in antidepressant 
mechanism of action. Furthermore, we examined whether changes in β-arrestin 1 levels in 
mouse PBMCs were observed in a model of anxiety/depression (David et al., 2009; Guilloux 
et al., 2011; Rainer et al., 2011) and whether these levels could be corrected by chronic 
treatment with the SSRI fluoxetine. 
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A limited number of biomarkers in the central and peripheral systems which are known
may be useful for diagnosing major depressive disorders and predicting the effectiveness
of antidepressant (AD) treatments. Since 60% of depressed patients do not respond
adequately to medication or are resistant to ADs, it is imperative to delineate more
accurate biomarkers. Recent clinical studies suggest that β-arrestin 1 levels in human
mononuclear leukocytes may be an efficient biomarker. If potential biomarkers such
as β-arrestin 1 could be assessed from a source such as peripheral blood cells, then
they could be easily monitored and used to predict therapeutic responses. However,
no previous studies have measured β-arrestin 1 levels in peripheral blood mononuclear
cells (PBMCs) in anxious/depressive rodents. This study aimed to develop a method to
detect β-arrestin protein levels through immunoblot analyses of mouse PBMCs isolated
from whole blood. In order to validate the approach, β-arrestin levels were then compared
in naïve, anxious/depressed mice, and anxious/depressed mice treated with a selective
serotonin reuptake inhibitor (fluoxetine, 18 mg/kg/day in the drinking water). The results
demonstrated that mouse whole blood collected by submandibular bleeding permitted
isolation of enough PBMCs to assess circulating proteins such as β-arrestin 1. β-Arrestin 1
levels were successfully measured in healthy human subject and naïve mouse PBMCs.
Interestingly, PBMCs from anxious/depressed mice showed significantly reduced β-
arrestin 1 levels. These decreased β-arrestin 1 expression levels were restored to normal
levels with chronic fluoxetine treatment. The results suggest that isolation of PBMCs from
mice by submandibular bleeding is a useful technique to screen putative biomarkers of the
pathophysiology of mood disorders and the response to ADs. In addition, these results
confirm that β-arrestin 1 is a potential biomarker for depression.
Keywords: peripheral blood mononuclear cells, β-arrestin 1, anxiety, depression, mouse models, fluoxetine,
biomarkers
INTRODUCTION
Elucidation of the neurobiological bases of depression and anx-
iety are significant challenges for today’s society. Mood dis-
orders impact 7% of the world’s population and rank among
the top 10 causes of disability (Kessler et al., 2005). Selective
serotonin reuptake inhibitors (SSRIs) and serotonin and nora-
drenaline reuptake inhibitors (SNRIs) are the most commonly
prescribed antidepressant (AD) drugs for major depressive disor-
ders (MDD; Samuels et al., 2011). However, key questions about
the molecular and cellular mechanisms underlying the effects
of ADs remain unanswered. Approximately 60% of depression
patients do not respond adequately or are resistant to these drugs
(Samuels et al., 2011). Therefore, there are clear benefits of hav-
ing valid, reliable, selective, and feasible biomarkers for MDD.
Several studies have reported genome-wide expression changes
associatedwithADresponses inMDD(Iga et al., 2007a,b; Belzeaux
et al., 2010; Lakhan et al., 2010; Mamdani et al., 2011). However,
candidate biomarkers that can accurately predict AD responses
must be identified. While there are currently no specific mark-
ers that are considered “gold standards,” a few candidates have
emerged. Peripheral/serum brain-derived neurotrophic factor
(BDNF), insulin-like growth factor 1 (IGF-1), and cytokines may
serve as biomarkers of MDD and treatment response (for review,
see Schmidt et al., 2011).
Recently, a substantial body of evidence indicates that β-
arrestins (β-arrestin 1 and 2), proteins that regulate G protein
receptor coupling, play major roles in the pathophysiology of
mood disorders and in the mechanisms underlying AD actions
(Avissar et al., 2004; Schreiber andAvissar, 2004;Matuzany-Ruban
et al., 2005; Beaulieu et al., 2008; David et al., 2009; Schreiber
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et al., 2009; Golan et al., 2010). The β-arrestin-signaling cascade
has recently gained attention as a potential pre-clinical/clinical
bridging biomarker for depressive states and treatment effects.
In naïve rats, SSRI, SNRI, and non-selective reuptake inhibitor
ADs significantly elevate β-arrestin 1 levels in the cortex and
the hippocampus (Avissar et al., 2004; Beaulieu and Caron, 2008;
Beaulieu et al., 2008; David et al., 2009). Similarly, β-arrestin 1
expression is decreased in the hypothalamus and hippocampus in
anxious/depressed mice exposed to glucocorticoid elevation, and
is restored by chronic fluoxetine treatment (David et al., 2009).
Moreover, β-arrestin 1 and 2 signaling is involved inmediating the
response to fluoxetine and lithium (Beaulieu et al., 2008; David
et al., 2009).
Clinical data from Avissar et al. (2004) suggest that β-arrestin
1 mRNA and protein levels are highest in peripheral blood leuko-
cytes of MDD patients. Therefore, β-arrestin 1 may be a putative
candidate biochemical marker in clinical practice for depressive
pathophysiology and the response toADs (for review, see Schreiber
et al., 2009). β-Arrestin mRNA levels and β-arrestin 1 protein lev-
els in mononuclear leukocytes of untreated patients with MDD
are lower than the levels found in healthy subjects. Furthermore,
reduced levels of β-arrestin 1 protein and mRNA are significantly
correlated with the severity of depressive symptoms (Avissar et al.,
2004; Schreiber et al., 2009). However, the low β-arrestin 1 protein
and mRNA levels are alleviated by AD treatment. Therefore, these
low levels can predict clinical improvement (Avissar et al., 2004;
Golan et al., 2010).
These clinical data suggest that assessment of β-arrestin 1 levels
may prove useful for diagnosing depression with high sensitiv-
ity and specificity (Golan et al., 2013). This hypothesis must first
be validated in animal models of anxiety–depression. Most of
the current understandings of mood disorders and AD activities
are based on studies performed on animal models of anxiety–
depression (Belzung and Lemoine, 2011). No animal studies have
investigatedwhether β-arrestin 1 protein levels in peripheral blood
mononuclear cells (PBMCs) area marker of the pathophysiology
of depression and the AD response. However, if PBMCs can be
successfully used to define biomarkers, they provide a system of
circulating cells that can be easily collected from patients and
monitored to predict therapeutic responses.
In this study, we developed amethod tomeasure and assess cir-
culating proteins (such asβ-arrestin 1 in PBMCs) that are collected
through submandibular bleeding from unanesthetized animals.
Furthermore, we examined whether changes in β-arrestin 1 levels
in mouse PBMCs were observed in a model of anxiety/depression
(David et al., 2009; Guilloux et al., 2011; Rainer et al., 2012b), and
whether these levels could be corrected by chronic treatment with
the SSRI fluoxetine.
EXPERIMENTAL PROCEDURES
SUBJECTS
Adult male C57BL/6Ntac mice were purchased from Taconic
Farms (Lille Skensved, Denmark). All mice were 7–8 weeks old,
weighed 23–25 g at the beginning of the treatment and weremain-
tained on a 12L:12D schedule (lights on at 0600 hours). The mice
were group-housed with each cage containing five animals. Food
and water were provided ad libitum. All testing were conducted
in compliance with the laboratory animal care guidelines and
with protocols approved by the Institutional Animal Care and
Use Committee (Council directive # 87-848, October 19, 1987,
Ministère de l’Agriculture et de la Forêt, Service Vétérinaire de la
Santé et de la Protection Animale, permissions # 92-256B to Denis
J. David).
DRUGS
Corticosterone (4-pregnen-11b-DIOL-3 20-DIONE 21-hemi-
succinate from Sigma (Sigma-Aldrich, Saint-Quentin-Fallavier,
France) was dissolved in 0.45% hydroxypropyl-β-cyclodextrin
(Sigma-Aldrich, Saint-Quentin-Fallavier, France). Fluoxetine
hydrochloride (18mg/kg/day in thedrinkingwater)waspurchased
from Anawa Trading (Zurich, Switzerland).
ISOLATION OF HUMAN AND MOUSE PERIPHERAL BLOOD
MONONUCLEAR CELLS
Collection of human blood and isolation of peripheral blood
mononuclear cells
Peripheral blood mononuclear cells were purified from 7.5 ml
of human whole circulating blood obtained from Etablissement
Français du Sang (Ivry-Sur-Seine, France) through density cen-
trifugation (850 g at 20◦C for 20 min) using a Ficoll gradient
(PAA Laboratories GmbH,Pashing,Austria; Figure 1A). This cen-
trifugation separated lymphocytes, monocytes, and plasma. The
PBMC layerswere carefully removed from the tube and transferred
to a new 50 ml conical tube. The PBMCs were then washed twice
(1 min each) with 1× phosphate-buffered saline (PBS)/fetal calf
serum (FCS, 2%). After centrifugations (150 g at 20◦C for 7 min),
the cells were resuspended in the appropriate volume of 1× PBS.
ThehumanPBMCswere then recoveredwith afinal centrifugation
(1,000 g at 4◦C for 5 min) and were stored at −80◦C.
Collection of mouse blood and isolation of peripheral blood
mononuclear cells
Blood was collected from unanesthetized mice as previously
described (Golde et al., 2005; Joslin, 2009). In compliance with
the laboratory animal care guidelines, approximately 0.4 ml of
blood per mouse was collected in K3EDTA tubes with a sub-
mandibular bleeding procedure. Five millimeters point size sterile
lancets (MediPoint, Mineola, NY, USA; Figure 1B) were used
to puncture the location where the orbital vein and the sub-
mandibular vein join to form the jugular vein (Joslin, 2009). A
light pressure with dry gauze was applied to the punctured area
for hemostasis. Separation and extraction of PBMCs were per-
formed using an iodixanol mixer technique (Ford and Rickwood,
1990). Mouse PBMCs were purified from whole blood by den-
sity centrifugation (300 g at 20◦C for 30 min) using solution B
(see Table 1 for preparation) of the OptiPrepTM gradient solution
(Sigma-Aldrich, Saint-Quentin-Fallavier, France). Specifically, the
OptiPrepTM gradient solution was used to separate blood into
PBMC and plasma layers with centrifugation. The PBMC lay-
ers were then carefully removed from the tube and transferred to
a new 50 ml conical tube. The PBMCs were then washed twice
with solution B (1 min each). After another centrifugation (150 g
at 20◦C for 7 min) and two washing steps (1 min each), mouse
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FIGURE 1 | Experimental protocol for isolating human and mouse
peripheral blood mononuclear cells from whole blood. (A) Cartoon
representing the different steps for isolating human PBMC from whole
circulating blood (for full details of the method, see Blood collection and
Peripheral blood mononuclear cells Isolation in human from the Section
“Experimental Procedures”). Some elements of this figure were produced
using Servier Medical Art image bank (www.servier.com). (B) Cartoon
representing the different steps for isolating mouse PBMC from whole
circulating blood (for full details of the method, see Blood collection and
Peripheral blood mononuclear cells Isolation in mouse from the Section
“Experimental Procedures”). Some elements of this figure were produced
using Servier Medical Art image bank (www.servier.com).
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Table 1 | Solution used to prepare peripheral blood mononuclear cells from mouse whole blood.
OptiPrepTM density
gradient medium
Tricine-buffered saline (TBS) Solution B
Solutions D1556-250ML
(Sigma-Aldrich, France)
0.85% NaCl, 10 mM;Tricine-NaOH, pH 7.4
(Tricine as 100 mM stock solution at 4◦C;
1.79 g/100 ml water )
Dissolve 0.85 g NaCl in 50 ml water; add 10 ml of
Tricine stock; adjust to pH 7.4 with 1 M NaOH and
make up to 100 ml
PBMCs were recovered with a final centrifugation (1,000 g at 4◦C
for 5 min) and were stored at−80◦C.
β-ARRESTIN 1 LEVELS IN HUMAN AND MOUSE PERIPHERAL BLOOD
MONONUCLEAR CELLS
Protein extraction from peripheral blood mononuclear cells and
immunoblots
Peripheral blood mononuclear cells were thawed and homoge-
nizedwith cell lysis buffer containing [20mMTris pH7.4, 137mM
NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA) pH 7.4,
1% Triton X-100, 25 mM β-glycerophosphate, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 10 µg/ml aprotinin, 10 µg/ml
leupeptin, and 10 µg/ml pepstatin and 100 mM orthovanadate],
were incubated on ice for 20 min, were then subjected to cen-
trifugation at 21,130 g at 4◦C for 20 min. Protein concentrations
were quantified using a BCA Protein Assay Kit (Pierce Biotech-
nology).
β-Arrestin 1 level measurements with immunoblot analyses
Equal amounts of proteins were separated by 10% sodiumdodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to polyvinylidene difluoride (PVDF) membranes (Amer-
sham Biosciences, Les Ulis, France). The membranes were then
incubated overnight with a primary mouse monoclonal anti-β-
arrestin 1 antibody (#610551, BDBiosciences Pharmingen, France;
1:100). In order to ensure that equal amounts of total protein
(30 µg) were loaded in each lane, β-actin protein levels were also
assessed [β-actin (C4) horseradish peroxidase (HRP), Santa Cruz
Biotechnology, Germany, 1:10,000]. Immune complexes were
detected using appropriate peroxide-conjugated secondary anti-
bodies and a chemiluminescent reagent kit (PierceBiotechnology).
Immunoblot quantifications were performed by densitometric
scanning with Image Lab Software (Bio-Rad). Signals were in the
linear range. The densitometry values were normalized against the
β-actin values (Figures 2 and 3).
CORTICOSTERONE MODEL AND TREATMENT
The dose and duration of corticosterone treatment (CORT
model) were selected based on previous studies (David et al.,
2009; Guilloux et al., 2011; Hache et al., 2012; Rainer et al.,
2012a,b). Exposure to chronic corticosterone results in a phe-
notype that is similar to a chronic stress phenotype, including
a deterioration of the coat state and anxiety/depression-related
behaviors. At the end, a higher emotionality score is observed
(Guilloux et al., 2011). Corticosterone (35 µg/ml/day, equiva-
lent to about 5 mg/kg/day) or vehicle (0.45% β-cyclodextrin,
β-CD) were available to mice ad libitum in the drinking water in
FIGURE 2 | β-Arrestin 1 is measurable in both human and mouse
peripheral blood mononuclear cells obtained from a low collection
volume of fresh blood. Representative western blot of β-arrestin 1 levels
in PBMCs isolated either from CD14− human cells, human or naïve mouse
whole blood. In each blot, 30 µg of total protein were run. β-Actin was used
as a control.
opaque bottles. Corticosterone-treated water was changed every
3 days to prevent degradation. Group-housed mice were also
treated with the SSRI fluoxetine (18 mg/kg/day) for the last
4 weeks of the experiment (see the experimental protocol on
Figure 3A).
STATISTICAL ANALYSIS
β-Arrestin 1 levels were quantified and then expressed with a scat-
terplot or as mean± SEM normalized to vehicle levels. Data were
analyzed using Prism 6.0 software (GraphPad, La Jolla, USA).
One-way ANOVAs were used to evaluate data when appropriate.
Significant main effects were further analyzed by Fisher’s post hoc
test. Statistical significance was set at p < 0.05.
RESULTS
β-ARRESTIN 1 IS DETECTED IN HUMAN AND MOUSE PBMC
We first collected blood in order to assess whether β-arrestin 1
could be detected. Single-use lancets were used for submandibu-
lar bleeding and permitted drawing of ∼0.4 ml of blood without
the use of anesthesia (Golde et al., 2005). The mouse PBMCs
were lysed and subjected to immunoblotting. A ∼55 kDa band
that corresponded to the molecular weight of β-arrestin 1 protein
was detected with a monoclonal antibody against mouse anti-β-
arrestin 1 that is known to detect human β-arrestin 1 (Avissar et al.,
2004; Matuzany-Ruban et al., 2005; Golan et al., 2013; Figure 2).
Therefore, this method of PBMC isolation from fresh mouse
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FIGURE 3 | Chronic fluoxetine treatment (18 mg/kg/day for 28
days) restored β-arrestin 1 levels in the peripheral blood mononuclear
cells from anxio/depressive mice treated with chronic corticosterone
treatment. (A) Experimental timeline used to measure β-arrestin 1 levels in
peripheral blood mononuclear cells from naïve or anxio-depressive mouse
submandibular bleeding chronically treated or not with fluoxetine during 28
days (18 mg/kg/day in the drinking water). (B) Representative western blot
of β-arrestin 1 levels in peripheral blood mononuclear cells isolated from
naïve (vehicle/vehicle, V/V), corticosterone (35 µg/ml/day; corticosterone/
vehicle, C/V) or corticosterone/fluoxetine (18 mg/kg/day; corticosterone/
fluoxetine, C/F) mouse whole blood. In each blot, 30 µg of protein
from mouse PBMC were run. The densitometry values for each band
allowed the calculation of a ratio: optical density for β-arrestin 1/optical
density β-actin value. (C,D) Scatterplot of the individual effects (C) or bar
charts of mean ± SEM of the effects (D) of a chronic administration (28
days) treatment with fluoxetine on β-arrestin 1 levels in the peripheral blood
mononuclear cells from mice treated with chronic corticosterone in com-
parison to untreated animals. Data are expressed in percentage normalized
to vehicle/vehicle expression; n = 9–10). *p < 0.05, versus control vehicle/
vehicle group.
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blood successfully permitted measurements of β-arrestin 1 lev-
els. This method can potentially be used to investigate levels of
other proteins as well. Lysates of human total PBMCs and CD14
negative PBMC fraction cells (CD14−) were used as positive con-
trols. In addition, wewere also able to detect β-arrestin 1 in human
PBMCs isolated from low fresh circulating blood volume (7.5 ml)
of healthy adult donors obtained from Etablissement Français du
Sang (Figure 2). To our knowledge, this is the first study to detect
β-arrestin 1 in this fashion.
Next, we decided to quantify β-arrestin 1 levels in PBMCs iso-
lated from C57BL/6Ntac mice exposed to chronic corticosterone
(David et al., 2009; Rainer et al., 2012b) that was given either
alone or in combination with the SSRI fluoxetine (18 mg/kg/day;
Figure 3A).
CHRONIC FLUOXETINE TREATMENT NORMALIZES β-ARRESTIN 1
EXPRESSION IN PBMC ISOLATED FROM ANXIOUS/DEPRESSIVE-LIKE
MICE
In mouse PBMCs isolated from blood of mice treated chronically
with corticosterone (35µg/ml/day),we found thatβ-arrestin 1 lev-
els were significantly lower (−41%; 59% of expression compared
to 100% in the control group) than the levels in naïve animals
[one-way ANOVA, F(2,25) = 3.81; *p < 0.05; Figures 3C,D].
Interestingly, a 4-week treatment with the SSRI fluoxetine nor-
malized these β-arrestin 1 expression levels so that they were not
significantly different than the levels observed in naïve animals
(Figures 3C,D).
DISCUSSION
We developed a new method to assess circulating proteins such
as β-arrestin 1 through immunoblot analyses of mouse PBMCs
isolated from whole blood. We showed significantly reduced β-
arrestin 1 levels in PBMCs from anxious/depressed mice. These
decreased β-arrestin 1 expression levels were restored to normal
levels with chronic fluoxetine treatment.
PBMCs WERE ISOLATED FROM UNANESTHETIZED MICE
A recent review from Duman’s group highlighted the need to
develop a biomarker panel for depression. This biomarker panel
should profile diverse peripheral factors that together will provide
a biological signature of MDD subtypes and predict treatment
response (Schmidt et al., 2011). Assessing peripheral protein levels
in PBMCs is an attractive method because PBMCs are circulating
cells that can be easily collected and monitored. Previous stud-
ies demonstrated that PBMCs can be isolated from mouse blood
to assess immunological responses (Fuss et al., 2009). However,
to our knowledge this is the first study to collect PBMCs from
circulating blood of unanesthetized animals. Single-use lancets
were used for submandibular bleeding. This method permit-
ted PBMCs to be collected from peripheral blood circulation
in living and unanesthetized mice. Thus, submandibular bleed-
ing is a useful method to screen putative biomarkers of the
pathophysiology of mood disorders and the response to ADs.
This technique can be easily performed multiple times in the
same animals and can be used with other rodent species such
as rats.
β-ARRESTIN 1 PROTEIN LEVELS CAN BE MEASURED IN MOUSE AND
HUMAN PBMCs
We measured β-arrestin 1 protein levels to determine whether
mouse PBMCs are useful biological materials to screen biomark-
ers for MDD pathophysiology and the AD response. Over the last
decade, several G protein receptor-related genes such asβ-arrestins
were found to be involved in the pathophysiology of mood disor-
ders (Schreiber andAvissar, 2004; Beaulieu et al., 2008; David et al.,
2009). Numerous data from clinical studies support the impor-
tance of measuring β-arrestin 1 levels as a peripheral biomarker
of the pathophysiology of mood disorders and predicting the AD
response (Avissar et al., 2004; Schreiber et al., 2009; Golan et al.,
2013). However, no previous study demonstrated ex vivomeasure-
ments of β-arrestin 1 levels in leukocytes isolated fromwhole blood
to compare levels betweennaïve and anxious/depressed rodents. In
addition, this is the first study to assess β-arrestin 1 by immunoblot
in human and in mouse leukocytes simultaneously by using the
same monoclonal antibody.
In the human experiments, we were able to recover PBMCs
from 7.5 ml of whole circulating blood from healthy volun-
teers. Previous studies showed that larger amounts of blood were
needed for the detection of β-arrestin 1 in human leucocytes (Avis-
sar et al., 2004; Matuzany-Ruban et al., 2005; Golan et al., 2013).
Here, 7.5 ml was sufficient to acquire 30 µg of PBMC lysate for
immunoblotting (Figure 2).
Avissar et al. (2004) demonstrated that β-arrestin 1 levels were
elevated by chronic ADs in rat cortex and hippocampus. How-
ever, by contrast with their human study, they did not provide
data showing that β-arrestin 1 levels in rat PBMCs are affected
by chronic AD treatment (Avissar et al., 2004). Therefore, we also
compared β-arrestin 1 levels in PBMCs of anxious/depressedmice
before and after chronic AD treatment (Figure 3).
β-ARRESTIN 1 IS A PREDICTIVE MARKER OF THE PATHOPHYSIOLOGY
OF DEPRESSION AND THE ANTIDEPRESSANT RESPONSE
To induce an anxious/depression-related phenotype, we utilized
a chronic corticosterone treatment that results in hallmark char-
acteristics of anxiety and depression (for review, see David et al.,
2009; Mendez-David et al., 2013). In order to delineate a panel of
biomarkers of the pathophysiology and the treatment of depres-
sion, it is first essential to screen putative candidates in a model of
anxiety/depression. β-Arrestin 1 protein levels in leukocytes were
reduced when mice were exposed to chronic corticosterone. As
found in previous human studies (Matuzany-Ruban et al., 2005;
Golan et al., 2013), these reduced β-arrestin 1 levels were alleviated
by AD treatment.
LIMITATIONS OF THE STUDY
Measuring protein levels inmouse PBMCs at several time points is
a powerful technique that can be used to reveal potential biomark-
ers for the pathophysiology of depression and the AD response.
However, this study has some limitations that must be consid-
ered when interpreting the current findings. For example, it is
important to distinguish diagnostic biomarkers from treatment
biomarkers (Schmidt et al., 2011). This study does not address
this difference. Further studies are required to assess whether
β-arrestin 1 is a reasonable biomarker for diagnostic and/or drug
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treatments. A study that compares peripheral levels of β-arrestin
1 in stressed animals before and after AD treatment could defini-
tively address this question. It also may be interesting to study
whether there is a correlation between β-arrestin 1 levels and
the severity of the anxio/depressive state (Guilloux et al., 2011).
Moreover, disease conditions are most often signified by the dys-
regulation of complex biological pathways involving multiple key
factors (Dudley andButte,2009). Thus, it is unlikely thatβ-arrestin
1 alone will be a sufficient diagnostic and treatment biomarker.
However, mouse PBMCs might provide useful material to screen
a panel of biomarkers and to provide biological signatures of
MDD and AD treatments. Finally, in our study, β-arrestin 1 levels
were measured using western blots, which is a semi-quantitative
method of evaluating protein levels. The development of an
enzyme-linked immunosorbent assay (ELISA) to assess β-arrestin
1 levels would provide a more quantitative method.
CONCLUSION
In this study, we demonstrated that PBMCs isolated from a small
volume of whole blood in unanesthetized mice using a sub-
mandibular bleeding method may provide a useful biological tool
to assess circulating proteins. This method will permit future
studies to screen potential biomarkers for the pathophysiology
of depression andAD responses.We also confirmed that measure-
ments of β-arrestin 1 levels in PBMCs may serve as a biochemical
marker of depression in humans (Avissar et al., 2004). Overall,
we developed a powerful tool for translational studies that can
easily be used to assess proteins measurements and to provide a
biological signature of treatment response. Identification of a bio-
logical signature could predict the effectiveness of ADs (Fuss et al.,
2009).
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Conclusion	  of	  the	  study	  
In this study, we demonstrated that PBMCs isolated from a small volume of whole 
blood in unanesthetized mice using a submandibular bleeding method may provide a useful 
biological tool to assess circulating proteins. This method will permit future studies to screen 
potential biomarkers for the pathophysiology of depression and AD responses.  
We also confirmed that measurements of β-arrestin 1 levels in PBMCs may serve as a 
biochemical marker of depression in humans (Avissar et al., 2004). Overall, we developed a 
powerful tool for translational studies that can easily be used to assess proteins measurements 
and to provide a biological signature of treatment response. Identification of a biological 
signature could predict the effectiveness of ADs (Fuss et al., 2009). 
Thus, we used this method to assess the fast anxiolytic-like activity induced by 5-HT4 
receptor stimulation with RS67333 could be predicted by measuring β-arrestin 1 levels in 
PBMCs.  
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Résultats	  complémentaires:	  A	  method	  for	  biomarker	  measurements	   in	  β-­‐arrestin	  
1	  protein	  levels	   in	  peripheral	  blood	  mononuclear	  cells	   isolated	  from	  anxious	  
and	  depressed	  mice	  can	  predict	  fast	  onset	  of	  action	  of	  5-­‐HT4	  agonist	  
Indira	  Mendez-­‐David,	  Denis	  J	  David,	  René	  Hen,	  Saadia	  Kerdine-­‐Römer	  S,	  Alain	  M	  Gardier	  	  
Introduction	  of	  the	  study	  
The β-arrestin-signaling cascade has recently gained attention as a potential pre-
clinical/clinical bridging biomarker for depressive states and treatment effects (Golan et al., 
2013). Previously (article 5), we demonstrated that β-arrestin 1 measurement in PBMCs could 
serve as a biological marker in response to fluoxetine in our model of anxiety/depression 
(Mendez-David et al., 2013). We also corroborated previous evidences that agonist activation 
of 5-HT4 receptors mediate fast-acting antidepressant-like effects since the behavioral activity 
that we observed occurs at 7 days after the start of the treatment. Thus, in this study, we 
wanted to investigate whether, the fast anxiolytic-like activity induced by 5-HT4 receptor 
stimulation with RS67333 could be predicted by measuring β-arrestin 1 levels in PBMCs.  
It has been demonstrated that GRK5 as well as a post-translational modification of β-
arrestin 1 determine the nature of the signaling pathway, which is predominantly engage on 
activation of the 5-HT4 receptor. Overall,  β-arrestin 1 has been involved in 5-HT4 receptor 
desensitization (Barthet et al., 2009) and 5-HT4 receptor internalization (Mnie-Filali et al., 
2010). Such a control in signaling pathways could be critical for 5-HT4 receptor in behavior 
(Barthet et al., 2009). We also explored the consequences of a chronic treatment with 
RS67333 on  β-arrestin 1 expression in two brain areas involved in anxiolytic/antidepressant 
behavioral activtiy, the cortex and the hippocampus in corticosterone-treated mice. 
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EXPERIMENTAL PROCEDURES: 
Corticosterone treatment 
Our designed protocol consists in chronic administration of corticosterone in the drinking 
water. For this purpose, corticosterone (4-pregnen-11b-DIOL-3 20-DIONE 21-hemisuccinate 
(Sigma-Aldrich Saint-Quentin Fallavier, France) is dissolved in vehicle (0.45% 
hydroxypropyl-β-cyclodextrin, Sigma-Aldrich Saint-Quentin Fallavier, France). The dose and 
duration of corticosterone treatment are selected based on previous studies (David et al., 
2009). For a cohort of 60 animals corticosterone (35 µg/ml, equivalent to about 5 mg/kg/d) is 
available ad libitum in the drinking water in. Corticosterone powder begins to degrade once in 
solution. Thus, to protect corticosterone from light, opaque bottles should be used. Control 
animals (vehicle group) should receive the vehicle (0.45 % β-cyclodextrin, β-CD).  
 
Drugs treatment  
While administration with β-CD or corticosterone continued, mice are treated with vehicle 
(0.45% β-CD), fluoxetine hydrochloride (Anawa Trading, Zurich, Switzerland), RS67333 
hydrochloride (1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-butyl-4piperidinyl)-1-propanone 
hydrochloride) (Tocris Bioscience, Bristol, United Kinkdom). RS67333 is delivered by 
osmotic mini-pumps at a dose of 1.5 mg/kg/day. Fluoxetine (18 mg/kg per day) is delivered in 
the drinking water as previously described. Osmotic minipumps (42 days mini-pumps, 2006 
model, Alzet, Cupertino, CA) is implanted subcutaneously under light anesthesia 
(ketamine/xylazine; (75/20 mg/kg) from Sigma Aldrich (Sigma-Aldrich Saint-Quentin 
Fallavier, France). Treatment is always maintained until the end of the experiments. 
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β-arrestine expression 
Blood collection and Peripheral blood mononuclear cells (PBMC) Isolation 
The procedure is done on unanesthetized mice as previously described elsewhere22. 
About 0.4 ml of blood per mice was collected in K3_EDTA tubes using the submandibular 
bleeding method after 7 or 28 days of treatment. The punctures were preformed with 5 mm 
point size sterile lancets (MediPoint, Mineola, NY). Briefly, blood was mixed with the 
OptiPrepTMgradient solution and extractions of Peripheral blood mononuclear cells (PBMC) 
were done using the iodixanol mixer technique. After centrifugation and several washing 
steps the PBMC’s were recovered and stored at -80°C. 
Protein extraction from PBMC’s and Immunoblots 
PBMC’s were thawed and homogenized with cell lysates buffer containing (20mM 
Tris PH :7.4, 137mM NaCl, 2mM ethylenediaminetetraacetic acid (EDTA) Ph7.4, 1% triton 
X 100, 25mM β -glycerophosphate, 1mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 
10 µg/ml pepstatin and 100mM Orthovanadate), incubated on ice for 20 min and followed by 
centrifugation at 15,000 rpm at 4°C for 20 min. Protein concentration was quantified using 
BCA Protein Assay Kit (Pierce Biotechnology). Equal amount of proteins were separated by 
10% sodium dodecyl sulfate–polyacrylamide electrophoresis (SDS-PAGE) and transferred to 
polyvinylidene difluoride membranes (PVDF), (Amersham Biosciences, Les Ulis, France). 
Membranes were incubated overnight in the following antibodies: a primary monoclonal 
antibody Mouse Anti- β -Arrestin 1 (BD Bioscience Pharmigen) and β-Actin (Santa Cruz 
Biotechnology, CA). Immune complexes were detected using appropriate peroxide-
conjugated secondary antibodies along with a Chemiluminescent reagent kit (Pierce 
Biotechnology). Proteins bands were quantified with Image lab software (Bio-Rad).  
Western blotting analysis 
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For Western Blot analysis, mice were killed by cervical dislocation, cortex and 
hippocampi were rapidly dissected and the proteins were extracted in 20 mM Tris-HCl pH7,6, 
137 mM NaCl, 1% NP-40, 10% glycerol, 1% protease and phosphatase inhibitor cocktails 
(Sigma). Cell lysates were centrifuged 10,000g for 10 min at 4°C. Electrophoresis was 
performed in 8% (or 15% for BDNF detection) SDS-polyacrylamide gels and the proteins 
were transferred to Protran nitrocellulose membranes (Whatman). After blocking in 10 mM 
Tris-HCl, pH:7,6, 200 mM NaCl, 0,1% Tween-20 and 5% BSA, membranes were incubated 
with primary monoclonal antibody Mouse Anti- β-Arrestin 1 (BD Bioscience Pharmigen) and 
β-Actin (Santa Cruz Biotechnology, CA).Primary antibodies were detected with appropriate 
HRP-coupled secondary antibodies and ECL signals (SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Erembodegem, Belgium) were quantitated with Image 
lab software (Bio-Rad). 
Data Analysis and Statistics 
Results from data analyses were expressed as mean ± SEM. Data were analyzed using 
StatView 5.0 software (SAS Institute, Cary, NC). For all experiments, one-way ANOVAs 
was applied to the data as appropriate. Significant main effects and were followed by Fisher’s 
PLSD post hoc analysis. 
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Figure 12 : β-arrestin 1 levels in peripheral blood mononuclear cells after subchronic (7 
days) and chronic treatment (28 days) with the 5-HT4 agonist, RS67333 (1.5 mg/kg/day) 
or the Selective Serotonin Reuptake Inhibitor, fluoxetine (18 mg/kg/day) in 
corticosterone-treated mice. Peripheral	   Blood	   Mononuclear	   Cells	   (PBMCs)	   were	   isolated	   from	   small	   volume	   of	   whole	   blood	   in	  unanesthetized	  mice	  using	  a	  submandibular	  bleeding	  method	  (A).	  Data	  are	  expressed	  in	  %	  β-­‐arrestin	  1	  of	  the	   Vehicle/Vehicle	   Group	   ±	   SEM	   in	   mouse	   PBMCs.	   One-­‐factor	   ANOVA	   with	   Fisher’s	   PLSD	   post	   hoc	  analysis	   against	   the	   control	   group	   (vehicle/vehicle)	   revealed	   that	   only	   chronic	   RS67333	   treatment	  reversed	  decrease	  in	  β-­‐arrestin	  1	  levels	  in	  peripheral	  blood	  mononuclear	  cells	  induced	  by	  corticosterone	  after	   subchronic	   treatment	   while	   it	   takes	   28	   days	   for	   fluoxetine	   treatment	   to	   reverse	   this	   effect	  (F(6,45)=3.62,	   p<0.01;	   p<0.05*	   versus	   vehicle/vehicle	   group,	   p<0.01##	   versus	   Corticosterone/vehicle	  group;	  p<0.05$	  versus	  corticosterone/fluoxetine	  group).	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Figure 13 : β-arrestin 1 levels in cortex after chronic treatment (28 days) with the 5-HT4 
agonist, RS67333 (1.5 mg/kg/day) or the Selective Serotonin Reuptake Inhibitor, 
fluoxetine (18 mg/kg/day) in corticosterone-treated mice. Data	  are	  expressed	  in	  %	  β-­‐arrestin	  1	  protein	  levels	  of	  the	  Vehicle/Vehicle	  Group	  ±	  SEM	  in	  mouse	  cortex	  (A)	  	  or	  in	  mouse	  hippocampus.	  One-­‐factor	  ANOVA	  with	  Fisher’s	  PLSD	  post	  hoc	  analysis	  against	  the	  control	  group	   (vehicle/vehicle)	   revealed	   that	   chronic	   RS67333	   treatment	   decreased	   in	   β-­‐arrestin	   1	   levels	   in	  mouse	   cortex	   treated	   by	   corticosterone	   (F(3,	   20)=3.41,	   p<0.05),	   while,	   as	   fluoxetine,	   	   it	   reversed	  decreased	   in	   β-­‐arrestin	   1	   levels	   in	   the	   mouse	   hippocampus	   (F(3,	   20)=3.22,	   p<0.05;	   p<0.01**	   versus	  vehicle/vehicle	  group,	  p<0.05#	  versus	  Corticosterone/vehicle	  group). 
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Conclusion	  
In this study, we wanted to further explore whether the fast onset of action of a 5-HT4 
receptor activation by RS67333 could be predicted by a peripheral biomarker expression. To 
this end, we used β-arrestin 1 expression in leukocyte as a candidate since previously 
preclinical and clinical studies linked this protein to mood disorders (Golan et al., 2013). 
Thus, peripheral blood mononuclear cells were isolated from non-stressed and stressed-
treated animals with vehicle, RS67333 (1.5 mg/kg/d) or fluoxetine (18 mg/kg/d) (Figure A). 
Interestingly, β-Arrestin 1 level, measured by immunoblot, were lowered in our cort model of 
Stress-Related (Anxiety/Depression), as previously shown (article #5) (Mendez-David et al., 
2013). This results goes in line with recent clinical data that point out the role of β-arrestin 1 
level for biochemical diagnostic purposes.  
Previous behavioral data (article #4) showed that, unlike fluoxetine, a 5-HT4 receptor 
stimulation with RS67333, induced rapid anxiolytic/antidepressant-like activity in a stress-
related model of Anxiety/Depression. If we did not detect any change in β-arrestin 1 mouse 
leukocytes under fluoxetine in corticosterone-treated animals after 7 days of treatment, a short 
term exposure with RS67333, restored the level of this protein. This effect with RS67333 
lasted after 28 days of treatment. In regard to the fluoxetine-treated animals, a restoration was 
only observed in the corticosterone model after a longer exposure. 
The effects of a chronic treatment with RS67333 on β-arrestin 1 expression levels in 
the mouse brain treated with chronic corticosterone gave us opposite effect depending on the 
brain region. We observed that, in contrast to the hippocampus, a chronic treatment with the 
5-HT4 agonist reduced the expression of β-arrestin 1 protein in the cortex. These results point 
out region-specific consequences of a chronic treatment with RS67333 on β-arrestin 1 protein 
expression.  
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Recent reports showed that chronic treatment with various classes of antidepressants 
(SSRIs fluoxetine and paroxetine or dual antidepressant venlafaxine) induced desensitization 
and/or downregulation of the 5-HT4 receptors in cerebral regions implicated in depression 
including basal ganglia and hippocampus (Licht et al., 2009; Vidal et al., 2009; Vidal et al., 
2010), probably reflecting a desensitization process, due to a less efficient coupling to Gs 
proteins. Another study, demonstrated that short-term administration (7 days) of RS67333 is 
required to fully desensitize the post-receptor signaling pathway associated to 5-HT4 receptors 
(Pascual-Brazo et al., 2012). The fact that chronic SSRI treatments led to 5-HT4 receptor 
stimulation is also suggested by the observation that such treatments induced a 
downregulation of those receptors in hippocampus (particularly CA1 region), striatum, and 
substantia nigra but, interestingly, not in medial Prefrontal Cortex (mPFC) (for review, 
Bockaert et al., 2011). There results are in line with ours demonstrating a restoration of β-
arrestin 1 expression in the hippocampus under RS67333 or fluoxetine chronic treatment. 
Indeed, β-arrestin proteins are involved in desensitization and internalization of 5-HT4 
receptor (for review, Mnie-Filali and Pineyro, 2012). In contrast, the decrease in β-arrestin 
proteins expression in the cortex after RS67333 or fluoxetine treatment is in favor to an 
absence of downregulation in the cortex. Further studies investigating the difference of β-
arrestin 1 expression, using local application of antidepressant or RS6733 are required to 
understand the link of β-arrestin1 and 5-HT4 receptors and behavioral activity. 
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Discussion	  	  
Most current antidepressant treatments are limited by a significant degree of non 
responsiveness among patients (Trivedi et al, 2006), delayed onset of therapeutic efficacy, 
and a number of side effects (Kato and Serretti, 2010). The development of new 
antidepressants is therefore of considerable importance (Wong et al, 2010), and understanding 
the mechanisms underlying the delayed onset should offer insights into new approaches.	  
Selective Serotonin Reuptake Inhibitors (SSRI) act as indirect agonists of monoamine 
receptors. Serotonin is released throughout the forebrain by axons emanating from cell bodies 
located in the midbrain raphe (Barnes and Sharp, 1999). The largely neuromodulatory effects 
of 5-HT are mediated through 14 receptor subtypes, whereas 5-HT levels are limited by two 
inhibitory autoreceptors expressed on 5-HT raphe neurons (Barnes and Sharp, 1999). The 5-
HT1A receptor, a major inhibitory receptor subtype, is expressed on 5-HT raphe neurons as an 
autoreceptor, limiting released of 5-HT at nerve terminals, and in diverse target regions as a 
heteroreceptor mediating cellular responses to release 5-HT. A diversity of evidence has 
demonstrated that 5-HT1A receptors contribute to the establishment of anxiety-related 
behaviors and to antidepressant response (Richardson-Jones et al., 2011). It is believed that 
overactivation and/or overexpression of 5-HT1A autoreceptor would delay the onset of 
antidepressant effect, whereas the functional desensitization of this receptor after sustained 
administration of SSRIs is an adaptive change relevant to their therapeutic activity (Gardier et 
al., 1996). At the postsynaptic levels, the absence of the 5-HT1A receptor prevents the 
behavioral effects of fluoxetine (Santarelli et al., 2003, Richardson et al., 2011). SSRIs are 
also potent stimulators of adult hippocampal neurogenesis (for review Mendez-David et al., 
2013; Santarelli et al., 2003) and the role of each serotoninergic receptor in the neurogenic 
effects of SSRIs is still a matter of investigation. 
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The recent findings raising the possibility that 5-HT4 receptor activation may 
constitute a new way to treat anxiety/depression triggered my interest for further investigation 
of this 5-HT receptor. 5-HT4 receptors are localized in the limbic system suggesting a role in 
emotion control. These receptors mediate intracellular signaling through cAMP increase, 
PKA activation, phosphorylation of CREB, and transcription of BDNF (Bockaert et al., 
2004). This same signal transduction machinery is activated by chronic antidepressants as 
well (Nibuya et al., 1996). Due to these same mechanisms, direct activation of 5-HT4 
receptors may also yield antidepressant-like effects (Lucas et al., 2007; Pascual-Brazo et al., 
2012; Tamburella et al., 2009). However, the current literature in regard to the antidepressant-
like activity of 5-HT4 receptor is limited. Indeed, almost all related studies have been 
performed in non-stressed rats (except one study measuring the locomotor activity in 
olfactory bulbectomized rats, and another study measuring sucrose consumption after 2 weeks 
of chronic mild stress in rats) (Lucas et al., 2007; Pascual-Brazo et al., 2012) and none have 
so far evaluated the anxiolytic-like profile of 5-HT4 agonists. Moreover, only one step of the 
adult neurogenesis process was investigated, i.e. proliferation. Thus, the 5-HT4 hypothesis is 
far from being validated and more studies are required to evaluate the rapid 
anxiolytic/antidepressant-like effect of 5-HT4 receptor agonists. 
The first aim of my thesis was to focus on whether 5-HT4 receptor stimulation was 
necessary for the effects of SSRIs in a mouse model of anxiety/depression and whether this 
effect occurs rapidly. Thus, using the mouse corticosterone model of anxiety/depression, we 
assessed whether chronic treatment with a 5-HT4 receptor agonist (RS67333, 1.5 mg/kg/day) 
had effects on anxiety and depression-related behaviors as well as on hippocampal 
neurogenesis in comparison to chronic fluoxetine treatment (18 mg/kg/day). 
We showed that the 5-HT4 receptor agonist, RS67333, elicits, like SSRIs, both 
anxiolytic and antidepressant effects, as well as an increase in neurogenesis in the dentate 
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gyrus (article 4). We also showed, using a brain penetrant 5-HT4 receptor antagonist, GR 
125487, that activation of 5-HT4 receptors by endogenous 5-HT is necessary to both 
anxiolytic/antidepressant-like and neurogenic effects of the indirect 5-HT receptor agonist, 
fluoxetine. Serotonin has a high affinity with a pKd = 8.4 and 7.7 for the human and the rat 5-
HT4 receptors respectively (Bender et al., 2000; Adham et al., 1996). Thus, the 
anxiolytic/antidepressant-like effects of fluoxetine likely resulted from an indirect activation 
of the 5-HT4 receptor through an increase in endogenous 5-HT levels in the synaptic cleft, 
which is a consequence of the blockade of the selective serotonin transporter (SSRI).  
In addition to behavioral data, and in agreement with a previous report from Lucas and 
colleagues (Lucas et al., 2007), a recent study performed in naïve rats confirmed that a short 
period of treatment with RS67333 increased the number of newborn cells in the dentate gyrus 
(Pascual-Brazo et al, 2012). However, our data showed that maturation of newborn neurons 
seems to be the most important neurogenesis step. These results are interesting because 
hippocampal neurogenesis has been implicated in some of the behavioral effects of 
antidepressants in adult rodents (David et al, 2009; Santarelli et al, 2003). While no direct 
evidence has yet linked the antidepressant-like effects of 5-HT4 receptor activation and its 
neurogenic effects, we demonstrated that the 5-HT4 agonist acts faster than SSRIs and that its 
anxiolytic effects do not require hippocampal neurogenesis (table 10). 
We then explored whether the fast onset of action of 5-HT4 receptors activation by 
RS67333 could be predicted by a peripheral biomarker expression. There are clear benefits of 
having valid, reliable, selective, and feasible biomarkers for MDD. The β-arrestin-signaling 
cascade has recently gained attention as a potential pre-clinical/clinical bridging biomarker for 
depressive states and treatment effects (Golan et al., 2013). Moreover,  β-arrestin 1 has been 
involved in 5-HT4 receptors desensitization (Barthet et al., 2009), and 5-HT4 receptors 
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internalization process (Mnie-Filali et al., 2010). Thus, β-arrestin 1 could be a good candidate 
to predict fast onset of antidepressant activity. 
However, no animal studies have investigated whether β-arrestin 1 protein levels in 
peripheral blood mononuclear cells (PBMCs) can be used as a biomarker tool for the 
pathophysiology of depression and the antidepressant response. Thus, we developed a new 
method to assess circulating proteins through immunoblot analyses of mouse PBMCs isolated 
from whole blood in anesthetized animals. Measuring protein levels in mouse PBMCs at 
several time points is a powerful technique that can be used to reveal potential biomarkers for 
the pathophysiology of depression and the antidepressant response. We showed significantly 
reduced β-arrestin 1 levels in PBMCs from anxious/depressed mice. These decreased β-
arrestin 1 expression levels were restored to normal levels with chronic fluoxetine treatment. 
We next apply this strategy to corticosterone-treated animals receiving a subchronic or 
a chronic treatment of the 5-HT4 agonist, RS67333, in comparison to chronic fluoxetine. 
Interestingly, β-Arrestin 1 levels, measured by immunoblot, were lowered in our CORT 
model, as previously shown (article # 5) (Mendez-David et al., 2013). This result goes in line 
with recent clinical data that suggest that β-arrestin 1 level may be used for biochemical 
diagnostic purposes. Previous behavioral data (article #4) showed that, unlike fluoxetine, a 5-
HT4 receptor stimulation with RS67333, induced rapid anxiolytic/antidepressant-like activity 
in a stress-related model of anxiety/depression. While we did not detect any change in β-
arrestin 1 levels in mouse leukocytes after 7 days of treatment with fluoxetine in 
corticosterone-treated animals, a short term exposure with RS67333, restored the level of this 
protein to control levels. This effect of RS67333 lasted after 28 days of treatment. In 
fluoxetine-treated animals, a restoration was only observed in the corticosterone model after a 
longer exposure. 
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The effects of a chronic treatment with RS67333 on β-arrestin 1 expression levels in 
the mouse brain treated with chronic corticosterone gave us opposite effect depending on the 
brain region. We observed that, in contrast to the hippocampus, a chronic treatment with a 5-
HT4 agonist, reduced the expression of β-arrestin 1 protein in the cortex. These results point 
out region-specific consequences of a chronic treatment with RS67333 on β-arrestin 1 protein 
expression.  
Tableau 11: β-arrestin 1 levels in peripheral blood mononuclear cells after subchronic 
and chronic treatment with the SSRI, fluoxetine and with the 5-HT4 agonist, RS67333. 
             Treatment 
 
 
Duration 
Corticosterone/
Vehicle 
Corticosterone/ 
Fluoxetine  
(18 mg/kg/day) 
Corticosterone/ 
RS67333  
(1.5 mg/kg/day) 
7 days àà à = 
28 days àà = = 
à ; àà : Decrease in β-arrestin expression ; = no change in comparison to vehicle/vehicle group 
Finally, some important findings of our investigaton such as (fast onset of action of a 
5-HT4 receptor stimulation, neurogenesis-dependent/independent effects, detection of a 
putative biomarker of response) come from methodological choices made during the study. 
Indeed, to demonstrate a fast onset of action, a neurogenesis dependent/independent 
mechanism and a biomarker of response, some critical steps have to be respected: 
- Need for chronic treatment: depression is a chronic, recurrant disease and 
antidepressant efficacy takes time.  
- Comparison with a reference molecule: we have chosen to use fluoxetine, since 
its behavioral effects in our CORT model have been well characterized. 
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- The mouse CORT model: we previously showed that in stressed-animals, the 
neurogenic response is potentiated (for review: David et al., 2010; Mendez-David 
et al., 2013, article 2). 
- Role of the genetic background of mice in response to the tests: strains with a 
high number of basal proliferating cells in the dentate gyrus of the hippocampus 
should be used only under stressed conditions to detect the effects of 
antidepressants on adult neurogenesis (for review David et al., 2010).  
- Characteristics of the protocol to highlight a rapid effect of onset: behavioral 
studies occurred at different time points of the treatment, 7 days versus 28 days.  
- Different steps of adult neurogenesis, with various markers (BrdU, Ki67, 
DCX), have been studied in the dentate gyrus: it allowed us to unravel the 
effects of 5-HT4 receptor agonist on specific stages of the neurogenic process. 
- Need to use a large battery of behavioral tests to assess both anxiolytic and 
antidepressive-like responses of a molecule: Anxiety disorders have a lifetime 
prevalence of over 25% making them the most common psychiatric disorders 
(Hirschfeld, 2001). Moreover, a co-morbidity between depression and anxiety 
disorders is commonly observed. 
- X-irradiation of a restricted region of mouse brain containing the 
hippocampus: it allows the classification of these behavioral tests as 
neurogenesis-dependent and neurogenesis-independent tests, demonstrating in our 
study the neurogenic and behavioral effects of RS 67333 and fluoxetine.  
- Develop a simple and repeatable method to collect blood samples and isolate 
PBMC in mice at different period of time: it will allow to search for biomarkers 
of this fast action of the drugs and make some correlation between changes in 
levels of these biomarkers in the CNS and the periphery system (article 5).  
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Conclusions	  &	  Perspectives	  	  
We demonstrated that 5-HT4 receptors act on at least two distinct brain circuits:  
- one that is independent of hippocampal neurogenesis and that results in rapid 
anxiolytic effects.  
- one that requires hippocampal neurogenesis and that results in delayed 
antidepressant-like effects. 
It is now important to dissect the mechanism of action involved in the fast onset of 
action of the 5-HT4 receptor agonists. Lucas et al. suggested that 5-HT4 receptors exert an 
excitatory control on the firing activity of rat DRN 5-HT neurons. Nonetheless, several 
studies performed in rodent brain have shown that the DRN is lacking of 5-HT4 receptor 
mRNA and protein (Waeber et al., 1994). Perhaps, an indirect control may involve 5-HT4 
receptors located in the medial prefrontal cortex? A new study has used optogenetic methods 
to stimulate prefrontal-brainstem neuromodulatory pathways while animals face 
environmental stressors; these results provided further compelling evidence that prefrontal 
control of neuromodulatory function can have a dramatic effect on motivated behavior 
(Warden et al., 2012). Indeed, they were able to show that the amount of time the rat spends 
engaging in motivated behavior is specifically influenced by these projections from mPFC to 
DRN. Complementary experiments, with intracerebral injection of RS67333 directly in the 
mPFC or in the hippocampus followed by behavioral testing should validate our current 
hypothesis: perhaps, fast onset of antidepressant action results in mPFC/DRN activation and 
will lead to a neurogenesis-independent response. Someone can argue that the selectivity of 
the 5-HT4 receptor agonist tested, RS67333, is not optimal. However, except for the sigma 
receptors, which are bound to affinities comparable to 5-HT4 receptor (5-HT4: pKi =8.7; 
sigma 1: pKi = 8.9; and sigma 2: pKi = 8.0), RS67333 shows low binding affinity for other 
neurotransmitter receptors including 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2C, dopamine D1, D2 and 
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muscarinic M1-M3 receptors (pKi< 6.7) (Bockaert et al, 2004; Eglen et al, 1995). Ultimately, 
the development of a new strategy to manipulate 5-HT4 receptors in the mPFC without 
affecting the dentate gyrus and vice versa and generating inducible tissue specific 5-HT4 KO 
mice, might resolve this question (for instance breeding flox/flox 5-HT4 receptors KO mice 
with Calcium/calmodulin-dependent protein kinase II alpha CreERT2 or NestinCre ERT2 
mice. 
 
 
 
 
 
Figure 14 : A hypothesis on the physiological role of the 5-HT4-mediated cortico-raphé 
positive long-loop and its impact on serotonin levels and behavior under stress (adpated 
from Lucas et al., 2009). Prefrontal	  Cortex	  projections	  to	  the	  dorsal	  raphe	  nucleus	  specifically	  induce	  antidepressant-­‐like	  activity,	  activating	  behavioral	  responses	  with	  an	  increase	  in	  swimming	  behavior	  in	  the	  Forced	  Swim	  test	  (Warden	  et	   al.,	   2012).	   When	   mPFC	   pyramidal	   neurons	   become	   activated,	   the	   5-­‐HT4-­‐dependent	   control	   also	  becomes	  more	  excitatory,	  therefore	  modifying	  the	  equilibrium	  of	  the	  loop	  in	  favor	  of	  its	  5-­‐HT4	  component.	  Consequently,	   DR	   extracellular	   concentrations	   of	   glutamate	   are	   increased,	   which	   results	   in	   a	   stronger	  excitation	  of	  5-­‐HT	  cell	  bodies.	  The	  impulse	  flow	  of	  5-­‐HT	  projections	  is	  enhanced,	  allowing	  an	  elevation	  of	  5-­‐HT	   release	   in	   the	   different	   brain	   areas	   innervated	   by	   the	   5-­‐	   HT	   neuron.	   The	   role	   of	   DR	   GABA	  interneurons,	  which	  also	   receive	  glutamatergic	  projections	   from	   the	  mPFC	   is	   still	  unclear	   (Shenhav	  and	  Botvinick,	  2013).	  
Another important result of our study concern the neurogenesis process. We 
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concluded that maturation of newborn neurons seems to be the most important neurogenesis 
step linked to 5-HT4 receptors activation. Our results suggested that 5-HT4 receptors 
contribute to the effects of fluoxetine on proliferation and maturation of newborn neurons, but 
that other 5-HT receptors are likely to be involved, including the 5-HT1A or the 5-HT2 
receptor (Santarelli et al., 2003; Klempin et al., 2010). Interestingly, both receptors are 
expressed in the dentate gyrus, which may be the site responsible for their effects on 
neurogenesis. Recently, it has been suggested that 5-HT4 receptors activation may also be 
involved in antidepressant-induced dematuration process of mature dentate granule cells 
(Kobayashi et al, 2010). However, the exact mechanisms underlying this phenomenon still 
need further investigations. 
Finally, the activation of 5-HT4 receptors in the brain could represent an innovative 
and rapid onset therapeutic approach to treat depression with comorbid anxiety (new 
classification of MDD in the DSM 5.0). However, the use of the 5-HT4 receptor as a novel 
antidepressant target may be hampered by the fact that it also plays important roles outside 
the central nervous system. For instance, its cardiac and intestinal distribution makes it 
delicate the use of 5-HT4 receptor agonists with the development of side effects such as 
arrhytmia (Tonini and Pace, 2006; Bockaert et al., 2004, 2008). Thus, signaling molecules 
that interact with the 5-HT4 receptor such as P11 (Egeland et al., 2011; Warner-Schmidt et al., 
2009) may represent novel targets for fast-acting anxiolytic/antidepressant treatments. There 
is indeed recent evidence that cortical neurons that express both P11 and 5-HT4 receptors are 
involved in the behavioral effects of SSRIs (Schmidt et al., 2012). 
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TITRE	  :	  Effets	  anxiolytiques/antidépresseurs	  et	  neurogéniques	  des	   ligands	  du	   récepteurs	  
5-­‐HT4	  chez	  la	  souris	  :	  rôle	  de	  la	  protéine	  β-­‐arrestine	  1	  	  
RESUME	  :	  Les inhibiteurs sélectifs de recapture de la sérotonine (ISRS), agonistes indirects 
des récepteurs de la sérotonine (5-HT), ont un début d'effet antidépresseur retardé de plusieurs 
semaines. Des travaux antérieurs suggèrent que le récepteur 5-HT4 de la sérotonine serait une 
cible directe pour traiter la dépression et un nouvel espoir pour traiter plus rapidement ces 
pathologies anxio-dépressives. Toutefois, l'hypothèse « 5-HT4 » doit encore être validée dans 
des modèles animaux d'anxiété/dépression. Les questions posées étaient : la stimulation des 
récepteurs 5-HT4 centraux est-elle nécessaire aux effets comportementaux des ISRS ? la 
neurogenèse hippocampique adulte contribue-t-elle à ces effets ? En utilisant le modèle de 
stress chronique à la corticostérone (CORT) chez la souris, nous avons évalué les effets sur 
ces paramètres d’un traitement chronique avec un agoniste du récepteur 5-HT4 (RS67333, 1,5 
mg/kg/jour pendant 4 semaines) comparé à un traitement à la fluoxétine (18 mg/kg/jour). 
Nous avons ensuite utilisé ce modèle murin combiné à l’ablation de la neurogenèse 
hippocampique par rayons-X afin d’examiner si la neurogenèse est nécessaire aux effets 
comportementaux d’un traitement subchronique (7 jours) ou chronique (28 jours) avec le 
RS67333. Nous avons également évalué le blocage des effets de la fluoxétine par un 
antagoniste du récepteur 5-HT4 (GR125487, 1 mg/kg/jour). Le traitement chronique avec 
RS67333, comme celui de la fluoxétine, induit une activité anxiolytique/antidépressive et 
stimule la neurogenèse hippocampique adulte. Cependant, contrairement à la fluoxétine , les 
effets anxiolytiques du RS67333 sont déjà présents après 7 jours de traitement, sans nécessité 
l’activation de la neurogenèse. Le traitement chronique avec le GR125487 empêche les deux 
effets anxiolytique/antidépresseur et neurogènique de la fluoxétine, indiquant que l'activation 
du récepteur 5-HT4 est nécessaire à ces effets de l’ISRS. Nous avons ensuite cherché à savoir 
si le court délai d’action antidépresseur du RS67333 peut être prédit par l'expression d'un 
biomarqueur périphérique. Des données de la littérature indiquent que la cascade de 
signalisation de β-arrestine 1 (impliquée dans la désensibilisation et l’internalisation du 
récepteur 5-HT4) serait un biomarqueur potentiel pré-clinique/clinique des états dépressifs et 
des effets d’un traitement antidépresseur. À cette fin, nous avons développé une nouvelle 
méthode d’évaluation des taux de protéines circulantes grâce à une analyse par immunoblot 
des leucocytes (PBMC) isolés à partir du sang total de souris. Les taux de β-arrestine 1 sont 
diminués dans les leucocytes des souris pré-traitées à la CORT. Il faut 7 jours de traitement 
avec le RS67333, mais 28 jours avec la fluoxétine chez ces animaux pour restaurer un taux de 
β-arrestine 1 comparable à celui des animaux contrôles. Ces résultats suggèrent que le taux 
sanguin de β-arrestine 1 est un biomarqueur de la rapidité de la réponse antidépressive. Enfin, 
l'activation du récepteur 5-HT4 dans le cerveau peut représenter une approche thérapeutique 
innovante d’apparition pour traiter plus rapidement des symptômes dépressifs associés à 
l’anxiété. 
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  dépression,	  neurogenèse,	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